

Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

Promosso da



e da

INMI, Istituto Nazionale per le Malattie Infettive

ISS, Istituto Superiore di Sanità

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

SITA, Società italiana per la Terapia Antinfettiva

SIV-ISV, Società Italiana di Virologia - Italian

Society for Virology

ANLAIDS, Associazione Nazionale per la lotta all'AIDS

ARCIGAY, Associazione LGBT Italiana

ARCOBALENO Aids ODV, Associazione

ARCOBALENO Aids ODV

ASA Onlus, Associazione Solidarietà AIDS Onlus

C.I.C.A., Coordinamento Italiano delle case alloggio per persone con HIV/AIDS

EpaC Onlus, Associazione EpaC Onlus

LILA, Lega Italiana per la Lotta contro l'AIDS

MARIO MIELI, Circolo di Cultura Omosessuale

Milano Check Point, Associazione Milano Check Point

NADIR, Associazione Nadir

NPS Italia Onlus, Network Persone Sieropositive

PLUS, Rete persone LGBT+ sieropositive Aps

Con il Patrocinio di

Ministero della Salute



Consiglio Nazionale delle Ricerche



Scientific Programme

www.icar2022.it





Restate connessi al sito e alle pagine social!

Seguici su



www.icar2022.it

Sedi Congressuali

Centro Congressi Giovanni XXIII

Viale Papa Giovanni XXIII, 106 - 24121 Bergamo

Bergamo Science Center

Viale Papa Giovanni XXIII, 57 - 24121 Bergamo

Provider e Segreteria Organizzativa

Effetti srl

Via G.B. Giorgini, 16 - 20151 Milano

Tel. +39 02 3343281 - Fax +39 02 38002105 - icar2022@effetti.it - @ICARcongress





Endorsements

INSTITUTIONS

Ministero della Salute



Consiglio Nazionale delle Ricerche



Provincia di Bergamo



COMUNE DI BERGAMO



CONSIGLIO DEI SINDACI
BERGAMO



Bergamo
Capitale Italiana del
Volontariato 2022

INSTITUTES

Ospedale di Bergamo
ASST Papa Giovanni XXIII

INMI Lazzaro
Spallanzani

IRCCS Ospedale
San Raffaele

Università
di Siena

SCIENTIFIC SOCIETIES

AIMI, Associazione Infermieri Malattie Infettive

AISF, Associazione Italiana per lo Studio del Fegato

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

SIM, Società Italiana di Microbiologia

SIMIT, Società Italiana di Malattie Infettive e Tropicali

SITA, Società italiana per la Terapia Antinfettiva

SIV-ISV, Società Italiana di Virologia - Italian Society for Virology

FOUNDATIONS

Fondazione ICONA, Italian Cohort Naive Antiretrovirals

Fondazione Villa Maraini Onlus, Agenzia Nazionale di Croce Rossa Italiana per le dipendenze patologiche

ASSOCIATIONS

ANLAIDS, Associazione Nazionale per la lotta all'AIDS

ARCIGAY, Associazione LGBT Italiana

ARCOBALENO Aids ODV, Associazione ARCOBALENO Aids ODV

ASA Onlus, Associazione Solidarietà AIDS Onlus

Bergamo Fast-Track City

C.I.C.A., Coordinamento Italiano delle case alloggio per persone con HIV/AIDS

Differenza Lesbica, Associazione culturale laica, antifascista, antirazzista per le donne lesbiche, bisessuali, transessuali

EpaC Onlus, Associazione EpaC Onlus

Gay Center, casa di tutte le persone LGBT+ (lesbiche, gay, bisex e trans)

IAPAC, International Association of Providers of AIDS care

LILA, Lega Italiana per la Lotta contro l'AIDS

MARIO MIELI, Circolo di Cultura Omosessuale

Milano Check Point, Associazione Milano Check Point

NADIR, Associazione Nadir

NPS Italia Onlus, Network Persone Sieropositive

PLUS, Rete persone LGBT+ sieropositive Aps





Scientific Committee

Chairs

Andrea Antinori, Roma
Massimo Cernuschi, Milano
Franco Maggiolo, Bergamo
Maurizio Zazzi, Siena

Abstract Coordinator

Antonio Di Biagio, Genova

Scientific Secretariat

Chiara Agrati, Roma
Guido Antonelli, Roma
Alessandra Bandera, Milano
Andrea Calcagno, Torino
Annapaola Callegaro, Bergamo
Daniele Calzavara, Milano
Anna Maria Cattelan, Padova
Francesca Ceccherini-Silberstein, Roma
Stefania Cicalini, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Nicola Coppola, Napoli
Giulio Maria Corbelli, Bologna
Andrea Cossarizza, Modena
Gabriella d'Ettore, Roma
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano

Enrico Girardi, Roma
Giovanni Guaraldi, Modena
Miriam Lichtner, Latina
Sergio Lo Caputo, Foggia
Giordano Madeddu, Sassari
Giulia Marchetti, Milano
Paolo Meli, Bergamo
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Stefano Rusconi, Legnano (MI)
Francesco Saladini, Siena
Mariella Santoro, Roma
Annalisa Saracino, Bari
Valentina Svicher, Roma
Lucia Taramasso, Genova
Alessandra Vergori, Roma
Ilaria Vicenti, Siena

Pre-Conference Course Secretariat

Giorgia Fracca, Milano
Roberta Gagliardini, Roma

Michele Lanza, Milano
Valentina Mazzotta, Roma
Valeria Micheli, Milano
Roberto Rossotti, Milano
Ombretta Turriziani, Roma

Annual Programme Committee

Massimo Andreoni, Roma
Andrea Antinori, Roma
Antonella Castagna, Milano
Massimo Cernuschi, Milano
Antonella d'Arminio Monforte, Milano
Massimo Farinella, Roma
Andrea Gori, Milano
Franco Maggiolo, Bergamo
Cristina Mussini, Modena
Massimo Puoti, Milano
Maurizio Zazzi, Siena

Government Bodies

SPC (Scientific Programme Committee)

Massimo Andreoni, Roma
Andrea Antinori, Roma
Guido Antonelli, Roma
Matteo Bassetti, Genova
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Sergio Carbonara, Bari

Arnaldo Caruso, Brescia
Antonio Cascio, Palermo
Antonella Castagna, Milano
Francesco Castelli, Brescia
Anna Maria Cattelan, Padova
Benedetto Maurizio Cesia, Catania
Antonella Cingolani, Roma
Massimo Clementi, Milano
Andrea Cossarizza, Modena
Marco Cusini, Milano
Antonella d'Arminio Monforte, Milano

Antonio Di Biagio, Genova
Giovanni Di Perri, Torino
Massimo Di Pietro, Firenze
Vincenzo Esposito, Napoli
Enrico Girardi, Roma
Andrea Gori, Milano
Sergio Lo Caputo, Foggia
Fabrizio Maggi, Varese
Paolo Maggi, Napoli
Franco Maggiolo, Bergamo
Giulia Marchetti, Milano





Claudio Maria Mastroianni, Roma
Cristina Mussini, Modena
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Giustino Parruti, Pescara
Carlo Federico Perno, Roma
Massimo Puoti, Milano
Giuliano Rizzardini, Milano
Stefano Rusconi, Legnano (MI)
Laura Sighinolfi, Ferrara

Guido Silvestri, Atlanta USA
Barbara Suligoj, Roma
Marcello Tavio, Ancona
Carlo Torti, Catanzaro
Maurizio Zazzi, Siena

CsC (Community sub-Committee)

Alberto Bignardi, Bologna
Daniele Calzavara, Milano

Giulio Maria Corbelli, Bologna
Maria Grazia Di Benedetto, Catania
Massimo Farinella, Roma
Nicoletta Frattini, Milano
Ivan Gardini, Forlì
Bruno Marchini, Roma
Paolo Meli, Bergamo
Ada Moznich, Milano
Stefano Patrucco, Torino
Filippo von Schloesser, Roma

Faculty

Chiara Agrati, Roma
Claudia Alteri, Milano
Massimo Andreoni, Roma
Andrea Antinori, Roma
Guido Antonelli, Roma
Max Appenroth, Berlin D
Bertrand Audoin, Paris F
Alessandra Bandera, Milano
Matteo Bassetti, Genova
Alessandra Bianchi, Milano
Teresa Bini, Milano
Isabella Bon, Bologna
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Marco Borderi, Bologna
Vanni Borghi, Modena
Michele Breveglieri, Bologna
Raffaele Bruno, Pavia
Francesca Caccuri, Brescia
Andrea Calcagno, Torino
Annapaola Callegaro, Bergamo
Giulia Valeria Calvino, Roma
Leonardo Calza, Bologna
Daniele Calzavara, Milano
Diana Canetti, Milano
Anna Caraglia, Roma
Sergio Carbonara, Bisceglie (BT)
Antonio Cascio, Palermo
Antonella Castagna, Milano
Francesco Castelli, Brescia
Dario Cattaneo, Milano
Anna Maria Cattelan, Padova
Roberto Cauda, Roma
Francesca Ceccherini-Silberstein, Roma

Benedetto Maurizio Celesia, Catania
Giovanni Cenderello, Sanremo
Valeria Cento, Rozzano (MI)
Massimo Cernuschi, Milano
Stefania Cicalini, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Massimo Clementi, Milano
Mario Salvatore Clerici, Milano
Pietro Colletti, Marsala
Nicola Coppola, Napoli
Giulio Maria Corbelli, Bologna
Davide Corti, Bellinzona CH
Maria Luisa Cosmaro, Milano
Andrea Cossarizza, Modena
Marco Cusini, Milano
Antonella d'Arminio Monforte, Milano
Gabriella d'Ettore, Roma
Gianpiero D'Offizi, Roma
Michele De Gennaro, Lucca
Fabio De Iaco, Torino
Andrea De Maria, Genova
Steven G. Deeks, San Francisco USA
Maria Grazia Di Benedetto, Catania
Antonio Di Biagio, Genova
Tania Di Giovanni, Roma
Speranza Di Maggio, Padova
Giovanni Di Perri, Torino
Massimo Antonio Di Pietro, Firenze
Vincenzo Esposito, Napoli
Marco Falcone, Pisa
Massimo Farinella, Roma
Emanuele Focà, Brescia
Giorgia Fracca, Milano

Nicoletta Frattini, Milano
Giovanni Gabutti, Lavagna (GE)
Roberta Gagliardini, Roma
Giovanni Gaiera, Milano
Rosario Galipò, Roma
Massimo Galli, Milano
Cecilia Garlanda, Pieve Emanuele (MI)
Lidia Gazzola, Milano
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Vania Giacomet, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Roberto Gulminetti, Pavia
Fiona Lampe, London UK
Pietro Lampertico, Milano
Michele Lanza, Milano
Giuseppe Lapadula, Monza
Adriano Lazzarin, Milano
Filippo Leserri, Roma
Miriam Lichtner, Latina
Sergio Lo Caputo, Foggia
Giordano Madeddu, Sassari
Fabrizio Maggi, Varese
Paolo Maggi, Caserta
Franco Maggiolo, Bergamo
Lara Manganaro, Milano
Giulia Marchetti, Milano
Bruno Marchini, Roma
Maria Giulia Marini, Milano
Massimo Marra, Roma
Claudio Maria Mastroianni, Roma





Alberto Matteelli, Brescia
Sandro Mattioli, Bologna
Giovanni Mazzola, Caltanissetta
Valentina Mazzotta, Roma
Paolo Meli, Bergamo
Valeria Micheli, Milano
Francesca Moccia, Roma
Perry Mohammed, London UK
Ada Moznich, Milano
Cristina Mussini, Modena
Paola Nasta, Brescia
Alice Nava, Milano
Emanuele Nicastrì, Roma
Filippo M. Nimbi, Roma
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
William Richard Nutland, London UK
Giancarlo Orofino, Torino
Saverio Parisi, Padova
Giustino Parruti, Pescara

Stefano Patrucco, Torino
Dimitra Peppà, London UK
Carlo Federico Perno, Roma
Carmela Pinnetti, Roma
Silvia Pittalis, Roma
Guido Poli, Milano
Massimo Puoti, Milano
Maria Eugenia Quiros Roldan, Brescia
Laura Amelia Rachele Rancilio, Milano
Diego Ripamonti, Bergamo
Agostino Riva, Milano
Giuliano Rizzardini, Milano
Marco Rizzi, Bergamo
Roberto Rossotti, Milano
Stefano Rusconi, Legnano (MI)
Francesco Saladini, Siena
Maria Santoro, Roma
Annalisa Saracino, Bari
Lolita Sasset, Padova
Gabriella Scarlatti, Milano

Laura Sighinolfi, Ferrara
Francesco Roberto Simonetti, Baltimore USA
Vincenzo Spagnuolo, Milano
Nicola Squillace, Monza
Valentina Svicher, Roma
Lucia Taramasso, Genova
Marcello Tavio, Ancona
Camilla Tincati, Milano
Ombretta Turriziani, Roma
Stefano Vella, Roma
Alessandra Vergori, Roma
Pierluigi Viale, Bologna
Ilaria Vicenti, Siena
Francesca Vichi, Firenze
Giovanni Villa, Brighton UK
Pietro Leone Giovanni Vinti, Milano
Eleonora Volpato, Milano
Donatello Zagato, Milano
Maurizio Zazzi, Siena

Abstract Reviewers

Isabella Abbate, Roma
Chiara Agrati, Roma
Guido Antonelli, Roma
Lorenzo Badia, Bologna
Alessandra Bandera, Milano
Teresa Bini, Milano
Paolo Bonfanti, Monza
Stefano Bonora, Torino
Marco Borderi, Bologna
Andrea Calcagno, Torino
Anna Paola Callegaro, Bergamo
Daniele Calzavara, Milano
Antonella Castagna, Milano
Dario Cattaneo, Milano
Anna Maria Cattelan, Padova
Francesca Ceccherini-Silberstein, Roma
Benedetto Maurizio Celesia, Catania
Stefania Cicalini, Roma
Antonella Cingolani, Roma
Paola Cinque, Milano
Nicola Coppola, Napoli
Giulio Maria Corbelli, Bologna
Maria Luisa Cosmaro, Milano

Andrea Cossarizza, Modena
Gabriella d'Ettore, Roma
Antonio Di Biagio, Genova
Carlo Ferrari, Parma
Giorgia Fracca, Milano
Roberta Gagliardini, Roma
Anna Maria Geretti, Roma
Cristina Gervasoni, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Andrea Gori, Milano
Giovanni Guaraldi, Modena
Miriam Lichtner, Latina
Giuseppina Liuzzi, Roma
Sergio Lo Caputo, Foggia
Lucia Lopalco, Milano
Giordano Madeddu, Sassari
Paolo Maggi, Caserta
Franco Maggiolo, Bergamo
Giulia Marchetti, Milano
Valentina Mazzotta, Roma
Paolo Meli, Bergamo
Valeria Micheli, Milano

Ada Moznich, Milano
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Giancarlo Orofino, Torino
Carmela Pinnetti, Roma
Tullio Prestileo, Palermo
Diego Ripamonti, Bergamo
Roberto Rossotti, Milano
Stefano Rusconi, Legnano (MI)
Francesco Saladini, Siena
Maria Santoro, Roma
Annalisa Saracino, Bari
Loredana Sarmati, Roma
Nicola Squillace, Monza
Valentina Svicher, Roma
Gloria Taliani, Roma
Lucia Taramasso, Genova
Camilla Tincati, Milano
Ombretta Turriziani, Roma
Alessandra Vergori, Roma
Ilaria Vicenti, Siena
Francesca Vichi, Firenze





Andrea Antinori



Massimo Cernuschi



Franco Maggiolo



Maurizio Zazzi

Dear Colleagues and Friends

It is our great pleasure to welcome you to the **14th ICAR**, the Italian Conference on AIDS and Antiviral Research.

This year, the Conference claim **“alliance to leave no one behind”** highlights the spirit of 2022 edition. The HIV transmission curve is being influenced, perhaps for the first time, by ARV therapies and by the effort of the entire Italian scientific and clinical society to widely apply the concept of therapy for all, without limitations induced by immune or clinical levels.

It is time to make a qualitative leap in two directions. The first, to strengthen the alliance between all the scientific, clinical and social components that are committed in various ways in the fight against HIV/AIDS. The second, to reach the most fragile and exposed populations, whom the COVID-19 pandemic has made even more fragile.

Crises can be profound catalysts for change and generate new opportunities to create much more value over time: recent years have clearly shown that only by working together we can effectively address the multidimensional consequences of a pandemic. Based on what we learnt from the recent pandemic, we need to reflect on how the fight against HIV can be strengthened and become even more effective.

With this spirit we choose to support, through **Scholarships and Special Awards**, our young researchers, the non-medical health personnel, the Community of patient associations and volunteers.

At the same time, ICAR 2022 maintains its commitment to civil society in the prevention of infectious diseases, by offering **free HIV, HCV and Syphilis Rapid Test** to the local population, and by continuing to promote the **RaccontART contest**, now at its 8th edition, that involves high school students.

Special thanks go to the Scientific Committee and Secretariat, to the Abstract Coordinator and Reviewers, to our Faculty Members, to the ICAR Governing Board, SIMIT, to the Community of Patient Associations and Volunteers, Institutions, Scientific Societies, Schools and Students, to the Municipality and the Province of Bergamo and to our Sponsors who enabled us to involve and host hundreds of participants from all over the Country.

We are greatly honored to welcome you and **leave no one behind in Bergamo!**

Welcome to **ICAR 2022**

The Chairs





Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

PROGRAMME AT A GLANCE

ORARI	AUDITORIUM SALA OGGIONI	SALA STUCCHI	ALABASTRO A	ALABASTRO B
13.30 16.30	SPECIAL SESSION Incontro scuole RaccontART 13.30-16.00	PRE-CONFERENCE ADVANCED COURSE Focus on viral resistance and variability 14.30-16.30	PRE-CONFERENCE ADVANCED COURSE Clinical and point of care diagnostics for STIs in a PrEP service 14.30-16.30	PRE-CONFERENCE ADVANCED COURSE New psychoactive substances and chemsex. David Stuart Course 14.30-16.30
	AUDITORIUM SALA OGGIONI			
17.00 18.00	SATELLITE SYMPOSIUM Defining new patient-centric goals to improve long-term treatment success in HIV			
18.20 20.00	<p>ICAR 2022</p> <p><i>Opening Session</i></p> <p>18.00-18.20 Introducing ICAR 2022 - Chairs and Authorities' Welcome addresses</p> <p>18.20-18.40 RaccontART contest Awards</p> <p>18.40-19.10 Mauro Moroni Memorial Lecture COVID-19 past, present and future. Will Covid ever retire?</p> <p>19.10-19.40 HIV as a chronic disease: myth or truth?</p> <p>19.40-20.00 Opening session closing remarks</p>			
20.00 22.00	ICAR 2022 Welcome Reception			

CONFERENCE SESSIONS

ORAL POSTERS

ORAL COMMUNICATIONS

SPONSORED SESSIONS

SATELLITE SESSIONS





ORARI	AUDITORIUM SALA OGGIONI	SALA STUCCHI	ALABASTRO A	ALABASTRO B	BERGAMO SCIENCE CENTER
09.00 10.00	Keynote Lectures				
10.05 11.05	SPONSORED SYMPOSIUM Being pioneers of a new paradigm: what have we learned so far?	ORAL COMMUNICATIONS PrEP: new data and issues	SATELLITE SYMPOSIUM Hepatitis Delta in HIV/HBV Infected Patients		ORAL POSTER COVID-19: treatment strategies I 10.05-10.55
11.10 12.10	SATELLITE SYMPOSIUM HIV: act in the present and challenge the future	ORAL COMMUNICATIONS Immunological efficacy of SARS-CoV-2 vaccine I	ORAL POSTER COVID-19: treatment strategies II 11.10-12.00	ORAL POSTER Treatment of naive PLWH: current strategies and rapid start of ART 11.10-12.00	ORAL POSTER PrEP: real life experience 11.10-12.00
12.15 13.15	SYMPOSIUM New Insights and Challenges on Hepatitis and HIV Co-infections	EXPERT MEETING Narrative Medicine applied to Vaccination during COVID-19 pandemic	SPONSORED SYMPOSIUM Cabotegravir + rilpivirine long-acting: are we ready for the new era?		ORAL POSTER Access test and educational aspects 12.15-13.05
13.15 14.30		SPECIAL SESSION How to use U=U to fight stigma	ORAL COMMUNICATIONS Metabolic issues in effective HAART 13.15-14.15	ORAL POSTER Predictors of COVID-19 severity 13.25-14.15	ORAL POSTER HCV eradication: general and key populations 13.25-14.15
14.30 15.30	SPONSORED SYMPOSIUM Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF	ORAL COMMUNICATIONS COVID-19: clinical management	EXPERT MEETING The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations	ORAL POSTER Viro-immunological correlates of COVID-19 severity 14.30-15.20	ORAL POSTER Issues on mental health, sexual health and STIs 14.30-15.20
15.35 16.35	SYMPOSIUM At the edge of PrEP	ORAL COMMUNICATIONS Pathogenesis and Immunology	INTERACTIVE EXPERT MEETING Affairs of the heart in HIV: redundant or a key challenge?	ORAL POSTER Neuropsychological complications in COVID-19 15.35-16.25	ORAL POSTER New issues on dual therapy 15.35-16.25
16.40 17.40	SYMPOSIUM Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates	ORAL COMMUNICATIONS From HIV to SARS-CoV-2	EXPERT MEETING Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies	ORAL POSTER Cardiovascular diseases, osteoporosis but not only 16.40-17.30	ORAL POSTER Vulnerable and key population: local experiences 16.40-17.30
17.45 18.45	SYMPOSIUM Challenges in HIV cure: getting to zero reservoir	ORAL COMMUNICATIONS Metabolic alterations: effect of drugs and diseases	ORAL COMMUNICATIONS Special issues in clinical HIV	ORAL POSTER Measuring HIV stigma and disclosure 17.45-18.35	ORAL POSTER Models of COVID-19 pathogenesis and response to vaccination 17.45-18.35



ORARI	AUDITORIUM SALA OGGIONI	SALA STUCCHI	ALABASTRO A	ALABASTRO B	BERGAMO SCIENCE CENTER
09.00 10.00	Keynote Lectures				
10.05 11.05	SYMPOSIUM Comorbidities of contemporary relevance	EXPERT MEETING Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?	SYMPOSIUM The Italian Fast-Track Cities Network 10.05-12.10	ORAL POSTER COVID-19: considerations of special populations 10.05-10.55	ORAL POSTER Toxicity of antiretroviral therapy 10.05-10.55
11.10 12.10	SPONSORED SYMPOSIUM Remdesivir: key-role in COVID-19 management	ORAL COMMUNICATIONS Resistance to antiretroviral		ORAL POSTER HIV and SARS-CoV-2: from in vivo to in vitro 11.10-12.00	
12.15 13.15	SYMPOSIUM A practical approach to HIV patients' management	ORAL COMMUNICATIONS HIV and SARS-CoV-2: two intersecting epidemics	EXPERT MEETING Redefining manage- ment and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus	ORAL POSTER Acute COVID-19 and post COVID-19 syndrome 12.15-13.05	ORAL POSTER Immunological efficacy of COVID-19 vaccination in vulnerable populations 12.15-13.05
13.15 14.15	SYMPOSIUM Immunological control over HIV: from models of spontaneous control to immunotherapeutic approaches	ORAL COMMUNICATIONS Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities	ORAL COMMUNICATIONS Immunological efficacy of SARS-CoV-2 vaccine II	ORAL POSTER Open questions about ART efficacy 13.15-14.05	ORAL POSTER Immunological complexity in COVID-19 13.15-14.05
14.15 15.15	SYMPOSIUM COVID-19 from early treatment to long-term care	ORAL COMMUNICATIONS Dual therapy in naive and switched PLWH	ORAL COMMUNICATIONS Mental health and predictors of AIDS and non-AIDS defining co-pathologies	ORAL POSTER Prevention and access to services during COVID pandemic 14.20-15.10	ORAL POSTER SARS-CoV-2: from in vivo to in vitro 14.20-15.10
15.20 16.20	SYMPOSIUM Update on antiretroviral therapy: answers and suggestions during a pandemic era	ORAL COMMUNICATIONS Complexities of SARS-CoV-2 infection	ORAL COMMUNICATIONS Insights on epidemiological and clinical management of hepatitis viruses	ORAL POSTER Immunopathogenesis of HIV 15.20-16.10	
16.25 16.45	ICAR 2022 Special Awards and Closing Remarks				



Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

**PRE-CONFERENCE
ADVANCED COURSES**


PRE-CONFERENCE ADVANCED COURSE 14.30-16.30

SALA STUCCHI
Focus on viral resistance and variability

Chairs: R. Gagliardini (Roma), V. Micheli (Milano), O. Turriziani (Roma)

RNA viruses show a great potential for genetic variation, rapid evolution and adaptation. Genetic variability may affect pathogenesis, epidemiology and the success of antiviral therapy. In the past months, several SARS-CoV-2 variants of concern (VOCs) have emerged and an intense monitoring of their circulation worldwide plays a crucial role not only in surveillance but also as part of containment and mitigation strategies. Different molecular methods to detect and characterize a specific viral variant have been developed. Many of these assays can accurately identify the variants, while others require confirmation by sequencing. Viral genetic variability is also responsible for drug resistance, a well known phenomenon in HIV infection. Despite successful antiretroviral therapy, a minority of people living with HIV (PLWH) still have difficulty in achieving and maintaining virological suppression, mainly due to HIV drug resistance, and a small group of them harbor multi-drug resistant viruses. In this scenario, the emergence of drug resistance mutations to the latest antiretroviral drugs should be carefully investigated. Nowadays, more than 90% of PLWH have undetectable viral load. ART optimization or simplification in this clinical setting can be critical, especially when previous ART history is complex or unknown. The current transition from Sanger sequencing to Next Generation Sequencing to detect archived HIV drug resistance mutations could offer novel treatment-relevant insights and improve the management of virologically suppressed patients.

14.30-15.00	HIV drug resistance mutations to new antiretroviral drugs	F. Saladini, Siena
15.00-15.30	Detection of archived HIV drug resistance mutations in virologically suppressed individuals by different genotyping techniques: from Sanger to NGS	M. Santoro, Roma
15.30-16.00	Molecular assays to characterize SARS-CoV-2 viral variants	F. Caccuri, Brescia
16.00-16.30	Discussion on Course issues	


PRE-CONFERENCE ADVANCED COURSE 14.30-16.30

ALABASTRO A
Clinical and point of care diagnostics for STIs in a PrEP service

Chairs: V. Mazzotta (Roma), R. Rossotti (Milano)

The syndromic approach for the management of sexually transmitted infections (STIs) relies on the assessment of patient's general complaints: clinical evaluation represents the best and fastest way to choose the appropriate treatment. Laboratory tests provide the correct etiologic diagnosis but turn-around times could be an issue in a clinic dedicated to PrEP care, where a high burden of STIs and heavily interconnected sexual networks require a rapid handling. Overtreatment and spread of antimicrobial resistance are additional drawbacks if microbial diagnosis is not readily available. Point-of-care diagnostics could be helpful both in hospital- and community-based services for rapid diagnosis and epidemiological monitoring of people in PrEP.

14.30-15.00	Traditional versus point of care diagnostics for STIs: pros and cons	A. Nava, Milano
15.00-15.30	Clinical approach to the diagnosis of STIs, treatment criteria and concerns about microbial resistance	S. Pittalis, Roma
15.30-16.00	Management of STIs diagnosis in a community-based, peer-run PrEP service	P.L.G. Vinti, Milano
16.00-16.30	Discussion on Course issues	





PRE-CONFERENCE ADVANCED COURSE 14.30-16.30

ALABASTRO B

**New psychoactive substances and chemsex.
David Stuart Course**

Chairs: G. Fracca (Milano), M. Lanza (Milano)

Chemsex can be defined as the use of specific drugs (chems), in a sexualized context, by gay men and other men who have sex with men. Chemsex is associated with peculiar socio-cultural aspects of MSM sexuality. Chems use also varies in different geographical areas according to availability, affordability or other circumstances. Initially three substances only have been named as chems. Other substances now are added to chems. Chemsex adds ritual aspects, often driven by dating networks, to MSM sexual behavior. It is a complex phenomenon that involves different areas and can have different impact on different people and require different approaches. There is a need for more information about substances and how to reduce risks associated with their use, while for more problematic aspects (social, behavioral, psychologic, psychiatric, and medical), a therapeutic group's experience - supervised by a psychotherapist - can be an opportunity to cope with abuse.

14.30-14.50	Definition and evolution of sexualized psychoactive substances' use in Italy	F.M. Nimbi, Roma
14.50-15.10	MPDV and free coke as chems. Harm reduction	M. Lanza, Milano
15.10-15.30	Chemsex as social ritual among MSM	G.M. Corbelli, Bologna
15.30-15.50	Chemsex addiction: dealing with the unconscious as a pathway for treatment	G. Fracca; Milano
15.50-16.30	Discussion on Course issues	





Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

SCIENTIFIC PROGRAMME

13.30-16.00 **AUDITORIUM SALA OGGIONI**



SPECIAL SESSION

ARTISTIC CONTEST

"RACCONTART"

INCONTRO CON LE SCUOLE FINALISTE

Chairs: A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano) Con la sponsorizzazione non condizionante di Gilead Sciences

13.30-13.40 **Benvenuto dei Presidenti ICAR** A. Antinori (Roma), M. Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

13.40-14.10 **Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica** A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano)

La Giuria Artistica

- **Elena Capparelli** *Direttrice di RaiPlay e Digital*
- **Alessandro Castellano** *Graphic Designer*
- **Andrea Maggiolo** *Video Maker*
- **Nefeli Misuraca** *Montatrice e regista di cortometraggi*
- **Enzo Porcelli** *Produttore cinematografico*
- **Francesco Suriano** *Scrittore di teatro, sceneggiatore e regista*

La Giuria Tecnico-Scientifica

- **Giulia Valeria Calvino** *ANLAIDS, Roma*
- **Daniele Calzavara** *Milano Check Point, Milano*
- **Anna Caraglia** *Direzione prevenzione sanitaria – Ministero della Salute, Roma*
- **Monica Maria Carlevari** *Gilead Sciences, Milano*
- **Francesca Ceccherini-Silberstein** *Università degli Studi di Roma Tor Vergata*
- **Massimo Cernuschi** *IRCCS Ospedale San Raffaele - ASA, Milano*
- **Antonella Cingolani** *Fondazione Policlinico Universitario Agostino Gemelli, Roma*
- **Paola Cinque** *IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano*
- **Maria Luisa Cosmaro** *LILA, Milano*
- **Giovanni Del Bene** *ANLAIDS, Milano*
- **Antonio Di Biagio** *Ospedale Policlinico San Martino, Genova*
- **Margherita Errico** *NPS Italia, Milano*
- **Massimo Farinella** *Circolo di Cultura Omosessuale Mario Mieli, Roma*
- **Rosario Galipò** *ANLAIDS Lazio, Roma*



- **Donatella Mainieri** ANLAIDS, Milano
- **Sandro Mattioli** Plus aps, Bologna
- **Paolo Meli** Associazione Comunità Emmaus, Bergamo
- **Silvia Nozza** IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
- **Laura Sighinolfi** Azienda Ospedaliero-Universitaria, Ferrara
- **Donatello Zagato** A.S.A. Onlus - Associazione Solidarietà AIDS

14.10-15.45 **Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici**

Gli Istituti Scolastici e le opere finaliste

- **Centro Studi Casnati - Liceo Artistico Giuseppe Terragni** Como
- **I.I.S. Caterina Caniana** Bergamo
- **I.I.S. Papareschi** Roma
- **I.I.S.S MK Gandhi** Besana (MB)
- **I.I.S.S. Francesco Orioli** Viterbo
- **I.S. Lorenzo Lotto** Trescore Balneario (BG)
- **I.S. Puecher-Olivetti** Rho (MI)
- **Liceo Artistico Andrea Fantoni** Bergamo
- **Liceo Artistico Simone Weil** Treviglio (BG)
- **Liceo Don Lorenzo Milani** Romano di Lombardia (BG)

15.45-16.00 **Conclusioni**

A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano)





SATELLITE SYMPOSIUM 17.00-18.00

AUDITORIUM SALA OGGIONI

Defining new patient-centric goals to improve long-term treatment success in HIV

Chair: G. Di Perri (Torino)

Con la sponsorizzazione non condizionante di Gilead Sciences

Although 30 years of research and pharmacological innovation have transformed HIV infection into a chronic disease, the persistence of issues related to direct and indirect harm of the virus, life-long ART exposure, higher risk of comorbidities and host peculiarities mean that life-expectancy and QoL of PLWH are still significantly lower compared with general population. In this scenario, the definition of a new and broader concept of long-term treatment success able to meet not only the clinical goals but also needs and expectations of PLWH, becomes even more crucial. A "tailored" approach based on the complexities of the individual (often not manifested) together with the availability of ARVs optimized in terms of efficacy, genetic barrier, forgiveness, tolerability, and convenience are probably the key to reach this ambitious goal. Through an interactive talk, experts will discuss on current challenges and available strategies to fill these gaps, also with the support of real-life data.

17.00-17.15	How to define long-term treatment success for PLWH and which attributes are requested to ARV?	M. Andreoni, Roma
17.15-17.55	Round-table discussion on how to improve outcomes with current antiretroviral therapy: - How important are high genetic barrier, forgiveness and adherence? - How to optimize the long-term treatment outcomes in experienced patients? - What is the added value of real-world evidence?	Conductor: A. Gori, Milano A. Calcagno, Torino R. Gagliardini, Roma L. Taramasso, Genova G. Di Perri, Torino
17.55-18.00	Take-home messages and conclusions	



Martedì
14 giugno

14° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research



ICAR 2022 OPENING SESSION

AUDITORIUM SALA OGGIONI

Conduce: T. Cartolano (Milano)

Chairs: A. Antinori (Roma), M. Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

18.00-18.20

Introducing ICAR 2022. Chairs and Authorities' Welcome addresses

Chairs: A. Antinori (Roma), M. Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

18.20-18.40

RaccontART contest Awards

A. Caraglia (Roma), F. Ceccherini-Silberstein (Roma), D. Zagato (Milano)

18.40-19.10

Mauro Moroni Memorial Lecture

COVID-19 past, present and future. Will Covid ever retire?

M. Andreoni (Roma)

19.10-19.40

HIV as a chronic disease: myth or truth?

F. Maggiolo (Bergamo), S. Mattioli (Bologna)

19.40-20.00

Opening session closing remarks




KEYNOTE LECTURES 09.00-10.00

AUDITORIUM SALA OGGIONI

Chairs: M.G. Di Benedetto (Catania), A. Lazzarin (Milano)

 09.00-09.30 **Virus spillover**

G. Antonelli, Roma

 09.30-10.00 **Innate immunity and COVID-19**

C. Garlanda, Pieve Emanuele (MI)


SPONSORED SYMPOSIUM 10.05-11.05

AUDITORIUM SALA OGGIONI
Being pioneers of a new paradigm: what have we learned so far?

Chairs: S. Cicalini (Roma), R. Gulminetti (Pavia)

Con il supporto di ViiV Healthcare

The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative people. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), the basis of which continuous improvement placed on providing optimal therapeutic options for long-term management. In this context, ART therapy has evolved in the direction of 2-drug regimens (2DR), which represent a new paradigm supported by solid evidence from clinical trials confirmed in real-life. In particular, dolutegravir/lamivudine (DTG/3TC) represents an important therapeutic option, both in the initial phase of treatment and in the switch from ARV. Starting from these assumptions, the session will focus on the learnings coming from the validation of this new paradigm which bases its foundations on robust data, and which means having an additional option to personalize treatment for PLHIV naïve and virologically suppressed. Regarding these aspects, the most recent data available for regimens containing dolutegravir and lamivudine (DTG / 3TC; DTG + 3TC) will be discussed.

 10.05-10.15 **Introduction**

 10.15-10.30 **The relevance of robust and valuable data**

P. Mohammed, London

 10.30-10.50 **The meaning of personalizing treatments**

C. Mussini, Modena

 10.50-11.05 **Questions & Answers**

ORAL COMMUNICATIONS 10.05-11.05

SALA STUCCHI
PrEP: new data and issues

Chairs: M. G. Di Benedetto (Catania), P. Meli (Bergamo)

OC 1 10.05-10.15 Impact of SIMIT PrEP eligibility criteria on retention in care and new sexually transmitted infections acquisition

 R. Rossotti^{1,5}, G. Mulè^{2,5}, A. Tavelli³, A. De Bona^{2,5}, C. Muccini^{4,5}, D. Moschese^{5,6}, S. Bossolasco^{4,5}, D. Calzavara⁵, A. Foschi^{5,6}, V. Ferrara⁵, R. Repossi⁵, M. Cernuschi^{4,5}, A. d'Arminio Monforte^{2,7}
¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, ²Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, ³ICONA Foundation, Milan, ⁴Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, ⁵Milano Checkpoint, Milan, ⁶I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, ⁷University of Milano, Milan

OC 2 10.17-10.27 Sexually transmitted infection and adherence in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)

 V. Mazzotta¹, S. Lanini¹, D. Calzavara², A. Tavelli³, A. De Bona³, F. De Zottis¹, V. Ferrara², S. La Monica⁴, S. Mattioli⁵, A. Bianchi⁶, G. Mulè³, L. Badia⁵, S. Bossolasco², E. Rozenn⁷, R. Bellagamba¹, D. Tesoro³, R. Rossotti⁸, M. Pedone⁵, S. Nozza⁹, P. Tomasi⁵, L. Biasoli³, F. Gili⁷, M. Bonanni⁵, A. Copes³, A. Castagna⁹, A. Gori¹⁰, M. Puoti⁸, G. Rizzardini¹¹, M. Andreoni¹², C. Mastroianni¹³, R. Cauda⁴, V. Puro⁷, A. Cingolani⁴, G.M. Corbelli⁵, M. Cernuschi^{2,6}, A. d'Arminio Monforte³, A. Antinori¹
¹HIV/AIDS Unit, INMI L. Spallanzani IRCCS, Roma, ²Milano Checkpoint, Milano, ³ASST Santi Paolo e Carlo, University of Milano, ⁴Fondazione Policlinico A. Gemelli, Catholic University, Roma, ⁵PLUS aps (BLQ Checkpoint), Bologna, ⁶ASA Onlus, Milano, ⁷CRAIDS, INMI L. Spallanzani IRCCS, Roma, ⁸ASST Niguarda Hospital, Milano, ⁹HSR San Raffaele Scientific Institute, Milano, ¹⁰IRCCS Policlinico Ospedale Maggiore, Milano, ¹¹ASST L. Sacco Hospital, Milano, ¹²Tor Vergata University, Roma, ¹³Sapienza University, Roma

OC 3 10.29-10.39 Prevalence of anal HPV infection among PrEP users screened through a self-administered Point-of-Care test: data from a community-based PrEP programme in Milan

 L. Biasoli^{1,3}, R. Rossotti^{1,4}, A. Tavelli^{1,3}, A. De Bona^{1,3}, C. Tincati³, D. Calzavara¹, P. Vinti¹, C. Baiguera^{1,4}, R. Repossi¹, V. Ferrara¹, S. Bossolasco^{1,2}, C. Muccini^{1,2}, D. Tesoro^{1,3}, A. D'Arminio Monforte^{1,3}, M. Cernuschi^{1,2} on behalf of the Milano Check Point Group

¹Milano Check Point, Milano, ²IRCCS San Raffaele Scientific Institute, Milano, ³ASST Santi Paolo e Carlo, Milano, ⁴ASST Niguarda Hospital, Milano


OC 4 10.41-10.51 PrEP use disclosure to sexual partners, friends and relatives: a psycho-social analysis

A. Bianchi^{1,2}, A. Tavelli³, P.L. Vinti², D. Calzavara², V. Ferrara², A. Antonino^{1,2}, F. Rossi^{1,2}, M. Massa², A. De Bona³, D. Rossotti^{2,4}, S. Bossolasco^{2,5}, D. Canetti⁵, A. Foschi^{2,6}, D. Tesoro³, G. Mulé^{2,3}, R. Repossi^{1,2}, N. Frattini^{1,2}, E. Garavaglia^{1,2}, C. Ferrara^{1,2}, D. De Cia Warzanowski², M. Cernuschi^{1,2,5}

¹ASA. Associazione Solidarietà AIDS, Milan, Italy, ²Milano Checkpoint, Milan, ³San Paolo Hospital, Milan, Italy, ⁴ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁵San Raffaele Hospital, Milan, Italy, ⁶Luigi Sacco Hospital, Milan, Italy



SATELLITE SYMPOSIUM 10.05-11.05

ALABASTRO A + ALABASTRO B

Hepatitis Delta in HIV/HBV Infected Patients

Chair: M. Puoti (Milano)

Con la sponsorizzazione non condizionante di Gilead Sciences

Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Due to similarities in transmission routes, persons living with HIV (PLWH) are at risk for HDV infection. The lack of satisfactory treatment for hepatitis delta virus (HDV) infection has meant a major threat for developing cirrhosis and liver cancer in this population. Recent data gathered from HIV ICONA cohort suggest that HDV infection among PLWH is underdiagnosed, although HDV entails a high risk of liver disease progression. Because effective drugs to treat HDV are now available, it is even more crucial increase awareness to identify patients at an early stage of liver disease. During the meeting we will provide an exceptional overview of HDV disease among PLWH, from its diagnosis to its management, sharing the most up to date evidences of HDV treatment.

10.05-10.10 **Introduction**

10.10-10.30 **Epidemiological characteristics of HDV infection in HIV patients - Coorte ICONA** A. d'Arminio Monforte, Milano

10.30-10.50 **Managing Viral Hepatitis D and new treatment option for HDV** P. Lampertico, Milano

10.50-11.05 **Discussion on Symposium issues**



ORAL POSTER 10.05-10.55

BERGAMO SCIENCE CENTER

COVID-19: treatment strategies I

Chairs: C. Alteri (Milano), G. Cenderello (Sanremo)

OP 1 10.05-10.10 Real-life data on early treatment with antivirals in outpatients with mild COVID-19 symptoms

A. Rugova¹, G. Ghilardi², G. Lapadula^{1,2}, N. Squillace¹, A. Cappelletti¹, F. Sabbatini¹, A. Ranzani¹, M. Rossi¹, F. Iannuzzi¹, E. Pollastri¹, P. Columpsi¹, L. Bisi¹, E. Colella¹, S. Limonta¹, I. De Benedetto¹, N. Corti^{1,2}, G.M. Migliorino¹, S. Foresti¹, A. Soria¹, P. Bonfanti^{1,2}

¹Clinic of Infectious Diseases San Gerardo Hospital ASST Monza, Monza, ²School of Medicine and Surgery University of Milano-Bicocca, Monza

OP 2 10.12-10.17 Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 and delta sub-lineage AY.4.2

L. Fiaschi¹, F. Dragoni¹, E. Schiaroli², A. Bergna³, B. Rossetti⁴, F. Giammarino¹, C. Biba¹, A. Gidari², A. Lai³, C. Nencioni⁴, D. Francisci², M. Zazzi¹, I. Vicenti¹

¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Department of Medicine and Surgery, Clinic of Infectious Diseases, University of Perugia, Perugia, Italy, ³Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ⁴Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy

OP 3 10.19-10.24 Sarilumab plus standard of care versus standard of care for the treatment of severe COVID-19: a phase 3, randomized, openlabeled, multi-center study (ESCAPE Study)

I. Mastroianni¹, R. Gagliardini¹, F.V. Segala², A. Mondì¹, P. Lorenzini¹, C. Cerva¹, E. Taddei², F. Bai³, M. Negri², C. Pinnetti¹, S. Cicalini¹, R. Murri², V. Mazzotta¹, M. Camici¹, S. Mosti¹, T. Bini³, A. Beccacece¹, E. Milozzi¹, M. Iannetta⁴, M. Fusto¹, M.M. Plazzi¹, M. Lichtenner⁵, M. Fantoni², M. Andreoni⁴, L. Sarmati⁴, R. Cauda², E. Nicastrì¹, A. D'Arminio Monforte³, F. Palmieri¹, A. Cingolani², A. Antinori¹

¹Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, ²Fondazione Policlinico A. Gemelli IRCCS- Università Cattolica S. Cuore, Rome, Italy, ³Azienda Ospedaliera San Paolo, Milan, Italy, ⁴University of Rome Tor Vergata, Rome, Italy, ⁵Sapienza University of Rome, Italy, Polo Pontino

OP 4 10.26-10.31 Safety and efficacy of antiviral agents in SARS-CoV-2 infected patients: a real-life experience

A. De Vito, A. Colpani, A. Bitti, V. Manca, B. Zauli, M.C. Meloni, M. Fois, L. Denti, S. Bacciu, C. Marcia, I. Maida, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy



OP 5 10.33-10.38 Efficacy of Early Antiviral Therapies among High-Risk Patients with Mild to Moderate COVID-19
S. Amadasi¹, M. Degli Antoni¹, P. Grechi², A. Tregambe², S. Arsuffi¹, F. Pennati¹, M.A. Forleo¹, F. Castelli¹, E. Quiros-Roldan¹

¹Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, ²Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia

OP 6 10.40-10.45 Real life experience on the use of anti-SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression among inpatients and outpatients: a monocentric experience

C. Leanza¹, S. Di Bari¹, N. Perrotta², L.A. Fiorito², R. Gentile³, V. Cioffi², G. Casini², F. Cogliati Dezza¹, D. Fago¹, C. Ajassa¹, G. Iaiani¹, R. Lobello², E.M. Prolì², C.M. Mastroianni¹, G. Russo¹

¹Infectious Diseases Unit, AOU Policlinico Umberto 1st Sapienza University, Rome, Italy, ²Pharmacy, AOU Policlinico Umberto 1st, Rome, Italy, ³Pharmacy, G. D'annunzio University, Chieti Pescara, Italy



SATELLITE SYMPOSIUM 11.10-12.10

AUDITORIUM SALA OGGIONI

HIV: act in the present and challenge the future

Chairs: A. Cingolani (Roma), G.M. Corbelli (Bologna)

Con la sponsorizzazione non condizionante di Janssen-Cilag

Since the introduction of ART there has been increased survival in PLWH; nowadays it is important to answer to needs of every single HIV-positive patient - requiring long-life antiretroviral treatments providing durability and tolerability- but also to consider the challenges raising from HIV-negative at-risk population. The aim of this Symposium is to deepen the challenge coming from the HIV vaccine as public health measure, focusing on clinical and social aspects. Furthermore, it is of utmost importance keep the focus in the present days for discussing the appropriate treatment strategies to adopt in daily practice for improving patients care.

11.10-11.30 **What we know about HIV Vaccine?**

S. Nozza, Milano

11.30-11.50 **PI-based learning**

S. Rusconi, Legnano (MI)

11.50-12.10 **Discussion on Symposium issues**



ORAL COMMUNICATIONS 11.10-12.10

SALA STUCCHI

Immunological efficacy of SARS-CoV-2 vaccine I

Chairs: A. Castagna (Milano), S. Parisi (Padova)

OC 5 11.10-11.20 Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count

A. Vergori¹, A. Cozzi-Lepri², M. Giannella³, A. Tavelli⁴, A.M. Azzini⁵, L. Marconi³, S. Cicalini¹, A. Rodanò⁴, S. Meschi¹, M. Fusto¹, A. Sartor⁶, G. Matusali¹, S. Piconi⁷, G. Pellicano⁸, A. Cascio⁹, G. Levy-Hara¹⁰, A. Costantini¹¹, G. Madeddu¹², G. Marchetti⁴, P. Viale³, E. Tacconelli⁵, A. d'Arminio Monforte⁴, A. Antinori¹ for the VAXICONA-ORCHESTRA Study Group

¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, ²CREME, Institute for Global Health, UCL, London, UK, ³Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ⁴Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, ⁵Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy, ⁶Microbiology Unit, Udine University Hospital, Udine, Italy, ⁷Infectious Diseases Unit, A. Manzoni ASST Lecco, Lecco, Italy, ⁸Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, ⁹Infectious and Tropical Diseases Unit, PROMISE, University of Palermo, Palermo, Italy, ¹⁰Istituto Alberto Taquini de Investigación en Medicina Traslacional, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina, ¹¹Clinical Immunology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy, ¹²Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

OC 6 11.22-11.32 Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count

A. Antinori¹, A. Cozzi-Lepri², A. Vergori¹, A. Tavelli³, M. Giannella⁴, S. Cicalini¹, L. Marconi⁴, V. Yellenki³, S. Meschi¹, G. Pellicano⁵, N. Carroccia⁴, G. Matusali¹, A. Latini⁶, M. Lichtner⁷, S. Lo Caputo⁸, F.M. Fusco⁹, G. Marchetti³, E. Tacconelli¹⁰, A. d'Arminio Monforte³ for the VAXICONAORCHESTRA Study Group

¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, ²CREME, Institute for Global Health, UCL, London, UK, ³Unit of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ⁴Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy, ⁵Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, ⁶Department of Dermatology, San Gallicano Institute IRCCS, Roma, Italy, ⁷Santa M. Goretti Hospital, Sapienza University, Latina, Italy, ⁸Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ⁹AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy, ¹⁰Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy





- OC 7 11.34-11.44 Longitudinal characterization of interferon and antibody response following vaccination against SARS-CoV-2 in patients with HIV-1 infection**
M. Scordio¹, F. Frasca¹, L. Santinelli², L. Maddaloni², L. Sorrentino¹, M. Fracella¹, E.N. Cavallari², A. Napoli², L. Cinti², P. Roberto², G. Ceccarelli², A. Gaeta², G. Antonelli^{1,3}, C. M. Mastroianni², G. d'Etorre², C. Scagnolari¹
¹Laboratory of Virology, Department of Molecular Medicine, Sapienza University, Rome, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ³Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy
- OC 8 11.46-11.56 T-cell and humoral responses to mRNA-1273 vaccine up to 6 months in late presenter people living with HIV (PLWH)**
M. Augello, V. Bono, R. Rovito, M. Hadla, V. Yellenki, C. Tincati, A. d'Arminio Monforte, G. Marchetti
 Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy



ORAL POSTER 11.10-12.00

COVID-19: treatment strategies II

ALABASTRO A

Chairs: V. Cento (Rozzano MI), L. Sasset (Padova)

- OP 7 11.10-11.15 Use of Sotrovimab in a cohort of Pregnant Women with a high risk of COVID 19 progression: a single-center experience**
L. Frallonardo¹, A. Vimercati¹, R. Novara¹, D.F. Bavaro¹, G. Brindicci¹, C.R. Santoro¹, I. Ferrante², G. Chiarello², C. Lepera², M. Mongelli², R. Cicinelli², F. Di Gennaro¹, E. Cicinelli², A. Saracino¹
¹Clinic of Infectious Diseases, University of "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, Italy, ²Clinic of Obstetrics & Gynaecology, University of "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Bari, Italy
- OP 8 11.17-11.22 Remdesivir does not influence SARS-CoV-2 RNA viral load kinetics in nasopharyngeal swab specimens of COVID-19 hospitalized patients: a real-life experience**
L. Campogiani^{1,2}, M. Iannetta^{1,2}, A. Di Lorenzo^{1,2}, M. Zordan^{1,2}, L. Coppola^{1,2}, M. Compagno^{1,2}, V. Malagnino^{1,2}, E. Teti^{1,2}, M. Andreoni^{1,2}, L. Sarmati^{1,2}
¹Department of System Medicine, Tor Vergata University, Rome, Italy, ²Infectious Disease Clinic, Policlinico Tor Vergata, Rome Italy
- OP 9 11.24-11.29 Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: preliminary data of an ongoing large observational multicenter study (CONDIVIDIAMO)**
A. Soria¹, G. Ghilardi², F. Graziano³, S.V. Benatti⁴, G. Lapadula^{1,2}, A. Ferraresi⁵, P. Brambilla⁶, D. Pocater⁷, M.E. Quiros Roldan⁷, M. Franzetti⁸, L. Bradanini⁹, A. Cappelletti¹, A. Rugova¹, M.L. Borghesi¹, S. Piconi⁹, S. Rusconi^{8,10}, F. Castelli⁷, P. Morelli⁶, A. Pan⁵, M. Rizzi⁴, S. Galimberti³, M.G. Valsecchi³, P. Bonfanti^{1,2}
¹San Gerardo Hospital ASST Monza, Monza, ²School of Medicine and Surgery University of Milano-Bicocca, Monza, ³Bicocca Bioinformatics Biostatistics and Bioimaging Center B4 School of Medicine and Surgery University of Milano-Bicocca, Monza, ⁴ASST Papa Giovanni XXIII, Bergamo, ⁵ASST Cremona, Cremona, ⁶Humanitas Clinical and Research Center, Milan, ⁷ASST Spedali Civili University of Brescia, Brescia, ⁸Legnano Hospital ASST Ovest Milanese, Legnano, ⁹ASST A Manzoni, Lecco, ¹⁰DIBIC "Luigi Sacco" Università degli Studi di Milano, Milan
- OP 10 11.31-11.36 Early Use of Short-Course Remdesivir and Monoclonal Antibodies May Reduce The Risk of Disease Progression in Hospitalized Patients With COVID-19: a Single Center Retrospective Study**
D.F. Bavaro¹, L. Diella¹, A. Belati¹, G. Brindicci¹, F. Balena¹, D. Fiordelisi¹, M.F. Mariani¹, F. Signorile¹, G. Metrangolo¹, L. De Santis¹, V. Spada¹, M. Camporeale¹, A. Dargenio¹, G. Nicoletta², F. Di Gennaro¹, M. Dell'Aera², A. Saracino¹
¹Clinic of Infectious Diseases, University Hospital of Bari, Bari, Italy, ²Hospital Pharmacy Department, University Hospital of Bari, Bari, Italy
- OP 11 11.38-11.43 Continuous Positive Airway Pressure in SARS-CoV-2 associated Acute Respiratory Distress Syndrome: timing to maximize results**
R. Nevola^{1,3}, A. Russo², S. Scuotto², S. Imbriani¹, C. Aprea¹, M. Abitabile¹, D. Beccia¹, C. Brin¹, C. Carusone¹, F. Cinone¹, G. Cirigliano¹, S. Colantuoni¹, D. Cozzolino¹, G. Cuomo¹, M. Del Core¹, K. Gjeshi¹, A. Marrone¹, G. Medicamento¹, L. Meo¹, F. Nappo¹, A. Padula¹, P.C. Pafundi¹, R. Ranieri¹, C. Riccozzi¹, L. Rinaldi¹, C.P. Romano¹, R. Ruocco¹, C. Ruosi¹, A. Salvati², F.C. Sasso¹, A. Sellitto¹, P. Sommesse¹, A. Villani¹, N. Coppola², L.E. Adinolfi¹
¹Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, ²Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, ³Internal Medicine and Hepatology Unit, Betania Evangelical Hospital, Naples, Italy
- OP 12 11.45-11.50 EpCOT: an open-label, controlled, randomized clinical trial on the efficacy of early prone-positioning in patients with mild pneumonia due to SARS-CoV-2**
M. Fezzi¹, G. Lapadula^{1,2}, L. Antolini¹, A. Soria², A. Rugova², M. Rossi², L. Bisi², F. Sabbatini², A. Cappelletti², S. Limonta², A. Ranzani², I. De Benedetto², N. Corti^{1,2}, P. Bonfanti^{1,2}
¹Università degli Studi di Milano Bicocca - Dipartimento di Medicina e Chirurgia, Monza, ²ASST Monza Ospedale San Gerardo, Monza





ORAL POSTER 11.10-12.00

ALABASTRO B

Treatment of naive PLWH: current strategies and rapid start of ART

Chairs: M. E. Quiros Roldan (Brescia), L. Sighinolfi (Ferrara)

OP 13 11.10-11.15 Reasons for choosing DRV/cob/FTC/TAF in ART-naïve and ART-experienced patients: data from the Icona Cohort

A. Tavelli¹, D. Tomasoni², N. Gianotti³, R. Gagliardini⁴, E. Bruzzesi³, P. Milini⁵, B. Menzaghi⁶, G. Lapadula⁷, P. Cinque⁸, L. Taramasso⁹, A. Antinori⁴, A. d'Arminio Monforte²

¹ICONA Foundation, Milan, Italy, ²Clinic of Infectious Diseases and Tropical Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ³Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, ⁵Infectious Diseases Unit, Macerata Hospital, Macerata, Italy, ⁶Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, ⁷Clinic of Infectious Diseases, San Gerardo Hospital - ASST Monza, University of Milano-Bicocca, Monza, Italy, ⁸Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, San Raffaele Vita-Salute University, Milan, Italy, ⁹Infectious Diseases Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy

OP 14 11.17-11.22 Blood telomere length in treatment-naïve HIV-infected adults starting dolutegravir plus lamivudine versus triple regimen with two nucleosides

F. Lombardi¹, A. Sanfilippo², M. Fabbiani³, A. Borghetti¹, A. Ciccullo⁴, S. Di Giambenedetto^{1,2}

¹Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, ²Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Roma Italia, ³UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italia, ⁴Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

OP 15 11.24-11.29 BIC/FTC/TAF in ART-naïve key populations: real-life data from the Icona cohort

A. Tavelli¹, G. Marchetti², A. Vergori³, E. Quiros-Roldan⁴, V. Malagnino⁵, F. Vichi⁶, M. Lichtner⁷, S. Nozza⁸, R. Rossotti⁹, L. Sarmati⁵, A. Antinori³, A. d'Arminio Monforte²

¹Icona Foundation, Milan, Italy, ²Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, University of Milan, Milan, Italy, ³Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ⁴Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, ⁵Unit of Clinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy, ⁶Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy, ⁷Infectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy, ⁸Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁹Department of Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

OP 16 11.31-11.36 A pilot study of the impact of a rapid ART initiation in advanced HIV disease

M. Camici, R. Gagliardini, S. Lanini, S. Ottou, A. Mondì, M.M. Plazzi, C. Pinnetti, A. Vergori, E. Grilli, F. De Zottis, I. Mastroi, V. Mazzotta, J. Paulicelli, R. Bellagamba, S. Cicalini, A. Antinori

HIV/AIDS Clinical Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

OP 17 11.38-11.43 Rapid ART initiation in a single-center Italian cohort: an observational analysis

R. Pincino^{1,3}, L. Taramasso², M. Berruti¹, G. Cenderello¹, M. Bassetti^{2,3}, A. Di Biagio^{2,3}

¹Infectious diseases unit, Borea Hospital, ASL-1 Imperiese, Sanremo, Italy, ²Infectious diseases unit, Policlinico San Martino Hospital, Genoa, Italy, ³Health and science department, Genoa University, Genoa, Italy

OP 18 11.45-11.50 Viro-immunological effectiveness of different integrase strand-transfer inhibitor-based antiretroviral therapy regimens. A single center retrospective study

M. Ceccarelli^{1,2,3}, D. Scuderi⁴, R. Bruno^{1,3}, G. Bruno⁵, A. Marino^{3,6}, V. Moscatt^{3,7}, Y. Rusotto⁷, C. Micali⁷, E. Venanzi Rullo⁷, G. Nunnari⁷, B. Santi Cacopardo¹, B.M. Celesia³

¹Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Catania, Catania, Italy, ²Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, Unit of Infectious Diseases, University of Messina, Messina, Italy, ³Unit of Infectious Diseases, ARNAS "Garibaldi", "Nesima" Hospital, Catania, Italy, ⁴Unit of Infectious Diseases, "Cannizzaro" Hospital, Catania, Italy, ⁵Department of Medical and Surgical Sciences, Unit of Infectious Diseases, "Magna Graecia" University of Catanzaro, Catanzaro, Italy, ⁶Department of Biomedical and Biotechnological Sciences, Unit of Infectious Diseases, University of Catania, Catania, Italy, ⁷Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, University of Messina, Messina, Italy





ORAL POSTER 11.10-12.00

PrEP: real life experience

BERGAMO SCIENCE CENTER

Chairs: F. Leserri (Roma), M. Marra (Roma)

- OP 19** 11.10-11.15 **PrEP in Italy: how many people access it and what kind of services are offered?**
M. Stizioli¹, G.M. Corbelli², M. Falaguasta¹, E. Nittolo¹
¹PrEP in Italia, ²Plus Roma
- OP 20** 11.17-11.22 **HIV Pre-Exposure Prophylaxis (PrEP): the experience of the outpatient clinic of Perugia**
G. Gamboni, C. Gabrielli, C. Papalini, C. Pallotto, G. De Socio, F. Paciosi, A. Zoffoli, S.Tordi, E. Schiaroli, D. Francisci
Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy
- OP 21** 11.24-11.29 **Impact of a pre-exposure prophylaxis program on HIV and other sexually transmitted infections over the last three years in a third level hospital: the experience from Padua**
F. Barbaro, S. Cavinato, M. Mazzitelli, L. Sasset, D. Leoni, A. Cattelan
Unità Operativa Complessa Malattie Infettive e Tropicali, Azienda Ospedale Università Padova, Padova, Italy
- OP 22** 11.31-11.36 **Pre-Exposure Prophylaxis (PrEP) Service in Bergamo: three-year experience**
S. Venturelli, F. Borghi, L. Baldassari, D. Ripamonti, F. Maggiolo, M. Rizzi
ASST Papa Giovanni XXIII, Bergamo
- OP 23** 11.38-11.43 **HIV Pre-exposure Prophylaxis in a Large Teaching Hospital in Milan: the CSL-PrEP Cohort experience**
A.R. Raccagni¹, R. Lolatto², L. Galli², F. Alberton¹, E. Bruzzesi¹, D. Canetti², M. Strano¹, M. Ripa², A. Castagna^{1,2}, S. Nozza²
¹Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit IRCCS San Raffaele, Milan, Italy
- OP 24** 11.45-11.50 **The Italian experience of Pre-Exposure Prophylaxis (PrEP) users and serum creatinine variation: a two centers retrospective analysis**
M. Menozzi¹, S. Volpi¹, G.J. Burastero¹, S. Colombaioni¹, B. Fontana¹, E. Martini¹, M. Martini Fasce², L. Labate², A. Di Biagio³, C. Mussini¹
¹Infectious Disease Clinic, University Hospital of Modena, Italy, ²Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS – Genoa, Italy, ³Department of Health Sciences (DISSAL), University of Genoa – Genoa, Italy



SYMPOSIUM 12.15-13.15

New Insights and Challenges on Hepatitis and HIV Co-infections

AUDITORIUM SALA OGGIONI

Chairs: N. Coppola (Napoli), V. Svicher (Roma)

This symposium is aimed at providing new insights on three topics in the field of hepatitis and HIV coinfections. In particular, the first lecture will provide a comprehensive overview on novel anti-HBV drugs, targeting different phases of HBV life cycle, that should go beyond the concept of virological suppression and aim at achieving HBV functional cure. Particular attention will be dedicated to the challenges that virologists and clinicians will have to cope to reach this important end-point. With a decade left to reach the ambitious WHO goals for viral hepatitis elimination, many challenges still remain concerning the need to scale-up HCV testing and expand access to HCV treatment particularly in marginalized populations at risk for HCV infection. The importance of these aspects in elimination efforts, with an emphasis on micro-elimination strategies, will be explored in the second lecture of the symposium. Finally, the third lecture will be dedicated to HIV+CMV coinfection, an intriguing and crucial aspect contributing to HIV pathogenesis. Indeed, persistent CMV replication or reactivation have been demonstrated to fuel HIV reservoir and to exacerbate the process of inflammaging and immune-senescence.

- 12.15-12.30 **Novel anti-HBV drugs on the horizon** A.M. Geretti, Roma
- 12.30-12.45 **The road towards HCV elimination: is the WHO target achievable in time?** M. Puoti, Milano
- 12.45-13.00 **What's new on HIV & CMV coinfection?** M. Lichtner, Latina
- 13.00-13.15 **Discussion on Symposium issues**




EXPERT MEETING 12.15-13.15

SALA STUCCHI
Narrative Medicine applied to Vaccination during Covid-19 pandemic

Moderator: S. Vella (Roma)

Con il supporto di Janssen-Cilag

Discussants: M.G. Marini (Milano), F. Moccia (Roma), E. Volpato (Milano)

Considering SARS-CoV-2 rapid spread and mortality rate, effective vaccines are needed to control the pandemic. Population is called to make a choice: to accept or refuse vaccination. Data of vaccination clinical trials have shown good results both in efficacy and safety, however long-term data are still to come; meanwhile the virus mutates, and the polarization between the Pro Vax and the No Vax groups, with a number in between identified as the Hesitancy group, is growing, despite the majority of people are Pro Vax. The aim of the Expert Meeting is to debate on different perceptions of people around vaccines and understand propensity to remain vaccinated against infectious diseases, taking advantage of the results of a research based on Narrative Medicine applied to COVID-19 vaccination.


SPONSORED SYMPOSIUM 12.15-13.15

ALABASTRO A + ALABASTRO B
Cabotegravir + rilpivirine long-acting: are we ready for the new era?

Chairs: S. Bonora (Torino), G. Rizzardini (Milano)

Con il supporto di ViiV Healthcare

Advances in the efficacy of antiretroviral therapy led to a shift in treatment focus to emphasize convenience, tolerability, and overall acceptability of HIV therapy. This has culminated in the development of efficacious single-tablet daily oral regimens, which offer simplicity and convenience. Despite this, the need for life-long daily pill-taking can present substantial challenges that can be broadly grouped into three categories: adherence issues, emotional issues (including stigmatization concerns and the daily reminder of HIV status) and medical issues, such as difficulty swallowing, drug-food and drug-drug interactions, and pill burden. Innovations and treatment options that can fill the unmet needs of people living with HIV, such as long-acting non-oral regimens, could support patients to overcome treatment barriers and improve their quality of life. Objective of this symposium is to discuss the clinical trials data about Cabotegravir + Rilpivirine long-acting regimen, both in terms of efficacy and safety as well as Patient Reported Outcomes and treatment preference reported by patients.

 12.15-12.35 **Cabotegravir + rilpivirine long-acting therapy: what the data tell us**

S. Nozza, Milano

 12.35-12.55 **Patient reporting outcomes and treatment preferences**

A. Cingolani, Roma

 12.55-13.15 **Questions & answers**

ORAL POSTER 12.15-13.05

BERGAMO SCIENCE CENTER
Access test and educational aspects

Chairs: A. Bianchi (Milano), G. D'Offizi (Roma)

OP 25 12.15-12.20 **HIV testing in community-based centers and MSM premises: different settings, same needs**

 A. Bianchi^{1,2}, D. Zagato¹, D. Calzavara², R. Repossi^{1,2}, P. Testoni^{1,2}, A. Antonino^{1,2}, G. Fracca¹, F. Rossi^{1,2}, A.J. Gallucci^{2,3}, I. Gott^{2,4}, N. Frattini^{1,2}, R. Rossotti^{2,6}, G. Pigliapochi², P. Russo^{2,3}, M. Albiani², M. Cernuschi^{1,2,5}
¹ASA Associazione Solidarietà AIDS Onlus, Milan, Italy, ²Milano CheckPoint, Milan, Italy, ³CIG Arcigay Milano, Milan, Italy, ⁴Anlaidi Sez. Lombarda, Milan, Italy, ⁵San Raffaele Hospital, Milan, Italy, ⁶ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

OP 26 12.22-12.27 **HIV testing: are we missing some opportunities?**

M. Mazzitelli, L. Sasset, D. Leoni, F. Barbaro, A.M. Cattelan

Infectious and Tropical Diseases Unit, Azienda Ospedale Università Padova, Italy

OP 27 12.29-12.34 **Population of the Bergamo Check-Point. A first analysis of Cobatest data**

 I. Mercurio¹, C. Pellegris², P. Meli², E. Zanetti², F. Maggiolo³, F. Radici⁴, R. Carissoli⁴
¹Croce Rossa Italiana – Comitato di Bergamo, ²Società Cooperativa Sociale Don Giuseppe Monticelli, ³ASST Papa Giovanni XXIII, ⁴Arcigay Bergamo Cives

OP 28 12.36-12.41 **Veneto Region "RECALL" project to discover HCV+people: the experience of the "Osservatorio Infettivologico" in Verona**

V. Del Punta, M. Fiscon, G. Giammarresi, S. Nardi, M. Malena

UOS Osservatorio Infettivologico Aziendale Azienda ULSS 9 Scaligera





OP 29 12.43-12.48 **Prejudice and perceived HIV risk among High School Students**

C. Pellegris¹, I. Mercurio¹, P. Meli¹, E. Zanetti¹, F. Maggiolo², I. Fontana³

¹Società Cooperativa Sociale Don Giuseppe Monticelli, ²ASST Papa Giovanni XXIII, ³Ufficio Scolastico Territoriale Bergamo

OP 30 12.50-12.55 **Pilot experience of comprehensive sexuality education among Italian adolescents: preliminary results from the EduForIST project, April 2022**

A. Chinelli¹, D. Martinelli², L. Ceccarelli¹, E. Torri¹, R. Galipò³, P. Meli⁴, A. Camposeragna⁵, L. Rancilio⁶, M. Farinella⁷, L. Colaprico⁸, M. Oldrini⁹, M.C. Salfa¹⁰, A. Cellini¹¹, M. Ubbiali¹², A. Caraglia¹³, L. Mortari¹², A.T. Palamara¹¹, B. Suligo¹⁰, L. Tavoschi¹

¹University of Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, ²University of Foggia, Department of Medical and Surgical Sciences, ³ANLAIDS - National Association for the Fight against AIDS, Rome, ⁴CICA - Italian Coordination of HIV/AIDS Housing Homes, Bergamo, ⁵CNCA - National Coordination of the Hospitality Community, Rome, ⁶Caritas Ambrosiana, Milan, ⁷Circolo di cultura omosessuale Mario Mieli, Rome, ⁸Italian Red Cross, Rome, ⁹LILA - Italian league for the fight against AIDS, Rome, ¹⁰Italian National Institute of Health, Rome, ¹¹Sapienza University of Rome, ¹²University of Verona, Department of Human Sciences, ¹³Ministry of Health, Department of Prevention, Rome



SPECIAL SESSION 13.15-14.30

How to use U=U to fight stigma

SALA STUCCHI

Chairs: G.V. Calvino (Roma), A. Moznich (Milano)

Undetectable=Untransmittable (U=U) concept represents a revolution for people living with HIV. It means the end of fear of transmitting the infection, even through unprotected sex. The end of stigma. In Italy, the Consensus Conference (published by sections L and M of Ministry of Health's CTS - Technical Scientific Committee) formulated U=U concept in an extensive, clear, doubt free approach. This evidence has neither been acquired by many doctors, nor explained to many people living with HIV. There is no communication campaign directed to the general population. In this session we share different experiences, showing how U=U positively improved the social life of people living with HIV, and how on the other hand the absence of adequate information directed to the general population and institutions, contributes to maintain heavy stigma against HIV.



ORAL COMMUNICATIONS 13.15-14.15

Metabolic issues in effective HAART

ALABASTRO A

Chairs: E. Focà (Brescia), C. Gervasoni (Milano)

OC 9 13.15-13.25 **Role of Emtricitabine/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: data from Surveillance Cohort Longterm Toxicity Antiretrovirals/antivirals (SCOLTA) project**

N. Squillace¹, E. Ricci², B. Menzaghi³, G.V. De Socio⁴, G. Orofino⁵, B.M. Celesia⁶, F. Vichi⁷, A. Di Biagio⁸, L. Taramasso⁸, C. Molteni⁹, E. Sarchi¹⁰, L. Valsecchi¹¹, G.F. Pellicanò¹², P. Bonfanti¹, for the CISAI Study Group

¹Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, ²Fondazione ASIA Onlus, Buccinasco (MI), Italy, ³Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Varese, ⁴Unit of Infectious Diseases, Santa Maria Hospital, Perugia, ⁵Division I of Infectious and Tropical Diseases, ASL Città di Torino, ⁶Unit of Infectious Diseases, Garibaldi Hospital, Catania, ⁷Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, ⁸Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, ⁹Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, ¹⁰Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ¹¹1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy, ¹²Infectious Diseases, G. Martino Hospital -University of Messina, Messina

OC 10 13.27-13.37 **Machine learning algorithm to predict weight change in ART experienced PWH**

F. Motta¹, J. Milic¹, S. Barbieri¹, L. Gozzi², E. Aprile², M. Belli², M. Venuta², G. Cuomo², F. Carli², G. Dolci², V. Iadisernia², G. Bura-stero², C. Mussini^{1,2}, F. Mandreoli³, G. Guaraldi^{1,2}

¹Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy, ³Department of Physics, Informatics and Mathematics, University of Modena and Reggio Emilia, Modena, Italy

OC 11 13.39-13.49 **In vitro model of adipocyte differentiation under TAF, TDF and INSTIs selective challenge**

M.A. Carleo¹, A. Perna², A. Guida¹, P. Rosario¹, S. Mascolo¹, A. Lucariello³, G. Palmiero¹, V. Rizzo¹, A. M. Rossomando¹, A. Baldi⁴, A. De Luca⁵, P. Maggi⁶, V. Esposito¹

¹Infectious Diseases and Gender Medicine Unit "D. Cotugno" Hospital - AO dei Colli, Naples Italy, ²Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy, ³Department of Sport Sciences and Wellness, University of Naples "Parthenope", Naples, Italy, ⁴Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "L. Vanvitelli", Caserta, Italy, ⁵Department of Mental and Physical Health and Preventive Medicine, Section of Human Anatomy, University of Campania "Luigi Vanvitelli", Naples, Italy, ⁶University of Campania "Luigi Vanvitelli", Caserta Italy



OC 12 13.51-14.01 Liver enzymes levels, metabolic and renal profile modifications after switching from TDF to TAF-based regimens among ART experienced PLWH in ICONA cohort

M. Poliseno¹, S. Lo Caputo¹, A. Tavelli², R. Gagliardini³, L. Gazzola², A. Saracino⁴, T.A. Santantonio¹, M. Puoti⁵, S. Cicalini³, A. Antinori³, A. d'Arminio Monforte², A. Cozzi-Lepri⁶

¹Unit of Infectious Diseases, University of Foggia, Foggia, Italy, ²Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, ³National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy, ⁴Operative Unit of Infectious Diseases, Hospital-University Polyclinic of Bari, Bari, Italy, ⁵Infectious Diseases Unit, Niguarda Hospital, Milan, Italy, ⁶Institute for Global Health UCL, University College London, London, UK



ORAL POSTER 13.25-14.15

ALABASTRO B

Predictors of COVID-19 severity

Chairs: G. Lapadula (Monza), P. Nasta (Brescia)

OP 31 13.25-13.30 Hospitalization for COVID-19 or with SARS-CoV-2 infection during two different epidemic periods in Milan, Italy: data from Luigi Sacco Hospital registry

A. Giacomelli¹, A.L. Ridolfo¹, L. Pezzati^{1,2}, M. Piscaglia^{1,2}, S. Caronni^{1,2}, F. Sabaini^{1,2}, L. Oreni¹, F. Borgonovo^{1,2}, M. Matone^{1,2}, M. Galimberti^{1,2}, M. Zacheo^{1,2}, A. Civati^{1,2}, A. Behring^{1,2}, M. Schiavini¹, G. Rizzardini¹, S. Antinori^{1,2}

¹Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy, ²Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, Università degli Studi di Milano, Milan, Italy

OP 32 13.32-13.37 Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19 - an observational retrospective study

R. Palladino, A. Russo, M. Pisaturo, P. Maggi, F.G. Numis, I. Gentile, V. Sangiovanni, V. Esposito, R. Punzi, G. Calabria, C. Rescigno, A. Salomone Megna, A. Masullo, E. Manzillo, G. Russo, R. Parrella, G. Dell'Aquila, M. Gambardella, A. Ponticello, N. Coppola on behalf of CoviCam group

Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, Infectious disease unit; University Federico II, Naples, Italy, Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, Infectious Diseases Unit, AO Avellino, Italy, Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, Pneumology Unit, AORN Caserta, Italy

OP 33 13.39-13.44 Early predictors of clinical deterioration in a cohort of outpatients with COVID-19 in Southern Italy: a multicenter observational study

C. Monari¹, M. Pisaturo¹, P. Maggi², M. Macera², G. Di Caprio², R. Pisapia³, V. Gentile¹, M. Fordellone⁴, P. Chiodini⁴, N. Coppola¹ on behalf of CoviCam group

¹Department of Mental Health and Public Medicine - Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Napoli, Italy, ²Infectious Disease Unit, AORN Caserta, ³Infectious Diseases Unit, AORN dei Colli, Naples, ⁴Medical Statistics Unit, University of Campania Luigi Vanvitelli, Naples, Italy

OP 34 13.46-13.51 Risk factors for in-hospital mortality in COVID-19 patients with end stage renal diseases requiring maintenance hemodialysis

A. Cingolani¹, M. Ambrogio², G. Micheli¹, G. De Luca², M. Chiuchiarelli¹, A. Spasiano², P. L. Salvo¹, E. Rosati², S.L. Cutuli³, E. Rando¹, G. De Pascale³ and Nicola Panocchia² for COVIDialysis-FPG Working Group: M. Ambrogio, G. De Luca, A. Spasiano, E. Rosati, N. Panocchia, R. Baccaro, M. Liberatori, A. Naticchia, F. D'Ascenzo, G. Grandaliano, G. Scoppettuolo, F. Damiano, P. Del Giacomo, F. Raffaelli, R. Losito, G. Maiuro, I. IZZI, A. Dusina, R. Passerotto, F. Iamanna, S. Guerriero, B. Liguoro, F. Salvati, V. Iannone, R. Cauda

¹Infectious Diseases, ²Nefrology, ³Intensive Care Unit, Fondazione Policlinico A. Gemelli, IRCCS, Roma

OP 35 13.53-13.58 Clinical characteristics and outcomes of COVID-19 hospitalized patients in the current pandemic phase

E.P. Drago¹, M. Poliseno¹, M.A. Poli³, M. Altamura², S.R. Bruno², A. Calamo², A. Giannelli², G. Infante², M. Mazzola², S.B. Morella², D. Moschetta², M. Tarallo², S. Lo Caputo¹, T.A. Santantonio¹, S. Carbonara²

¹Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Foggia, ²Infectious Disease Unit, Vittorio Emanuele II Hospital, Bisceglie, Barletta-Andria-Trani, ³Dermatology Unit, Department Internal Medicine, University of Bari





OP 36 14.00-14.05 Laboratory and clinical biomarkers helps to predict severity of CT score in COVID19 patients: an observational study

I. de Luca¹, A. Russo¹, F. Schettino², M.A. Pisaturo¹, P. Maggi¹, F.G. Numis³, I. Gentile⁴, V. Sangiovanni⁵, V. Esposito⁶, R. Punzi⁷, G. Calabria⁸, C. Rescigno⁹, A. Salomone Megna¹⁰, A. Masullo¹¹, E. Manzillo¹², G. Russo¹³, R. Parrella¹⁴, G. Dell'Aquila¹⁵, M. Gambardella¹⁶, A. Ponticello¹⁷, A. Reginelli², N. Coppola¹ on behalf of CoviCam group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ²Radiology Unit, Department of Precision Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ³Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, ⁴Infectious Disease Unit; University Federico II, Naples, Italy, ⁵Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁶IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁷Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁸IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁹First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁰Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, ¹¹Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, ¹²VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹³Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, ¹⁴Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁵Infectious Diseases Unit, AO Avellino, Italy, ¹⁶Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, ¹⁷Pneumology Unit, AORN Caserta, Italy



ORAL POSTER 13.25-14.15

BERGAMO SCIENCE CENTER

HCV eradication: general and key populations

Chairs: P. Colletti (Marsala), M. Cusini (Milano)

OP 37 13.25-13.30 Long-term outcomes in GT3 HCV/HIV co-infected subjects treated with DAAs: impact on metabolic profile

A. Siribelli¹, D. Ceccarelli², E. Messina², C. Bertoni¹, R. Lolatto², G. Morsica², C. Uberti-Foppa^{1,2}, A. Castagna^{1,2}, H. Hasson²

¹Vita-Salute University, Milan, Italy, ²Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

OP 38 13.32-13.37 Chronic Hepatitis C cascade of care in Prisoners. Is there still some work to be done? Analysis of two penitentiaries in northern Italy

A. Cambianica¹, V. Marchese¹, F. Pennati¹, A. Faustinelli¹, M. Tonni², F. Roda², A. Spinetti¹, S. Zaltron¹, S. Fiorentini³, E. Quiros-Roldan¹, F. Castelli¹, E. Focà¹

¹Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²Unit of Prison Health ASST Spedali Civili Hospital, Brescia, Italy, ³Unit Of Microbiology and Virology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

OP 39 13.39-13.44 HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy

M. Beltrami^{1,2}, G. Pagani³, F. Conti^{1,2}, L. Pezzati^{1,2}, G. Casalini^{1,2}, R. Rondanin⁴, A. Prina⁴, A. Zagari⁵, M. Galli^{1,2}, A. Giacomelli¹

¹Malattie Infettive III Divisione, ASST FBF-Sacco, Milan, Italy, ²Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Università degli Studi di Milano, Milan, Italy, ³Malattie Infettive, Ospedale Nuovo di Legnano, ASST Ovest Milanese, Legnano, Italy, ⁴Medispa S.r.l., Milan, Italy, ⁵Direzione Socio-Sanitaria, ASST FBF-Sacco, Milan, Italy

OP 40 13.46-13.51 Hepatitis C virus (HCV) micro-elimination in the hospital setting: the results of the HCV Caserta hospital project

V. Messina¹, M. Pisaturo², L. Alessio², A. Russo², E. Tripaldelli³, A. Petruzzello³, A. Annechiaro⁴, M.R. Romano⁵, P. Maggi^{1,2}, N. Coppola²

¹Infectious Disease Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ²Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, ³Clinical Pathology, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁴Direzione Sanitaria, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁵Regione Campania, Naples, Italy

OP 41 13.53-13.58 Patients' reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care and treatment

L. Ceccarelli^{1,2}, G. Moretti², I. Corazza², L. Tavoschi¹, M. Vainieri²

¹Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, ²Management and Healthcare Laboratory, Sant'Anna School of Advanced Studies, Pisa, Italy

OP 42 14.00-14.05 Characterisation of viral infections in a cohort of migrants living in southern Italy

S. Capuano^{1,9}, M. Pisaturo^{1,7}, A. Loredana^{1,7}, L. Occhiello¹, M. Macera^{1,4}, M. Starace¹, E. Cordua¹, L. Onorato¹, G. Scotto⁸, G. Di Caprio^{3,7}, F. Calò^{1,6}, C. Sagnelli^{1,5}, N. Coppola¹

¹Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, ²L. Vanvitelli University Hospital, Naples, ³UOC of Infectious Diseases, AORN Sant'Anna and San Sebastiano, Caserta, ⁴Abraham Tent; Reception Center, Caserta, ⁵Missionary Sisters of Charity Center, Naples, ⁶Center for the Protection of Immigrant Health, Naples, ⁷Social center "ex-canapificio", Caserta, ⁸UOC of Infectious Diseases, Foggia, ⁹Social center "ex-opg Je so Pazz", Napoli





SPONSORED SYMPOSIUM 14.30-15.30

AUDITORIUM SALA OGGIONI

Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF

Chair: A. Castagna (Milano)

Simposio promozionale di Gilead Sciences

Despite all the advances in therapeutic strategies, HIV remains a complex disease that has a significant impact on the lives of PLWH. To address this complexity, Gilead emphasizes the importance of Long-Term Treatment Success (LTTS). The LTTS has the patient's long-term therapeutic success as its objective. This is achieved not only with the classic parameters of effectiveness and safety but also with a whole series of other aspects that impact the quality of life of the patient living with HIV. Long Term Treatment Success should be the goal for every clinician when facing PLWH. Every person living with HIV must be able to live their lives in the best possible way. The Symposium will analyze how B/F/TAF ensures Long Term Treatment Success both through 5-year follow-up data from clinical trials and with numerous Real World Evidence data from various Italian centers that will be discussed in a roundtable.

14.30-14.45 **Long term treatment success in the clinical trials: 5 years data with B/F/TAF** S. Lo Caputo, Foggia

14.45-15.25 **Experiences from Italian cohorts: Round Table** Conductor: G. Madeddu, Sassari

Discussants: S. Cicalini, Roma; G. d'Etorre, Roma; V. Esposito, Napoli; L. Gazzola, Milano; N. Gianotti, Milano

15.25-15.30 **Discussion on Symposium issues**



ORAL COMMUNICATIONS 14.30-15.30

SALA STUCCHI

COVID-19: clinical management

Chairs: M. Bassetti (Genova), R. Cauda (Roma)

OC 13 14.30-14.40 Home prescription treatment and mortality risk after hospitalization with symptomatic COVID-19 disease

A. Dessilani, A. Cozzi-Lepri, E. Franceschini, G. Guaraldi, V. Borghi, M. D. Di Trapani, M. Del Monte, F. Medioli, I. Baldisserotto, S. Esperti, A. Mazzocchi, J. Conti, A. Gallerani, N. Barp, A. Spadoni, V. Menozzi, C. Mussini
Struttura Complessa di Malattie Infettive, AOU Policlinico di Modena, Modena

OC 14 14.42-14.52 In vivo efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages

V. Mazzotta^{1,2}, A. Cozzi Lepri³, F. Colavita¹, S. Lanini¹, R. Rosati¹, E. Lalle¹, C. Cimaglia¹, I. Mastrosera¹, J. Paulicelli¹, S. Vita¹, E. Caraffa¹, G. Matusali¹, A. Vergori¹, G. Giannico¹, G. Maffongelli¹, E. Milozzi¹, D. Donno¹, P. Vittozzi¹, F. De Zottis¹, P. Piselli¹, E. Girardi¹, A.R. Garbuglia¹, F. Vaia¹, E. Nicastri¹, A. Antinori¹

¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, Rome, Italy, ³Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

OC 15 14.54-15.04 Anemia is strongly associated with severity and mortality of COVID-19 in hospitalized patients

F. Di Gennaro, G. Brindicci, M. Cormio, V. Guerra, A. Lugli, L. De Santis, A. Procopio, D.F. Bavaro, E. Milano, N. De Gennaro, G. De Iaco, R. Lattanzio, C.R. Santoro, A. Saracino
Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari Italy

OC 16 15.06-15.16 Clinical characteristics and outcomes of COVID-19 in vaccinated versus not-vaccinated hospitalized patients: data from an Italian reference hospital

A. Mondì, I. Mastrosera, A. Navarra, S. Lanini, A. D'Annunzio, F. Vaia, E. Girardi, A. Antinori
National Institute for Infectious Diseases L. Spallanzani IRCCS, Rome, Italy





EXPERT MEETING 14.30-15.30

ALABASTRO A

The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations

Chair: C.M. Mastroianni (Roma)

Con il supporto di GSK

There is a substantial unmet medical need associated with herpes zoster (HZ) and its complications, particularly in older adults and those who are immunocompromised (IC). Current disease management of HZ is not optimal. Early treatment with antiviral drugs, initiated within 72 hours of rash onset, decreases the incidence of new lesion formation, accelerates healing and the resolution of acute pain. Populations at increased risk for developing HZ are those having a decline in immune function, including older adults or individuals who are IC. Individuals who are IC due to haematological malignancies (HM) and solid tumours, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), treatments such as chemo- or radiotherapy, haematopoietic stem cell transplantation (HSCT), immune suppression following organ transplantation or therapy with high doses of corticosteroids are also at increased risk of developing HZ. Individuals who are IC also have an increased risk of disseminated disease. The Recombinant Zoster Vaccine (RZV) is available in Italy since 2021. RZV has been shown to be highly effective at preventing shingles and post-herpetic neuralgia in adults older than 50 years. The vaccine is also effective at protecting adults older than 18 years who are at increased risk of herpes zoster. In the "Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations" document, published in 2021, SIMIT recommended RZV for the prevention of HZ and PHN in older adults (>65 yo) and for several categories of at higher risk subjects including HIV+ patients.

- 14.30-14.45 **Scientific and clinical profile of the new recombinant adjuvanted vaccine against HZ** G. Gabutti, Lavagna (GE)
- 14.45-15.00 **The prevention of HZ in at higher risk subjects: the Recommendations of the Italian Society for Infectious and Tropical Diseases (SIMIT)** M. Andreoni, Roma
- 15.00-15.15 **Vaccination against HZ directly offered in the Infectious Diseases center: the «Milan» experience** G. Rizzardini, Milano
- 15.15-15.30 **Discussion on Expert Meeting issues**



ORAL POSTER 14.30-15.20

ALABASTRO B

Viro-immunological correlates of COVID-19 severity

Chairs: I. Bon (Bologna), I. Vicenti (Siena)

- OP 43** 14.30-14.35 **PTX3 is a strong predictor of death among patients with COVID-19**
G. Lapadula^{1,2}, R. Leone³, D.P. Bernasconi⁴, A. Biondi^{1,5}, E. Rossi⁴, M. D'Angiò⁵, B. Bottazzi³, L.R. Bettini⁵, I. Beretta², C. Garlanda^{3,6}, M.G. Valsecchi⁴, A. Mantovani^{3,6,7}, P. Bonfanti^{1,2} for the COVID-19 STORM Study Group
¹University of Milano-Bicocca, Milan, Italy, ²Department of Infectious Diseases, San Gerardo Hospital, Monza, Italy, ³Humanitas Clinical and Research Institute – IRCCS, Rozzano (MI), Italy, ⁴Bicocca Bioinformatics Biostatistics and Bioimaging Center - B4, University of Milano-Bicocca, Milan, Italy, ⁵Department of Pediatrics, European Reference Network (ERN) PaedCan, EuroBloodNet, MetabERN, Fondazione MBBM/Ospedale San Gerardo, Monza, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy, ⁷William Harvey Research Institute, Queen Mary University, London, UK
- OP 44** 14.37-14.42 **The role of antigen load on viral clearance and severity in SARS-CoV-2 infection**
T. Clemente^{1,2}, P.E. Rovatti³, M. Punta^{3,4}, C. Muccini^{1,2}, L. Galli², C. Toffalori³, R. Papaioannu Borjesson^{1,2}, M. Bottanelli^{1,2}, C. Tresoldi⁵, F. Ciceri^{1,5,6}, A. Castagna^{1,2}, L. Vago^{3,6}, V. Spagnuolo², on the behalf of COVID-BioB Study Group
¹School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy, ³Unit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy, ⁴Center for Omics Sciences, San Raffaele Scientific Institute, Milan, Italy, ⁵Immuno-hematology and Transfusion Medicine Unit, San Raffaele Scientific Institute, Milan, Italy, ⁶Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy
- OP 45** 14.44-14.49 **Dysregulation in IFN-omega levels and anti-IFN-omega neutralizing antibodies correlate with biochemical and hematological parameters predictive of disease severity in COVID-19 male patients**
F. Frasca¹, M. Scordio¹, L. Sorrentino¹, M. Fracella¹, L. Santinelli², E. N. Cavallari², C. Bitossi¹, A. Viscido¹, G. Ceccarelli², A. Pierangelini¹, O. Turriziani¹, C. M. Mastroianni², G. Antonelli¹, G. d'Ettore², C. Scagnolari¹
¹Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Italy, ²Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Italy



- OP 46** 14.51-14.56 **Characterization of IFN response in PBMC from children and adolescent after SARS-CoV-2 infection**
L. Sorrentino¹, M.G. Conti², G. Oliveto¹, F. Frasca¹, M. Fracella, M. Scordio¹, A. D'Auria, M. Ardone¹, M. Di Lieto¹, L. Petrarca², R. Nenna², C. Scagnolari¹, G. Antonelli¹, F. Midulla², A. Pierangeli¹
¹Virology laboratory, molecular medicine department, Sapienza University, Rome, ²Maternal-Infantile and Urological Science Department, Sapienza University, Rome
- OP 47** 14.58-15.03 **Immunological profiles of SARS-CoV-2 infection: the link between cytokine storm, clinical severity and post-COVID syndrome**
A. Parente², M. Iuliano¹, R. Mongiovi¹, B. Kertusha², A. Carraro², R. Marocco², G. Mancarella², C. Del Borgo², T. Tieghi², L. Fondaco², G. Mangino¹, G. Romeo¹, M. Lichtner²
¹Dept. of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy, ²Dept. of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy
- OP 48** 15.05-15.10 **Respiratory and peripheral IFN response and frequency of T cell activation in COVID-19 patients**
L. Santinelli¹, L. Maddaloni¹, F. Frasca², M. Scordio², C.M. Lofaro¹, L. Sorrentino², M. Fracella², E.N. Cavallari¹, G. Ceccarelli¹, A. Pierangeli², C.M. Mastroianni¹, G. Antonelli^{2,3}, C. Scagnolari², G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, ³Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy



ORAL POSTER 14.30-15.20

BERGAMO SCIENCE CENTER

Issues on mental health, sexual health and STIs

Chairs: R. Galipò (Roma), D. Ripamonti (Bergamo)

- OP 49** 14.30-14.35 **Predictors of mental and sexual health after COVID-19 Pandemic in a group of MSM living with HIV**
F.M. Nimbi¹, G.M. Corbelli², G. Giovanardi¹, A. Tanzilli¹, V. Lingardi¹
¹Dept. Dynamic, Clinical and Health Psychology, Sapienza University of Rome, ²Plus Roma – APS, Rome
- OP 50** 14.37-14.42 **Single nucleotide polymorphisms affecting neuroinflammation biomarkers in different clinical groups of HIV-affected patients**
J. Cusato¹, M. Antonucci¹, A. Palermi¹, A. Manca¹, J. Mula¹, V. Avataneo¹, M. Trunfio², G. Di Perri², A. D'Avolio¹, A. Calcagno²
¹Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy
- OP 51** 14.44-14.49 **Treatment response in syphilis reinfection among People living with HIV: high baseline titer and delayed assessment affects the risk of serological-non-response**
G. Tiecco, V. Marchese, S. Storti, M. Degli Antoni, M. Gulletta, F. Viola, E. Focà, F. Castelli, E. Quiros-Roldan
 Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- OP 52** 14.51-14.56 **Increasing incidence of Mycoplasma genitalium infection in PLWHIV and PrEP users**
R. Rossotti¹, A. Nava², C. Baiguera¹, F. D'Amico¹, E. Inglese², C. Rogati¹, D. Fanti¹, N.B. Bana¹, C. Vismara², M. Puoti¹
¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- OP 53** 14.58-15.03 **Alteration of IFN pathways in anal cells from HIV-1/HPV co-infected men**
M. Fracella¹, M. Scordio¹, L. Sorrentino¹, F. Frasca¹, G. Oliveto¹, A. Viscido¹, L. Santinelli², E.N. Cavallari², G. D'Ettore², P. Gozzo², G. Antonelli¹, C. Scagnolari¹, A. Pierangeli¹
¹Department of Molecular Medicine, Virology Laboratory, Sapienza University of Rome, Rome, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome
- OP 54** 15.05-15.10 **Efficacy of late HPV vaccination in young HIV+ MSM**
E. Cavallari¹, L. Santinelli¹, L. Maddaloni¹, M. Ridolfi¹, M. Scordio², A. Pierangeli², G. Ceccarelli¹, C.M. Mastroianni¹, G. d'Ettore¹
¹Department of Public Health and Infectious Diseases "Sapienza" University of Rome, Rome, ²Department of Molecular Medicine "Sapienza" University of Rome, Rome





SYMPOSIUM 15.35-16.35

At the edge of PrEP

AUDITORIUM SALA OGGIONI

Chairs: D. Calzavara (Milano), S. Mattioli (Bologna)

The efficacy of PrEP as an HIV prevention tool is universally recognized. However, most literature data demonstrating PrEP efficacy and effectiveness come from studies on MSM. Some aspects of PrEP still need to be defined in order to understand its effectiveness and maximize its implementation. In this symposium we want to explore some aspects that still represent gray areas with regard to PrEP, in particular the effectiveness and efficacy in populations less represented in clinical trials, such as women, transgender population, IVDU population, etc., with an eye both to real world experiences in these populations and to regulatory aspects of use, or how PrEP can fit within protocols of vaccine prevention.

- | | | |
|-------------|---|------------------------|
| 15.35-15.45 | Populations not represented in clinical trials: regulatory aspects | W. Nutland, London UK |
| 15.45-15.55 | Populations not represented in clinical trials: experiences on the field | M. Appenroth, Berlin D |
| 15.55-16.10 | Ethicality of PrEP in vaccine protocols and beyond | G.M. Corbelli, Bologna |
| 16.10-16.25 | Cost-efficacy of PrEP | E. Girardi, Roma |
| 16.25-16.35 | Discussion on Symposium issues | |



ORAL COMMUNICATIONS 15.35-16.35

Pathogenesis and Immunology

SALA STUCCHI

Chairs: C. Agrati (Roma), G. Marchetti (Milano)

- OC 17 15.35-15.45 Impact of SARS-CoV-2 infection in a relevant three-dimensional human bronchial cell culture model of Cystic Fibrosis**
L. Pagani¹, L. J.V. Galiotta², N. Pedemonte³, V. Capurro³, A. Venturini², C. Cigana⁴, B. A. Franco⁴, A. Bragonzi⁴, E. Vicenzi¹
¹Viral Pathogenesis and Biosafety Unit, IRCCS-Ospedale San Raffaele, Milan, Italy, ²Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, NA, Italy, ³UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁴Infections and Cystic Fibrosis Unit, IRCCS-Ospedale San Raffaele, Milan, Italy
- OC 18 15.47-15.57 Oral immunity characterization in saliva from asymptomatic and severe COVID19 patients**
L. Saulle^{1,2}, M. Garziano^{1,2}, O. Utyro², S. Lo Caputo³, M. Polisenò³, T.A. Santantonio³, M. Clerici^{1,4}, M. Biasin²
¹Laboratory of Immunology, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ²Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ³Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, ⁴Don C. Gnocchi Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy
- OC 19 15.59-16.09 Therapeutic monoclonal antibody treatment restores immune homeostasis and did not prevent the expansion of anti-SARS-CoV-2 adaptive immune response in mild/moderate COVID-19 patients**
R. Casetti¹, A. Sacchi¹, V. Mazzotta², F. Cristofanelli¹, E. Cimini¹, S. Notari¹, G. Grassi¹, V. Bordoni¹, I. Mastroiosa², M.L. Giancola², A. Vergori², M. Tempestilli¹, S. Vita², M. Rubino¹, D. Mariotti¹, S. Gili¹, E. Lalle³, S. Meschi³, F. Colavita³, A.R. Garbuglia³, E. Girardi⁴, E. Nicastri², A. Antinori², C. Agrati¹
¹Cellular Immunology and Pharmacology Laboratory, INMI L Spallanzani, Rome, Italy, ²Clinical Department, INMI L Spallanzani, Rome, Italy, ³Virology Laboratory, INMI L Spallanzani, Rome, Italy, ⁴Scientific Directorate, INMI L Spallanzani, Rome, Italy
- OC 20 16.11-16.21 Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage**
S. D'Anna¹, L. Carioti¹, L. Piermatteo¹, A. Battisti^{1,2}, L. Benedetti¹, F. Ceccherini-Silberstein¹, U.S. Gill², P.T.F. Kennedy², V. Svicher¹, R. Salpini¹
¹University of Rome Tor Vergata, Department of Experimental Medicine, Rome, ²Barts Liver Centre, Blizard Institute, Barts and The London SMD, QMUL, London




INTERACTIVE EXPERT MEETING 15.35-16.35

ALABASTRO A
Affairs of the heart in HIV: redundant or a key challenge?

Moderator: C. Gervasoni (Milano)

Con la sponsorizzazione non condizionante di MSD Italia

Discussants: A. Cattelan (Padova), R. Gagliardini (Roma), A. Saracino (Bari)

PLWH may be predisposed to higher risk of Cardiometabolic Disorders such as dyslipidemia, cardiovascular disease and diabetes. In fact, metabolic syndrome affects up to 52% of PLWH. In this interactive round table, innovative individualized treatment strategies for the management of PLWH at risk or with cardiometabolic disorders will be discussed.


ORAL POSTER 15.35-16.25

ALABASTRO B
Neuropsychological complications in COVID-19

Chairs: V. Spagnuolo (Milano), A. Vergori (Roma)

OP 55 15.35-15.40 Dementia and COVID-19 outcomes: findings from a multicentric study in Campania region

R. Astorri¹, M. Pisaturo¹, A. Russo¹, P. Maggi², F.G. Numis³, I. Gentile⁴, V. Sangiovanni⁵, V. Esposito⁶, R. Punzi⁷, G. Calabria⁸, C. Rescigno⁹, A. Salomone Megna¹⁰, A. Masullo¹¹, E. Manzillo¹², G. Russo¹³, R. Parrella¹⁴, G. Dell'Aquila¹⁵, M. Gambardella¹⁶, A. Ponticello¹⁷, N. Coppola¹ on behalf of CoviCam group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ²Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, ³Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, ⁴Infectious disease unit; University Federico II, Naples, Italy, ⁵Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁶IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁷Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁸IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁹First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁰Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, ¹¹Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, ¹²VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹³Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, ¹⁴Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁵Infectious Diseases Unit, AO Avellino, Italy, ¹⁶Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, ¹⁷Pneumology Unit, AORN Caserta, Italy

OP 56 15.42-15.47 COVID-19 neurocognitive impairment (COVID-19-NCI): an attempt for definition and clinical assessment

G. Del Duca, A.C. Brita, I. Mastroiosa, A. Vergori, S. Lanini, M. Camici, M. Annalisa, C. Caligiuri, C. Pinnetti, A. Antinori
Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy

OP 57 15.49-15.54 Neuropsychological performance (NP) following COVID-19: prevalence and predictors

A. Vergori¹, G. Del Duca¹, S. Lanini¹, A.C. Brita², C. Pinnetti¹, I. Mastroiosa¹, M. Camici¹, A. Mondì¹, V. Mazzotta¹, P. Chinello¹, P. Mencarini¹, M.L. Giancola¹, A. Abdeddaim¹, E. Girardi³, F. Vaia⁴, A. Antinori^{1,5}

¹Clinical Department, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, ²Psychology Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ³Scientific Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, ⁴General Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, ⁵Health Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

OP 58 15.56-16.01 Is plasma neurofilament light chain measurement relevant in long-COVID?

M.A. Zingaropoli¹, P. Pasculli¹, T. Latronico², F. Dominelli¹, M. Guardiani¹, E. Tortellini¹, G. Saracino², G.M. Liuzzi², M. Lichtner^{1,3}, C.M. Mastroianni¹, M.R. Ciardi¹

¹Department of Public Health and Infectious Diseases, Sapienza, University of Rome, ²Department of Biosciences, Biotechnology and Biopharmaceutics, Aldo Moro, University of Bari, ³Infectious Diseases Unit, SM Goretti Hospital, Latina, Sapienza, University of Rome

OP 59 16.03-16.08 SARS-CoV-2 hampers Dopamine production in iPS-derived dopaminergic neurons

G. Cappelletti¹, E.M. Carsana², G. Lunghi², S. Breviario², C. Vanetti¹, A. Barnaba Di Fonzo³, M. Clerici³, M. Aureli², C. Fenizia³

¹Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ²Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy, ³Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

OP 60 16.10-16.15 Early phase approach in SARS CoV-2 infection: a single center one-year real life experience

D. Di Trento¹, S. Garattini¹, M. De Masi², A. Gasperin¹, A. Grimaldi¹, S.G. De Maria¹, S. Corazza¹, S. Gismondi², B. Bartolozzi², D. Caianiello³, S. De Filippis¹, B. Kertusha², A. Carraro², O. D'Onofrio², G. Bagagnini¹, G. Bonanni¹, D. Alunni Fegatelli⁵, A. Spagnoli⁵, S. Di Somma⁶, C. Del Borgo², M. Lichtner¹

¹Department of Public Health and Infectious Disease, "Sapienza University of Rome", ²Infectious Disease Unit, SM Goretti Hospital Latina, ³General practitioner, AUSL Latina, ⁴Pharmacy Service Unit, SM Goretti Hospital Latina, ⁵Statistic Department, "Sapienza University of Rome", ⁶Department of Medical-Surgical Sciences and Translational Medicine, "Sapienza University of Rome"





ORAL POSTER 15.35-16.25

New issues on dual therapy

BERGAMO SCIENCE CENTER

Chairs: M. De Gennaro (Lucca), S. Nozza (Milano)

OP 61 15.35-15.40 Efficacy and Durability of Dual Antiretroviral Regimens as switch therapy in treatment-experienced People Living with HIV (PLWH): data from the ARCA cohort

M. Poliseno¹, A. Borghetti², F. Conti³, G. Di Teodoro^{4,5}, F. Lombardi⁶, L. Montemurro¹, L. Pezzati³, A. Shallvari^{5,7}, A. Bezenchek^{5,7}, V. Borghi⁸, S. Rusconi^{3,9}

¹U.O. Malattie Infettive Universitaria, University of Foggia, Foggia, Italy, ²Policlinico Gemelli, Roma, Italy, ³Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milano, Italy, ⁴Dipartimento di Ingegneria informatica automatica e gestionale A. Ruberti, Sapienza Università di Roma, Roma, Italy, ⁵EuResist Network GEIE, Roma, Italy, ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy, ⁷InformaPRO SRL, Roma, Italy, ⁸Clinica Malattie Infettive, Azienda Ospedaliero Universitaria di Modena, Modena, Italy, ⁹OC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano, Milano, Italy

OP 62 15.42-15.47 Characterization of virologically suppressed HIV infected individuals potential eligible to the long-acting combination of cabotegravir plus rilpivirine: results from the Italian ARCA cohort

A. Cervo¹, A. Russo², D. Di Carlo³, A. De Vito⁴, L. Fabeni⁵, S. D'Anna⁶, L. Duca⁶, A. Colpani⁴, M. Fois⁴, B. Zauli⁴, G. Mancarella⁷, A. Carraro⁷, A. Bezenchek⁸, A. Cozzi-Lepri⁹, M.M. Santoro⁶

¹Infectious Diseases Clinic, University Hospital of Modena, Italy, ²Infectious Diseases Unit, Department of Mental Health, University of Campania "Luigi Vanvitelli", Naples, Italy, ³Pediatric Clinical Research Center "Romeo and Enrica Invernizzi", Department of Biomedical and Clinical Sciences "L. Sacco" University of Milan, Italy, ⁴Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy, ⁵National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁶University of Rome "Tor Vergata", Rome, Italy, ⁷Infectious Disease Unit, Sapienza University of Rome - Polo Pontino, Latina, Italy, ⁸InformaPRO SRL, Rome, Italy; EuResist Network GEIE, Rome, Italy, ⁹Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, London, UK

OP 63 15.49-15.54 Long acting cabotegravir plus rilpivirine compassionate use program: a narrative description of the Italian experience

R. Rossotti¹, G. Orofino², B. Canovari³, R. Viglietti⁴, F. D'Amico¹, N.B. Bana¹, L. Carani², M.C. Moiola¹, F. Barchiesi³, M. Puoti^{1,5}

¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, ²Unit of Infectious Diseases, "Divisione A," Amedeo di Savoia Hospital, Turin, ³Unit of Infectious Diseases, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, ⁴UOC Infezioni Sistemiche e dell'Immunodepresso, AORN Ospedali dei Colli, PO D. Cotugno, Naples, ⁵School of Medicine, University of Milano Bicocca, Milan

OP 64 15.56-16.01 Immunological recovery in PLWHIV starting dolutegravir plus lamivudine as first-line regimen: data from the ODOACRE cohort

A. Ciccullo¹, A. Dusina², A. Borghetti², M.V. Cossu³, D. Farinacci⁴, F. Lamanna⁴, R.A. Passerotto⁴, F. Lombardi⁴, A. Capetti³, G. Baldin^{2,5}, S. Di Giambenedetto^{2,4}

¹UOC Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italia, ²UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, ³Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ⁴Università Cattolica del Sacro Cuore, Roma, Italia, ⁵Ospedale Mater Olbia, Olbia, Italia

OP 65 16.03-16.08 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine and Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors: a multicenter cohort study in Italy

F. Lagi¹, A. Giacomelli², V. Borghi³, A. Ciccullo⁴, L. Taramasso⁵, G. Madeddu⁶, G. D'Ettore⁷, A. Giacometti⁸, F. Ducci⁹, A. De Vito⁶, R. Pincino¹⁰, S. Di Giambenedetto⁴, C. Mussini³, S. Antinori², G. Sterrantino⁹

¹Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, ²Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy, ³Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ⁴UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁵Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy, ⁶Infectious Diseases Operative Unit, University Hospital of Sassari, Sassari, Italy, ⁷Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, ⁸Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Ancona, Italy, ⁹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁰Infectious Diseases Unit, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

OP 66 16.10-16.15 Comparing the efficacy and tolerability of dolutegravir plus rilpivirine versus dolutegravir plus lamivudine in a multicenter cohort

A. Ciccullo¹, G. Baldin^{2,3}, M.V. Cossu³, A. Giacomelli⁴, F. Lagi⁵, F. Lamanna⁶, D. Farinacci⁶, V. Iannone⁶, R.A. Passerotto⁶, A. Capetti³, G. Sterrantino⁵, S. Antinori⁴, S. Di Giambenedetto^{2,6}

¹UOC Malattie Infettive, Ospedale San Salvatore, L'Aquila, Italia, ²UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, ³Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ⁴UOC Malattie Infettive III, DIBIC Luigi Sacco, University of Milan, Milano, Italy, ⁵Division of Tropical and Infectious Diseases, "Careggi" Hospital, Florence, Italy, ⁶Catholic University of the Sacred Heart, Rome, Italy




SYMPOSIUM 16.40-17.40

AUDITORIUM SALA OGGIONI

Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates

Chairs: A. Antinori (Roma), M. Zazzi (Siena)

The development of therapeutic monoclonal antibodies and direct antiviral agents is currently at the front line of fighting against the COVID-19 pandemic. However, the emergence of SARS-CoV-2 variants, as BA.1 and BA.2 lineages, inducing escape from most of monoclonal antibodies represents a great challenge. Furthermore, as additional variants of concern will likely continue to emerge, there is a high unmet medical need for therapeutics that, alone or in combination, can remain effective as the virus evolves. The Symposium will present the state of the art of virological, clinical and immunological research against COVID-19 with a look at the promising clinical data emerging from the use of monoclonal antibodies and the most recent clinical experiences in the field.

- 16.40-16.55 **Neutralizing antibodies overcome SARS-CoV-2 BA.1 and BA.2 antigenic shift** D. Corti, Bellinzona CH
- 16.55-17.10 **Evolving clinical use and real-life strategies for early treatment of not-hospitalized COVID-19 patients** V. Mazzotta, Roma
- 17.10-17.25 **Could monoclonal antibodies early exposure antagonize anomalies of innate and adaptive immune response in COVID-19?** A. Bandera, Milano
- 17.25-17.40 **Discussion on Symposium issues**


ORAL COMMUNICATIONS 16.40-17.40

SALA STUCCHI

From HIV to SARS-CoV-2

Chairs: A. Callegaro (Bergamo), F. Maggi (Varese)

- OC 21** 16.40-16.50 **Intact proviral DNA and chromosome integration sites in peripheral blood lympho-monocytes of early treated acute HIV infections**
G. Rozera¹, G. Sberna¹, G. Berno¹, C. Gruber¹, N. Orchi², V. Puro², A. Mondì³, A. Antinori³, L. Abbate¹
¹Virology Unit, ²AIDS Referral Center, ³HIV/AIDS Clinical Department of the National Institute for Infectious Diseases I.R.C.C.S. L. Spallanzani, Rome, Italy
- OC 22** 16.52-17.02 **Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change in Patients Treated During Primary HIV Infection: Results from the INACTION P25 Study**
A. De Nicolò¹, E. De Vivo¹, S. Dispinseri², G. Marchetti³, M. Trunfio⁴, A. Ianniello¹, A. D'Avolio¹, A. Muscatello⁵, A. Gori⁵, S. Rusconi^{6,7}, E. Bruzzeri⁸, A. Gabrieli⁹, D.P. Bernasconi¹⁰, S. Nozza¹¹, A. Calcagno⁴ on behalf of the INACTION (Italian Network of Acute HIV Infection) study group
¹Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, ²Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, ³Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, ⁴Unif of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, ⁵Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ⁶UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, ⁷University of Milan, Milan, ⁸Vita-Saluta San Raffaele University, Milan, ⁹Dipartimento di Scienze Biomediche e Cliniche, Ospedale L Sacco, Milan, ¹⁰Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, ¹¹Department of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy
- OC 23** 17.04-17.14 **Efficacy, tolerability and pharmacokinetics of doravirine in the clinical setting**
S. Fantino¹, M. Ferrara¹, G. Trevisan¹, G. Accardo¹, F. Alladio¹, E. Drappero¹, S. Biffi¹, A. Serra¹, L. Trentini¹, M. Tettoni¹, E. De Vivo², A. Ianniello², J. Mula², A. De Nicolò², A. D'Avolio², A. Calcagno¹, G. Di Perri¹, S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ²Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino
- OC 24** 17.16-17.26 **Are Minions useful in the lab workflow? Comparison between long and short sequencing in COVID-19 surveillance**
B. Bruzzone¹, V. Ricucci¹, V. De Pace¹, F. Stefanelli¹, N. Randazzo¹, G. Garzillo², M. Cavaletti³, S. Casali³, M. Rossi³, A. Domnich¹, C. Trombetta², A. Orsi^{1,2}, G. Icardi^{1,2}
¹Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy, ²Department of Health Science, Genoa University, Genoa, Italy, ³4bases Italia srl, Campospinoso, Pavia, Italy



OC 25 17.28-17.38 In vitro activity of molnupiravir in combination with GC-376 or PF-07321332 against SARS-CoV-2

A. Gidari¹, S. Bastianelli¹, S. Pierucci¹, C. Busti¹, S. Sabbatini², G. Genga¹, E. Svizzeretto¹, A. Tommasi¹, E. Schiaroli¹, D. Francisci¹

¹Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, ²Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, Perugia, Italy



EXPERT MEETING 16.40-17.40

ALABASTRO A

Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies

Chairs: F. De Iaco (Torino), C.M. Mastroianni (Roma)

The increase of multidrug resistance among Gram-positive pathogens, particularly among staphylococci and enterococci, represents a major health care problem, since it results in significant morbidity, mortality, and health care costs. The emergence of such resistant bacterial strains highlights the need to optimize treatment approaches. In this view, novel lipoglycopeptides endowed with long-term activity allowing single-shot administration would be extremely useful and may represent an attractive therapeutic option alternative for early hospital discharge, a cost-saving and a resource-saving approach. Furthermore, long-term intravenous antibiotic therapy poses a particular challenge, specially in this ongoing pandemic situation, for treating patients classified as vulnerable or at high risk for complications, such as PWID (persons who inject drugs) or those lacking social support, including frail elderly and/or those who are homeless or with an underlying psychiatric illness. This approach may offer improved quality of life for patients, considering benefits, such as no need for a central line for daily infusions, fast hospital discharge, and less need for laboratory monitoring.

16.40-16.45 **Introduction**

C.M. Mastroianni, Roma

16.45-17.05 **Bacterial Infections in difficult-to-treat patients**

A.M. Cattelan, Padova

17.05-17.25 **Interaction between emergency medicine and infectious disease**

S. Di Maggio, Padova

17.25-17.35 **Questions & Answers**

F. De Iaco, Torino; C.M. Mastroianni, Roma

17.35-17.40 **Final considerations and take-home messages**

F. De Iaco, Torino



ORAL POSTER 16.40-17.30

ALABASTRO B

Cardiovascular diseases, osteoporosis but not only

Chairs: L. Calza (Bologna), G. Mazzola (Caltanissetta)

OP 67 16.40-16.45 Weight gain in people living with HIV under antiretroviral therapy: do our strategies make a difference?

C. Muccini^{1,2}, D. Ceccarelli¹, R. Lolatto¹, V. Spagnuolo¹, C. Oltolini¹, A. Danise¹, I. Mainardi^{1,2}, R. Monardo^{1,2}, A. Castagna^{1,2}

¹Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

OP 68 16.47-16.52 PLWH (People Living With HIV): a single centre retrospective observational study on cardiovascular risk factors

G. Gasparro¹, B. Rossetti², M. Ruggeri^{1,3}, M. Tumbarello^{4,5}

¹Corso Formazione Specifica in Medicina Generale AOU Meyer/Formas, Regione Toscana, Firenze, Italy, ²Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, ³General Practitioner, Società Italiana di Medicina Generale e delle cure primarie, SIMG, Firenze, Italy, ⁴Dipartimento di Biotecnologie Mediche, Università degli Studi di Siena, Siena, Italy, ⁵UOC Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria Senese, Siena, Italy

OP 69 16.54-16.59 Relationship between vitamin D deficiency and cardiovascular disease in virologically suppressed HIV-1-infected patients

L. Calza¹, V. Colangeli¹, M. Borderi¹, R. Riccardi¹, F. Malerba¹, I. Bon², P. Viale¹

¹Unit of Infectious Diseases, IRCCS S.Orsola Hospital, ²Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

OP 70 17.01-17.06 Effect of bisphosphonates on vertebral fractures in HIV infected males: a 7-years study

L. Pezzaoli¹, T. Porcelli¹, S. Storti², G. Tiecco², M. degli Antoni², S. Amadasi², F. Castelli², E. Quiros-Roldan²

¹Unit of Endocrinology and Metabolism, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy



- OP 71** 17.08-17.13 **Association between Health Literacy, care engagement and assessment of risk behaviours in an Italian cohort of people living with HIV**
V. Massaroni¹, V. Delle Donne¹, A. Borghetti², S. Pierluigi², F. Lamanna², D. Farinacci², A. Ciccullo³, G. Baldin⁴, S. Di Giambenedetto^{1,2}
¹Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, ²UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila; Italy, ⁴Mater Olbia Hospital, Olbia, Italy
- OP 72** 17.15-17.20 **Mental health assessment in people living with HIV/AIDS (PLWHA): preliminary data from a referral HIV center**
F. Di Gennaro¹, D. Montalbò², R. Schiavoni¹, G.G. Panico¹, D.F. Bavaro¹, L. Diella¹, M. Di Tullio³, A. Calluso³, C.R. Santoro¹, G. Brindicci¹, F. Balena¹, N. De Gennaro¹, A. Belati¹, D. Fiordelisi¹, M. Sgambati², A. Bertolino², A. Saracino¹
¹Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari, University of Bari "Aldo Moro", Bari, Italy, ²Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy, ³C.A.M.A. – L.I.L.A, sezione Bari



ORAL POSTER 16.40-17.30

BERGAMO SCIENCE CENTER

Vulnerable and key population: local experiences

Chairs: E. Girardi (Roma), A. Moznich (Milano)

- OP 73** 16.40-16.45 **Community-Based Centers (CBCs): sexual health needs and prevention knowledge among MSM in Lazio**
G.M. Corbelli¹, V. Lingiardi², F.M. Nimbi²
¹Plus Roma – APS, Rome, ²Dept. of Dynamic, Clinical and Health Psychology, Sapienza University of Rome
- OP 74** 16.47-16.52 **Injecting drug use, irrespective of harm reduction measures, is strongly associated with HCV infection: results of a structured questionnaire administered during HCV screening sessions in low threshold harm reduction services**
A. Soria¹, G. Ghilardi¹, M. Comolatti¹, M. Di Gennaro¹, C. Gaboardi², A. De Pace³, P. Di Gloria², C. Bregamo², R. Gallizzi², A. Barni³, MG. Marconi⁴, GM. Migliorino¹, P. Bonfanti^{1,5}, G. Lapadula^{1,5}
¹Infectious Diseases San Gerardo Hospital ASST Monza, Monza, ²Cooperativa Lotta Contro l'Emarginazione, Monza, ³Comunità Nuova, Monza, ⁴ATS Brianza, Monza, ⁵University of Milano-Bicocca, Monza
- OP 75** 16.54-16.59 **High prevalence of HCV infection among people screened in unconventional low threshold settings: results of an outreach program of screening and linkage to care for people using drugs**
A. Soria¹, G. Lapadula^{1,2}, M. Comolatti¹, M. Di Gennaro¹, C. Gaboardi³, A. De Pace³, P. Di Gloria³, C. Bregamo³, R. Gallizzi³, A. Barni⁴, MG. Marconi⁵, G. Scaffidi⁶, M. Bramani-Araldi⁶, A. Caruso⁶, D. Leto⁷, A. Cardia⁷, P. Fortuna⁸, G. Galimberti⁸, S. Torlasco⁹, C. Fanzaga¹⁰, M. Belloni¹⁰, E. Chiesa¹¹, GM. Migliorino¹, P. Bonfanti^{1,2}
¹Infectious Diseases San Gerardo Hospital ASST Monza, Monza, ²University of Milano-Bicocca, Monza, ³Cooperativa Lotta Contro l'Emarginazione, Monza, ⁴Comunità Nuova, Monza, ⁵ATS Brianza, Monza, ⁶SerD Carate-Brianza ASST Brianza, Carate-Brianza, ⁷SerD Limbiate ASST Brianza, Limbiate, ⁸SerD Monza ASST Monza, Monza, ⁹Corpo Italiano Soccorso Ordine di Malta Monza Brianza, Monza, ¹⁰Servizi Sociali Comune di Monza, Monza, ¹¹Casa Circondariale di Monza, Monza
- OP 76** 17.01-17.06 **Descriptive analysis and retention in care of a cohort of HIV-positive migrants (AMIGO: A HIV-positive MIGRANTS cohort at AOU Careggi)**
F. Lagi¹, S.T. Kiros¹, M. Turco³, B. Borchi¹, F. Bartalesi¹, P. Corsi¹, E. Gotuzzo⁴, G. Sterrantino², A. Bartoloni^{1,2}
¹SOD Malattie Infettive e Tropicali, AOU Careggi, ²Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi Di Firenze, Firenze, ³Sezione di Dermatologia, Dipartimento di Scienze della Salute, Università degli studi di Firenze, Firenze, ⁴Universidad Peruana Cayetano Heredia, Lima, Peru
- OP 77** 17.08-17.13 **A qualitative survey on facilitating factors and barriers to access and continuum of care: point of view of HIV-positive transgender migrant women living in Florence**
F. Lagi¹, C. Gatteschi², M. Tili³, N. Zocco⁴, A. Avarello¹, S. Bellini⁵, S. Contanessi⁴, M.R. Zigliani⁵, M. Stagnitta⁴, L. Mariano⁴, E. Gazzarri⁴, L. Belloni⁶, A. Bartoloni^{1,3}, G. Sterrantino³, F. Ierardi²
¹SOD Malattie Infettive e Tropicali, AOU Careggi, Firenze, ²Agenzia Regionale di Sanità di Toscana, ³Dipartimento di medicina Sperimentale e Clinica, Università degli studi di Firenze, Firenze, ⁴CAT Cooperativa sociale Firenze, ⁵Lega Italiana Lotta all' AIDS, LILA, ⁶Centro di riferimento regionale criticità relazionali, AOU Careggi, Firenze





SYMPOSIUM 17.45-18.45

AUDITORIUM SALA OGGIONI

Challenges in HIV cure: getting to zero reservoir

Chairs: F. Ceccherini - Silberstein (Roma), M. Clementi (Milano)

Despite sustained control of HIV replication is now achievable with convenient and well-tolerated antiretroviral treatments, the establishment of a lifelong persistent cellular reservoir precludes the eradication of the infection. Thus, characterizing and quantifying the intact viral reservoir is considered an essential prerequisite for the development and the clinical evaluation of curative strategies. Moreover, viral persistence has been demonstrated in several organs and tissues with the highest amount in lymph nodes, gastrointestinal tract, and central nervous system. Understanding the dynamics of drug penetration in the different cellular reservoirs is vital for increasing the efficacy of both antiretroviral therapy and investigational curative approaches. This symposium aims to show and discuss the recent results and advances in laboratory techniques and pharmacology that might lead to pave the way for the eradication of HIV infection.

- 17.45-18.00 **Characterizing and quantifying the HIV reservoir** F.R. Simonetti, Baltimore USA
- 18.00-18.15 **Pharmacology of the HIV reservoir** A. Calcagno, Torino
- 18.15-18.45 **Round table** Discussants: A. Calcagno, Torino; A. De Maria, Genova; G. Nunnari, Messina; F. Simonetti, Baltimore USA; O. Turriziani, Roma



ORAL COMMUNICATIONS 17.45-18.45

SALA STUCCHI

Metabolic alterations: effect of drugs and diseases

Chairs: V. Borghi (Modena), L. Rancilio (Milano)

- OC 26 17.45-17.55 From NAFLD to MAFLD: implications of change in terminology in PWH**
L. Gozzi¹, J. Milic², S. Renzetti³, F. Motta², A. Cervo¹, G. Burastero¹, V. Iadisernia¹, B. Lebouche⁴, S. Al Hinai⁴, M. Deschenes⁴, M. Menozzi¹, P. Raggi⁵, S. Calza³, C. Mussini^{1,2}, G. Sebastiani⁴, G. Guaraldi^{1,2}
¹Azienda Ospedaliero - Universitaria, Policlinico of Modena, Modena, Italy, ²University of Modena and Reggio Emilia, Modena, Italy, ³University of Brescia, Brescia, Italy, ⁴McGill University Health Centre, Montreal, Canada, ⁵University of Alberta, Edmonton, Canada
- OC 27 17.57-18.07 The pathway of NAFLD vs MAFLD toward significant fibrosis**
J. Milic¹, S. Renzetti², F. Motta¹, L. Gozzi³, G. Besutti⁴, G. Burastero³, V. Iadisernia³, A. Dessilani³, M. Del Monte³, M. Faltoni³, S. Volpi³, B. Lebouche⁵, S. Al Hinai⁵, M. Deschenes⁵, S. Calza⁶, P. Raggi⁶, G. Mancini³, C. Mussini^{1,2}, G. Sebastiani⁴, G. Guaraldi^{1,2}
¹University of Modena and Reggio Emilia, Modena, Italy, ²University of Brescia, Italy, ³Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ⁴Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy, ⁵McGill University Health Centre, Montreal, Canada, ⁶University of Alberta, Edmonton, Canada
- OC 28 18.09-18.19 With or Without TAF? What is the difference? Data from a real-life setting**
N. Squillace¹, L. Taramasso², E. Ricci³, B. Menzaghi⁴, G. De Socio⁵, G. Orofino⁶, B.M. Celesia⁷, E. Sarchi⁸, C. Molteni⁹, G. Pellicano¹⁰, F. Conti¹¹, F. Vichi¹², A. Di Biagio², P. Bonfanti¹, for the CISA Study Group
¹Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital-University of Milano-Bicocca, Monza, ²Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa ³Fondazione ASIA Onlus, Buccinasco (MI), ⁴Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), ⁵Unit of Infectious Diseases, Santa Maria Hospital, Perugia, ⁶Division I of Infectious and Tropical Diseases, ASL Città di Torino, ⁷Unit of Infectious Diseases, Garibaldi Hospital, Catania, ⁸Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, ⁹Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, ¹⁰Infectious Diseases, G. Martino Hospital -University of Messina, Messina, ¹¹Department of Infectious Diseases, Luigi Sacco Hospital, Milan, Italy, ¹²Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence
- OC 29 18.21-18.31 Impact of COVID-19 pandemic on incidence and prevalence of metabolic syndrome in PLWH**
R. Papaioannu Borjesson¹, L. Galli², C. Muccini^{1,2}, A. Poli², T. Clemente¹, M. Bottanelli¹, N. Gianotti², S. Nozza², A. Castagna^{1,2}, V. Spagnuolo²
¹Vita-Salute San Raffaele University - Milan (Italy), ²Infectious Diseases Unit, San Raffaele Scientific Institute - Milan (Italy)





ORAL COMMUNICATIONS 17.45-18.45

ALABASTRO A

Special issues in clinical HIV

Chairs: G. Parruti (Pescara), A. Saracino (Bari)

OC 30 17.45-17.55 Final immunovirological data from the p25- Italian Network of Acute HIV Infection (INACTION) cohort

 E. Bruzzesi¹, A. Gabrieli², D. Bernasconi³, G. Marchetti⁴, M. Trunfio⁵, D. Ripamonti⁶, A. Antinori⁷, N. Squillace⁸, R. Cauda^{9,10}, M. Parisi¹¹, A. Muscatello¹², A. Bandera^{12,13}, G. Tambussi¹¹, S. Nozza¹¹, S. Rusconi¹⁴ on behalf of INACTION study group

¹Vita-Salute San Raffaele University, Milan, Italy, ²Dipartimento di Scienze Biomediche e Cliniche, Ospedale L. Sacco, Milan, Italy, ³Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, ⁴Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁵Unif of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, ⁶Infectious Disease Unit; ASST Papa Giovanni XXIII; Bergamo, Italy, ⁷National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS; Rome, Italy, ⁸Infectious Diseases Unit; Department of Internal Medicine; ASST San Gerardo; Monza, Italy, ⁹Istituto Clinica di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹¹Unit of Infectious Diseases, IRCCS Ospedale san Raffaele, Milan, Italy, ¹²Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹³School of Medicine and Surgery, University of Milan, Milan, Italy, ¹⁴UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, Italy

OC 31 17.57-18.07 Effect of 12-week cART on gut mucosal immunity and microbiome in PHI

 C. Tincati¹, M. Hadla¹, M. Falleni², D. Tosi², V. Yellenki¹, R. Rovito¹, V. Bono¹, S. Rusconi³, A. Giacomelli⁴, A. Muscatello⁵, S. Di-spinseri⁶, A. d'Arminio Monforte¹, A. Calcagno⁷, S. Nozza⁶, A. Gori⁵, G. Marchetti¹ for the Inaction (Italian Network of Acute HIV Infection) Study Group

¹Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, ²Pathology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, ³UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, ⁴Clinic of Infectious Diseases, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, ⁵Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ⁶Viral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, ⁷Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin

OC 32 18.09-18.19 PLWH with advanced HIV disease are at higher risk for becoming difficult to treat: data from a large cohort of PLWH starting modern ART regimens

 R. Gagliardini¹, A. Cozzi-Lepri², A. Tavelli³, S. Rusconi^{4,5}, V. Spagnuolo⁶, A. Giacomelli⁷, G. Burastero⁸, C. Agrati¹, M.M. Santoro⁹, G. Madeddu¹⁰, A. d'Arminio Monforte¹¹, A. Antinori¹
¹INMI Lazzaro Spallanzani IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, ³Icona Foundation, Milan, Italy, ⁴Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, Legnano, Italy, ⁵Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco" Università degli Studi di Milano, Milan, Italy, ⁶IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy, ⁷III Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco, Milan, Italy, ⁸Infectious Disease Clinic, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ⁹University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, ¹⁰Infectious Diseases Department of Medical, Surgical, and Experimental Sciences University of Sassari, Italy ¹¹University of Milan, Department of Health Sciences, Milan, Italy

OC 33 18.21-18.31 Weight change in obese and overweight PWH: the impact of SARS-CoV-2 pandemic

 S. Dettori^{1,2}, S. Lerta¹, L. Taramasso², S. Bianchi¹, F. Magnè², S. Mora³, M. Giacomini³, M. Bassetti^{1,2}, A. Di Biagio^{1,2}
¹Department of Health Sciences (DISSAL), University of Genoa - Genoa, Italy, ²Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS - Genoa, Italy, ³Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa - Genoa, Italy


ORAL POSTER 17.45-18.35

ALABASTRO B

Measuring HIV stigma and disclosure

Chairs: B.M. Celesia (Catania), T. Di Giovanni (Roma)

OP 78 17.45-17.50 Tackling the misunderstanding and stigma of HIV: a survey on 1007 Italian citizens

 D. Calzavara¹, A. Tavelli^{1,2,3}, A. d'Arminio Monforte^{1,2,3}
¹Associazione Milano Check Point, Milano, ²ASST Santi Paolo e Carlo, Milano, ³Fondazione Icona

OP 79 17.52-17.57 HIV-related stigma among Italian adults: results of an online survey

 Y. Regine¹, L. Pugliese¹, B. Suligoi¹, G. Briola², A. Simonetti², F. Marchionni², V. Saturni²
¹Istituto Superiore di Sanità, Rome, ²Associazione Volontari Italiani del Sangue, Milan


- OP 80** 17.59-18.04 **Determinants of non disclosure of HIV status in PLWHIV to others than health care workers**
A. Cingolani¹, A. Tavelli², V. Calvino³, L. Cosmaro⁴, F. Bai⁵, C. Pinnetti⁶, D. Tesoro⁵, F. Castelli⁷, F. Maggiolo⁸, A. Antinori⁶, M. Cernuschi⁹, A. d'Arminio Monforte⁵
¹Policlinico Fondazione A. Gemelli, IRCCS, Roma, ²Fondazione ICONA, Milano, ³ANLAIDS Onlus, Roma, ⁴LILA Milano Onlus, Milano, ⁵Università degli studi di Milano, Milano, ⁶INMI L.Spallanzani, IRCCS, Roma, ⁷Università degli studi di Brescia, Brescia, ⁸ASST Giovanni XXIII, Bergamo, ⁹ASA onlus, Milano
- OP 81** 18.06-18.11 **Knowledge and impact of U=U among PLHIV, healthcare professionals and the general population in Italy: a qualitative study**
M. Oldrini¹, M.L. Cosmaro¹, S. Curradori¹, S. Penon¹, D. Savarino¹, S. Mazzilli², D. Paganini², L. Tavoche²
¹Fondazione LILA Milano – Lega Italiana per la Lotta contro l'AIDS, Milano, ²Dipartimento di Ricerca traslazionale e delle nuove tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa
- OP 82** 18.13-18.18 **Do people living with HIV have a better knowledge of HIV and STIs compared to people without HIV? A survey study in Sardinia, Italy**
A. Colpani¹, A. De Vito¹, B. Zauli¹, V. Fiore¹, M.C. Meloni¹, M. Fois¹, A. Bitti¹, S. Bacciu¹, N. Leoni², G. Angioni², S. Babudieri¹, G. Madeddu¹
¹Unit of Infectious Disease, Department of Medical, Surgery, and Experimental Sciences, University of Sassari, Sassari, Italy, ²Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy
- OP 83** 18.20-18.25 **Impact of HIV-related stigma on social support, mental health and quality of life in an Italian cohort of people living with HIV**
V. Delle Donne¹, V. Massaroni¹, A. Borghetti², A. Dusina², R.A. Passerotto², R.J. Steiner², A. Ciccullo³, G. Balducci⁴, S. Di Giambenedetto^{1,2}
¹Infectious Diseases Institute, Department of Safety and Bioethics, Catholic University of Sacred Heart, Rome, Italy, ²UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³UOC Infectious Diseases, Ospedale S. Salvatore, L'Aquila, Italy, ⁴Olbia Mater Hospital, Olbia, Italy



ORAL POSTER 17.45-18.35

BERGAMO SCIENCE CENTER

Models of COVID-19 pathogenesis and response to vaccination

Chairs: C. Tincati (Milano), A. Riva (Milano)

- OP 84** 17.45-17.50 **Human iPSC-derived motor neurons are productively infected by SARS-CoV-2**
G. Cappellelli¹, C. Colombrita², F. Limanaqi^{1,5}, D. Trabattori¹, C. Moscheni¹, A. Tosoni⁶, M. Nebuloni^{1,6}, S. Santangelo^{2,3}, V. Silani^{2,4}, A. Ratti^{2,3}, M. Biasin¹
¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Italy, ²Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy, ³Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy, ⁴Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, University of Milan, Italy, ⁵Department of Pathophysiology and Transplantation, Milan, Italy, ⁶Pathology Unit, L. Sacco Hospital, Milan, Italy
- OP 85** 17.52-17.57 **SARS-CoV-2 infection of airway epithelium triggers endothelial cells activation**
D. Mariotti¹, G. Matusali¹, F. Colavita¹, C. Agrati¹, V. Bordoni¹
INMI L. Spallanzani, Roma
- OP 86** 17.59-18.04 **Specific CD4+ and CD8+ T cell response of SARS-CoV-2 S epitopes using tetramers & monocyte dysregulation in fully vaccinated donors and recovered patients**
A. Parente², M. Iuliano¹, R. Mongiovi¹, B. Kertusha², A. Carraro², R. Marocco², G. Mancarella², S. Garattini², F. Izzo², C. Del Borgo², T. Tieghi², L. Fondaco², G. Mangino¹, M. Lichtner², G. Romeo¹
¹Dept. of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy, ²Dept. of Public Health and Infectious Disease, S. Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy
- OP 87** 18.06-18.11 **Immune responses after three doses of BNT162b2 mRNA vaccine in a cohort of HIV-vertically transmitted patients**
C. Vanetti¹, M. Stracuzzi², F. Cicilano¹, V. Rubinacci^{2,4}, C. Fenizia³, G. Meraviglia², Clerici^{3,5}, M. Biasin¹, G.V. Zuccotti^{2,4}, V. Giacomè², D. Trabattori¹
¹University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, ²Ospedale L. Sacco, University of Milan, Department of Pediatric Infectious Diseases, Milan, ³University of Milan, Department of Pathophysiology and Transplantation, Milan, ⁴Ospedale dei Bambini V. Buzzi, Department of Paediatrics, Milan, ⁵IRCCS Fondazione Don Carlo Gnocchi



OP 88 18.13-18.18 Comparison between QuantiFERON SARS-CoV 2 kit and Activation Induced Cell Markers (AIMs) assay in 21 non-vaccinated patients with late COVID19 infection

A. Gatti¹, M. De Paschale², P. Clerici², M.P. Faggioli³, A. Tamburello³, L. Castelnuovo³, M. Franzetti⁴, S. Rusconi⁴, A. Mazzone³

¹Haematology Laboratory - Transfusion Center, ²Microbiology Unit, ³Internal Medicine Unit, ⁴Infectious Diseases Unit, Legnano Hospital, Milano, Italy; ⁵Department of Biomedical and Clinical Sciences DIBIC "Luigi Sacco", University of Milan, Italy

OP 89 18.20-18.25 An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein

M.C. Bellocchi¹, L. Carioti¹, R. Scutari¹, M. Iannetta², L. Piermatteo¹, M. Alkhatib¹, S. Tedde², L. Duca¹, L. Coppola², V. Malagnino², A. Crea², L. Ansaldo², S. D'Anna¹, M.M. Santoro¹, A. Bertoli^{1,2}, A. Di Lorenzo², R. Salpini¹, V. Svicher¹, E. Teti², N. Braccialarghe², R.A. Cavasio², L. Sarmati², M. Andreoni², F. Ceccherini-Silberstein¹

¹University of Rome Tor Vergata, Rome, Italy, ²University Hospital of Rome Tor Vergata, Rome, Italy





KEYNOTE LECTURES 09.00-10.00

AUDITORIUM SALA OGGIONI

Chairs: M.L. Cosmaro (Milano), M. Galli (Milano)

09.00-09.30 **Anti-HIV therapy as a guide to treat COVID-19**

C.F. Perno, Roma

09.30-10.00 **Comparing the Mental Health Trajectories of PLWH during the pandemic period with the prepandemic situation: impact of geographic differences and different access to health care facilities**

F. Lampe, London UK



SYMPOSIUM 10.05-11.05

AUDITORIUM SALA OGGIONI

Comorbidities of contemporary relevance

Chairs: P. Maggi (Caserta), B. Marchini (Roma)

Until recent years, the comorbidities of HIV infection, initially associated with side effects of ART, have turned into pathological conditions more often related to aging and lifestyles. Among ART side effects, weight gain remains a concern especially in PWH receiving integrase inhibitors, and mechanisms are still unclear. Beyond ART, sexually transmitted infections are among those more clinically relevant in PWH because of their high frequency and transmissibility, despite most can be prevented or treated. In this context, HPV infection is of particular interest because it is implicated in the development of tumors, which remain a relevant cause of mortality in PWH.

10.05-10.20 **Pathogenetic aspects of weight gain under ART**

L. Taramasso, Genova

10.20-10.35 **Evolving concepts in Sexually Transmitted Infections**

G. Villa, Brighton UK

10.35-10.50 **HPV infection and its consequences: where we stand now**

N. Squillace, Monza

10.50-11.05 **Discussion on Symposium issues**



EXPERT MEETING 10.05-11.05

SALA STUCCHI

**Heavily-treatment experienced (HTE) patients: who are they?
And how should be managed?**

Moderator: S. Lo Caputo (Foggia)

Con la sponsorizzazione non condizionante di ViiV Healthcare

Discussants: A. Castagna (Milano), C.F. Perno (Roma)

Despite the availability of new classes of antiretroviral (ARV) therapy with improved efficacy, some usually heavily-treatment experienced (HTE) patients eventually experience treatment failure due to various factors including viral resistance, drug toxicity, drug intolerance, and poor adherence. Long-term ARV therapy use could lead to decreased efficacy of multiple classes of ARVs, requiring increasingly tailored regimens, and few, if any, ARV options remaining. Therefore, it is important to consider new ARVs with different mechanism of action in the therapeutic approach of these patients: in this context, the oral attachment inhibitor has demonstrated efficacy in adults with multidrug resistant HIV-1 infection in urgent need of new treatment due to resistance, safety, or tolerability issues with their current regimens.





SYMPOSIUM 10.05-12.10

The Italian Fast-Track Cities Network

ALABASTRO A

Chairs: A. d'Arminio Monforte, S. Patrucco

Con la sponsorizzazione non condizionante di Gilead Sciences

The Fast-Track Cities initiative (FTCI) is a global partnership between cities and municipalities around the world and four core partners: the International Association of Providers of AIDS-Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat) and the City of Paris. Launched on World AIDS Day 2012, the Network has grown to include more than 330 Cities and municipalities that are committed to attain the UNAIDS 95-95-95 targets by 2030. The aim of the Symposium is to focus on the Italian Fast-Track Cities state of the art as now 12 Italian townships are potentially involved. Even if FTCI is mostly a locally organized micro-program, sharing good practice and ideas may improve the effect of single realities and may lead to common actions able to engrave deeply on the HIV epidemics.

10.05-10.20	The Global Network example of good practice	B. Audoin, Paris F
10.20-10.35	FTC experience from the municipality point of view	M. Messina, Bergamo
10.35-11.10	Italian Fast Track Cities calls Ukraine	B. Audoin, Paris F
11.10-11.40	Common projects already in place and sharing of Cobatest data	M.L. Cosmaro, Milano; P. Meli, Bergamo
11.40-12.10	Future common projects and actions. FTCI delegates	



ORAL POSTER 10.05-10.55

COVID-19: considerations of special populations

ALABASTRO B

Chairs: V. Giacomet (Milano), F. Vichi (Firenze)

OP 90 10.05-10.10 Impact of patients' characteristics and comorbidities on in-hospital mortality during the first three waves of COVID-19 pandemic. Results from the Brescia HUB project

E. Focà¹, S. Calza², S. Piva³, L. Ettori¹, F. Rasulo³, C. Agabiti Rosei⁴, C. Aggiusti⁵, B. Cerudelli⁶, F. Quadri⁷, M. Metra⁸, M. Castellano⁹, M. Nardin¹⁰, C. Ricci¹¹, R. Badolato¹², F. Odcino¹³, R. Orabona¹³, F. Scolari¹⁴, L.R. Tomasoni¹, F. Marinoni¹⁵, A.M. Roccaro¹⁶, C. Rossi¹⁷, F. Castelli¹

¹Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, ²Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, ³Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, ⁴Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, ⁵Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, ⁶Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁷Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, ⁸Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁹Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁰Third Unit of Internal Medicine, ASST Spedali Civili, Italy, ¹¹Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹²Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹³Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁴Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁵Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, ¹⁶Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, ¹⁷Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

OP 91 10.12-10.17 SARS-CoV-2 infection and COVID-19 disease in PLWH

F. Maggiolo¹, D. Valenti², M. Arosio¹, D. Guarneri¹, M. Rizzi¹, A.P. Callegaro³

¹ASST Papa Giovanni XXIII, ²Associazione FROM, ³ASST Bergamo Est, Bergamo, Italy

OP 92 10.19-10.24 Evolution of SARS-CoV-2 Variants of Concern (VOC) over a period of Delta and Omicron variants co-circulation: impact on clinical outcomes among patients (pts) hospitalized for COVID-19 in an Italian reference hospital in the first trimester of 2022

A. Mondì, I. Mastroiosa, C. Cimaglia, P. Piselli, G. Matusali, F. Carletti, L. Fabeni, E. Specchiarello, G. Giannico, E. Milozzi, E. Biliotti, S. Di Bari, P. Chinello, A. Beccacece, P. Vittozzi, S. Mosti, N. Tetaj, L. Marchioni, S. Ianniello, E. Nicastri, A.R. Garbuglia, F. Vaia, E. Girardi, A. Antinori

National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy

OP 93 10.26-10.31 New issues in SARS-CoV-2 vaccination response among Health-care workers: slow responders and peri-vaccination infections

S. Arsuffi¹, E. Focà¹, E. Sansone², T. Diaferia², E. Sala², F. Castelli¹, G. De Palma², E. Quiros-Roldan¹

¹Unit of Infectious and tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²University Department of Occupational Health and Industrial Hygiene, DSMC, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy





- OP 94** 10.33-10.38 **Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth**
A. Pani¹, A. Proto², S. Agliardi¹, O.M. Gagliardi¹, S. Renica¹, F. di Ruscio¹, C. Vismara³, D. Campisi³, F. Scaglione¹, S. Martinelli²
¹Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy, ²Neonatology and Neonatal Intensive Care Unit, Niguarda Hospital, Milan, Italy, ³Microbiology Unit, Niguarda Hospital, Milan, Italy
- OP 95** 10.40-10.45 **Predictors of mortality in a cohort of oldest old subjects hospitalized for COVID-19**
M. Mazzitelli, M. Biasin, M. Trevenzoli, S. Lo Menzo, S. Marinello, A. Ferrari, L. Sasset, M. Brundu, S. Gardin, M. Cola, A.M. Cattelan
Infectious and Tropical Diseases Unit, Azienda Ospedale Università, Padova



ORAL POSTER 10.05-10.55

BERGAMO SCIENCE CENTER

Toxicity of antiretroviral therapy

Chairs: C. Gervasoni (Milano), R. Gulminetti (Pavia)

- OP 96** 10.05-10.10 **Efficacy and safety of switching to lamivudine/dolutegravir in HIV-1-infected patients aged over 65 years**
L. Calza¹, V. Colangeli¹, M. Borderi¹, R. Riccardi¹, F. Malerba¹, I. Bon², P. Viale¹
¹Unit of Infectious Diseases, ²Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy
- OP 97** 10.12-10.17 **Specific neurodevelopmental consequences of dolutegravir exposure in a zebrafish embryo model and rescue with early folate treatment**
S. Ferretti¹, E. Quiros-Roldan¹, I. Zanella², F. Castelli¹, E. Massardi³, G. Borsani³, G. Tiecco¹, S. Storti¹, D. Zizioli³
¹Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; ²Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; ³Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; ⁴Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy; ⁵Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
- OP 98** 10.19-10.24 **Causes of HIV treatment interruption during the last 20 years: a multi-cohort real-life study**
A. De Vito¹, E. Ricci², B. Menzaghi³, G. Orofino⁴, C. Martinelli⁵, N. Squillace⁶, L. Taramasso⁷, G.V. De Socio⁸, C. Molteni⁹, F. Conti¹⁰, L. Valsecchi¹¹, C. Costa¹², B.M. Celesia¹³, G. Parruti¹⁴, G. Pellicanò¹⁵, E. Sarchi¹⁶, A. Cascio¹⁷, G. Cenderello¹⁸, K. Falasca¹⁹, A. Di Biagio⁷, P. Bonfanti⁶, G. Madeddu¹
¹Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ²Fondazione ASIA Onlus, Buccinasco (MI), Italy, ³Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, ⁴Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, ⁵SOD Malattie Infettive e Tropicali, AOU Careggi, Firenze, Italy, ⁶Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ⁷Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ⁸Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, ⁹Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, ¹⁰Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy, ¹¹Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, ¹²Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, Florence, Italy, ¹³Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, ¹⁴Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ¹⁵Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", Unit of Infectious Diseases, University of Messina, Messina, Italy, ¹⁶Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ¹⁷Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo, Italy, ¹⁸Infectious Disease Unit, Sanremo Hospital, Sanremo, Italy, ¹⁹Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy
- OP 99** 10.26-10.31 **First and second phase viral load decay in real-life using Nonlinear Bayesian Mixed Effect model**
D. Ceccarelli¹, R. Lolatto¹, N. Gianotti¹, C. Muccini^{1,2}, D. Canetti¹, C. Maci^{1,2}, C. Oltolini¹, B. Trentacapilli^{1,2}, A. Castagna^{1,2}, L. Galli¹
¹Infectious Diseases Unit, IRCCS San Raffaele Hospital, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

- OP 100** 10.33-10.38 **The effects of switching from dolutegravir/abacavir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomized study**
B. Rossetti^{1,2}, M. Ferrara³, L. Taramasso⁴, F. Bai⁵, F. Lombardi⁶, N. Ciccarelli⁷, M. Durante⁸, F. Alladio³, I. Rancan^{1,8}, F. Montagnani^{1,8}, A. Di Biagio⁹, A. d'Arminio Monforte⁵, M. Zazzi⁸, M. Fabbiani¹ for DOBINeuro study group
¹Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, ²Infectious Disease Department, USL SUDEST Toscana, Misericordia Hospital, Grosseto, Italy, ³Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ⁴Infectious Diseases Clinic, Department of Internal Medicine, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ⁵Clinic of Infectious Diseases, Department of



Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy, ⁶Infectious Diseases Unit, UOC Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Department of Psychology, Catholic University, Milan, Italy, ⁸Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁹Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, San Martino Hospital-IRCCS, Genoa, Italy

OP 101 10.40-10.45 Dynamic of lipid profile in HIV naive patients treated by TAF-based regimens: a multicenter observational study

S. Martini¹, P. Maggi^{1,2}, C. Gervasoni³, L. Onorato¹, S. Ferrara⁴, L. Alessio^{1,2}, C. Bellacosa⁵, V. Esposito⁶, G. Di Filippo⁷, A. Masiello⁸, A. Maddaloni⁹, S. Madonia¹⁰, G.D'Alessio¹¹, V. Rizzo⁶, N. Coppola¹

¹Infectious Disease, University of Campania, Luigi Vanvitelli, ²AORN Sant'Anna e San Sebastiano of Caserta, ³ASST FBF SACCO of Milan, ⁴University of studies of Foggia, ⁵University of studies of Bari, ⁶IV Division AORN dei Colli, ⁷University Federico II of Naples, ⁸AO San Giuseppe Moscati of Avellino, ⁹VII Divisione AORN dei Colli, ¹⁰AOU San Giovanni di Dio e Ruggi d'Aragona of Salerno, ¹¹AORN San Pio of Benevento



SPONSORED SYMPOSIUM 11.10-12.10

AUDITORIUM SALA OGGIONI

Remdesivir: key-role in COVID-19 management

Chair: R. Bruno (Pavia)

Simposio promozionale di Gilead Sciences

Remdesivir, the first antiviral drug authorized in Europe for the treatment of COVID-19, has demonstrated its efficacy in three randomized controlled clinical trials, including the gold-standard ACTT-1 study, and, increasingly, in numerous evidences from the real practice. Recent international real-world retrospective analyses on large data sets and a meta-analysis of the most important real-world publications confirmed that hospitalised COVID-19 patients treated with remdesivir had a statistically significant reduction in mortality and improved survival compared to matched controls. Moreover, the PINETREE phase III study on moderate COVID-19 patients revealed high efficacy of remdesivir in reducing hospitalization or mortality rate compared to placebo, results that granted the new recent EMA indication for high risk moderate patients. This Symposium will be an opportunity to give an overview of the evolving patient profile, to present a scientific update on remdesivir efficacy data and to discuss centres organization to manage the treatment of COVID-19 outpatients. The three talks composing the Symposium will then try to address the most important topics regarding COVID-19 patient management with remdesivir.

- | | | |
|---------------|--|-------------------|
| 11.10 - 11.15 | Introduction | R. Bruno, Pavia |
| 11.15 - 11.30 | The evolution of the COVID-19 patient profile | P. Viale, Bologna |
| 11.30 - 11.45 | Remdesivir in the severe patient: new evidences from the Real World | M. Falcone, Pisa |
| 11.45 - 12.00 | Remdesivir in the high risk moderate patient: efficacy profile and patient management | E. Nicastri, Roma |
| 12.00 - 12.10 | Discussion on Symposium issues | |



ORAL COMMUNICATIONS 11.10-12.10

SALA STUCCHI

Resistance to antiretroviral

Chairs: A. Cascio (Palermo), M. Di Pietro (Firenze)

OC 34 11.10-11.20 Evaluation of integrase resistance and its predictors in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

M.M. Santoro¹, D. Armenia², C. Charpentier³, A. Bertoli⁴, F. Forbici⁵, V. Calvez⁶, D. Descamps³, F. Ceccherini-Silberstein¹, A.G. Marcelin⁶, P. Flandre⁷, on behalf of the ANRS-MIE AC43 group and the Italian HIV-drug resistance group

¹University of Rome "Tor Vergata", Rome, Italy, ²Saint Camillus International University of Health Sciences, Rome, Italy, ³Paris University, AP-HP, Hôpital Bichat-Claude-Bernard, IAME, Paris, France, ⁴Polyclinic of Rome "Tor Vergata", Rome Italy, ⁵National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁶Sorbonne Université, AP-HP, Hôpital Pitié Salpêtrière, INSERM UMR-S1136, Paris, France, ⁷Sorbonne Université, INSERM UMR-S1136, Paris, France

OC 35 11.22-11.32 Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype

P.F. Salvo¹, D. Farinacci^{1,2}, A. Ciccullo³, V. Borghi⁴, P. Laghetti⁵, S. Rusconi⁶, A. Saracino⁷, W. Gennari⁴, B. Bruzzone⁸, I. Vicenti⁹, A. Callegaro¹⁰, A. Di Biagio¹¹, M. Zazzi⁹, A. Borghetti²

¹Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, ²UOC Malattie Infettive, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, ³Malattie Infettive, Ospedale San Salvatore, L'Aquila, ⁴Clinica delle Malattie Infettive e Tropicali, Università di Modena e Reggio Emilia, Modena, ⁵Microbiologia e Virologia, Università degli Studi di Bari, Bari, ⁶UOC Malattie Infettive, Ospedale Civile di Legnano, ASST Ovest Milanese, Legnano, ⁷Clinica Malattie Infettive, Università degli Studi di Bari, Bari, ⁸UO Igiene, Ospedale Policlinico San



Martino, Genova, ⁹Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, ¹⁰UO Microbiologia e Virologia, ASST Papa Giovanni XXIII, Bergamo, ¹¹Clinica di Malattie Infettive, Ospedale Policlinico San Martino, Dipartimento di Scienze della Salute (DISSAL), Università di Genova, Genova

OC 36 11.34-11.44 Clinical and virological outcomes of difficult to treat patients in a large cohort of PLWH starting modern ART regimens

R. Gagliardini¹, A. Tavelli², S. Rusconi^{3,4}, A. Costantini⁵, S. Cicalini¹, F. Maggiolo⁶, V. Spagnuolo⁷, E. Quiros Roldan⁸, S. Lo Caputo⁹, A. d'Arminio Monforte¹⁰, A. Antinori¹, A. Cozzi-Leperi¹¹

¹INMI Lazzaro Spallanzani IRCCS, Rome, Italy, ²Icna Foundation, Milan, Italy, ³Unità Operativa Malattie Infettive, Ospedale Civile di Legnano, Legnano, Italy, ⁴Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco" Università degli Studi di Milano, Milan, Italy, ⁵Clinical Immunology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy, ⁶ASST Papa Giovanni XXIII, Bergamo, Italy, ⁷IRCCS San Raffaele Scientific Institute, Infectious Diseases Unit, Milan, Italy, ⁸Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, ⁹Infectious Diseases Unit, University of Foggia, Foggia, Italy, ¹⁰University of Milan, Department of Health Sciences, Milan, Italy, ¹¹Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL

OC 37 11.46-11.56 Durability of Mega ART in a large cohort of treatment experienced people living with HIV: Data from ARCA database

L. Labate^{1,2}, B. Rossetti³, C. Russo^{1,2}, M. Bottanelli^{4,5}, C. Cassol^{6,7}, F. Bracchitta⁸, L. Graziani⁹, M. Tilli⁹, I. Rancan^{6,7}, C. Malcontenti¹⁰, S. Mora¹¹, R. Papaioannu^{4,5}, A. Bezenchek^{12,13}, A. Shallvari^{12,13}, A. Di Biagio^{1,2}

¹Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, ²Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ³Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy, ⁴Vita-Salute San Raffaele University- Milan (Italy), ⁵Infectious Diseases Unit, San Raffaele Scientific Institute-Milan (Italy), ⁶Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁷Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, ⁸Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy, ⁹Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy, ¹⁰SOD Malattie Infettive e Tropicali AOU Careggi, Firenze, ¹¹Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, ¹²INFORMA-PRO Srl, Rome, Italy, ¹³EURESIST Network GEIE, Rome, Italy



ORAL POSTER 11.10-12.00

HIV and SARS-CoV-2: from in vivo to in vitro

ALABASTRO B

Chairs: D. Cattaneo (Milano), F. Saladini (Siena)

OP 102 11.10-11.15 Trends of HIV-1 drug resistance and APOBEC editing in PBMC compartment over the last decade

D. Armenia¹, R. Gagliardini², C. Alteri^{3,4}, V. Svicher⁵, V. Cento⁶, V. Borghi⁷, A. Vergori², S. Cicalini², F. Forbici², L. Fabeni², A. Bertolli^{5,8}, W. Gennari⁷, V. Malagnino⁸, M. Andreoni⁹, C. Mussini⁷, A. Antinori², C.F. Perno⁴, M.M. Santoro⁵, F. Ceccherini-Silberstein⁵

¹UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy ³University of Milan, Milan, Italy, ⁴Bambino Gesù Children's Hospital, Rome, Italy, ⁵University of Rome "Tor Vergata", Rome, Italy, ⁶Humanitas Research Hospital, IRCCS, Milan, Italy, ⁷University of Modena and Reggio Emilia, Modena, Italy, ⁸Polyclinic of Rome "Tor Vergata", Rome Italy

OP 103 11.17-11.22 Trend over time of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and their drivers: cohort study from ARCA

I. Rancan^{1,2}, C. Cassol^{1,2}, L. Graziani³, M. Tilli³, C. Malcontenti⁴, C. Russo^{5,6}, M. Bottanelli^{7,8}, F. Bracchitta⁹, R. Papaioannu^{7,8}, L. Labate^{5,6}, S. Mora¹², A. Bezenchek^{10,11}, A. Shallvari^{10,11}, A. Di Biagio^{5,6}, B. Rossetti¹³

¹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ²Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, ³Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy, ⁴SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, ⁵Infectious Diseases Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neuroscience, Genoa, Italy, ⁶Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ⁷Vita-Salute San Raffaele University, Milan, Italy, ⁸Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy, ⁹Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy, ¹⁰INFORMA-PRO Srl, Rome, Italy, ¹¹EURESIST Network GEIE, Rome, Italy, ¹²Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy, ¹³Infectious Disease Department, USL SUDEST, Toscana, Misericordia Hospital, Grosseto, Italy

OP 104 11.24-11.29 Sotrovimab-emergent resistance in immunocompromised COVID-19 patients

F. Novazzi^{1,2}, D. Focosi³, F. Drago Ferrante¹, S. Boutahar¹, A. Genoni¹, F. Dentali², D. Dalla Gasperina², A. Bai^{1,2}, F. Maggi^{1,2}

¹Laboratory of Microbiology, ASST SetteLaghi, Varese, Italy, ²Department of Medicine and Surgery, University of Insubria, Varese, Italy, ³North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy



OP 105 11.31-11.36 Tenofovir plasma and intracellular pharmacokinetics in INSTI-based regimens

M. Ferrara¹, G. Accardo¹, S. Fantino¹, G. Trevisan¹, F. Alladio¹, E. Drappero¹, M. Tettoni¹, E. De Vivo², A. Ianniello², J. Mula², A. De Nicolò², A. D'Avolio², G. Di Perri¹, A. Calcagno¹, S. Bonora¹

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ²Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino

OP 106 11.38-11.43 Potent antiviral activity of new generation HIV-1 maturation inhibitors on human primary cells

L. Duca¹, P. Saccomandi¹, L. Piermatteo¹, R. Salpini¹, C. Stacchiotti¹, S. Aquaro², C.F. Perno³, V. Svicher¹, F. Ceccherini-Silberstein¹

¹Università degli Studi di Roma Tor Vergata, Dipartimento di Medicina Sperimentale, Roma, Italia, ²Università della Calabria, Dipartimento di Farmacia e Scienze della Salute e della Nutrizione, Arcavacata di Rende (CS), Italia, ³Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Roma, Italia

OP 107 11.45-11.50 Evaluation of the in vitro combinatorial activity of Ibalizumab and HIV-1 antivirals

F. Giammarino, N. Bartolini, L. Fiaschi, F. Dragoni, I. Vicenti, M. Zazzi, F. Saladini

Department of Medical Biotechnologies, University of Siena, Italy



SYMPOSIUM 12.15-13.15

AUDITORIUM SALA OGGIONI

A practical approach to HIV patients' management

Chairs: A. Gori (Milano), F. Vichi (Firenze)

The objectives of this symposium are to provide both clinical management insights on «late presentation in HIV» identifying the unmet needs of specific vulnerable patients, such as migrants, pregnant women, trans individuals, adolescents, and to increase the level of awareness for the HIV management in these specific populations. The program will also include new immuno-pharmacology concepts that may have a role in the future HIV therapy as well as a lecture on some new therapeutic approaches to tuberculosis that can impact the future management of people with HIV.

- 12.15-12.30 **Management of Late presentation in vulnerable populations - Interactive clinical case** C. Pinnetti, Roma
- 12.30-12.45 **Chasing inflammation: is there a role of the immunomodulant agents in HIV?**
- Interactive clinical case** G. Marchetti, Milano
- 12.45-13.00 **New therapeutic approaches to tuberculosis in people living with HIV** A. Matteelli, Brescia
- 13.00-13.15 **Discussion on Symposium issues**



ORAL COMMUNICATIONS 12.15-13.15

SALA STUCCHI

HIV and SARS-CoV-2: two intersecting epidemics

Chairs: M. Breveglieri (Bologna), S. Lo Caputo (Foggia)

OC 38 12.15-12.25 The Cascade of HIV Care (CoC) of Milan as compared to Italy: data derived from the COA Registry and the Icona cohort- Milan Fast Track City

A. d'Arminio Monforte^{1,3,7}, A. Navarra², A. Tavelli^{3,7}, B. Suligoj⁴, V. Regine⁴, L. Pugliese⁴, L. Timelli⁵, A. Caraglia⁵, M. Oldrini⁶, L. Cosmaro^{3,7}, D. Calzavara⁷, M. Cernuschi^{3,7}, G. Rizzardini⁸, A. Gori^{3,9}, S. Antinori¹⁰, M. Puoti^{3,11}, A. Castagna^{3,12}, E. Girardi^{2,3}

¹ASST Santi Paolo e Carlo, Unità Malattie Infettive e Tropicali, Milano, Italia, ²Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" - IRCCS, Roma, Italia, ³Fondazione Icona, Milano, Italia, ⁴Istituto Superiore di Sanità, Roma, Italia, ⁵Ministero della Salute, Roma, ⁶Fondazione LILA Milano, Milano, Italia, ⁷Milano Check Point, Milano, Italia, ⁸ASST Fatebenefratelli-Sacco, Divisione 1 Malattie Infettive, Milano, Italia, ⁹IRCCS Ca' Granda Ospedale Maggiore Policlinico, Clinica di Malattie Infettive, Milano, Italia, ¹⁰ASST Fatebenefratelli-Sacco, Divisione 3 Malattie Infettive, Milano, Italia, ¹¹ASST Grande Ospedale Metropolitano Niguarda, Unità Malattie Infettive, Milano, Italia, ¹²IRCCS Ospedale San Raffaele, Unità di Malattie Infettive, Milano, Italia

OC 39 12.27-12.37 Effect of COVID-19 pandemic on the HIV cascade of care at a Provincial level

F. Maggiolo¹, R. Teocchi¹, P. Meli², D. Valenti³, F. Radici⁴, I. Mercurio⁵, A.P. Callegaro⁶

¹ASST Papa Giovanni XXIII, ²Comunità Emmaus & Caritas Bergamasca, ³Associazione FROM, ⁴Arcigay Bergamo Cives, ⁵CRI-Comitato di Bergamo, ⁶ASST Bergamo Est, Bergamo



OC 40 12.39-12.49 **SARS-CoV-2 infection and vaccination coverage among fragile populations in a Local Health Area of Northern Italy**

G. Maifredi¹, I. Izzo², C. Gasparotti¹, C.V. Sileo¹, S. Storti², M. Degli Antoni², G. Tiecco², S. Amadasi², E. Focà², F. Castelli², E. Quirós-Roldán²

¹ATS Brescia (Brescia Health Protection Agency), Brescia, Italy, ²Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali di Brescia, Brescia, Italy

OC 41 12.51-13.01 **New diagnosis of HIV among transgender women sex-workers across time: results from a multi-year street-based intervention (2017-2020)**

G. Lapadula^{1,2}, E. Beretta¹, P. Columpsi¹, M. Comolatti¹, N. Corti², S. Limonta¹, A. Rugova¹, A. Ranzani¹, A. Soria¹, N. Squillace¹, E. Lungu³, A. Monopoli³, V. Cristiano³, P. Bonfanti^{1,2}

¹School of Medicine, University of Milano-Bicocca, Milan, Italy, ²San Gerardo Hospital, ASST Monza, Monza, Italy, ³ALA Milano Onlus, Milan, Italy



EXPERT MEETING 12.15-13.15

ALABASTRO A

Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus

Chair: A. Di Biagio (Genova)

Con la sponsorizzazione non condizionante di Gilead Sciences

Modern antiretroviral therapy (ART) offers several treatment options characterized by high efficacy and tolerability, and new strategies with less drug regimens and new drugs are now available for the treatment of HIV infection. As definitive data on the long-term success of these new strategies are lacking, a panel of Experts in the care of HIV infection expressed their consensus on which could be the best strategy to achieve and maintain long-term virological and clinical success for PLWH in course of antiretroviral therapy, using Delphi methodology. The main consensus statements developed will be presented and discussed during this Meeting.

12.15-12.30 **Optimizing the ARV treatment focusing on long-term effectiveness and a person-centred approach: consensus guidance using Delphi process**

A. Di Biagio, Genova

12.30-13.10 **Round table - Delphi Consensus results:**

Discussants: M. Borderi, Bologna; G. Guaraldi, Modena; P. Maggi, Caserta

- Clinical efficacy: ART-monitoring strategy
- Immunology and Pharmacology
- Long-term safety
- Quality of life assessment

13.10-13.15 **Final considerations**

A. Di Biagio, Genova



ORAL POSTER 12.15-13.05

ALABASTRO B

Acute COVID-19 and post COVID-19 syndrome

Chairs: M. Lichtner (Latina), A. Vergori (Roma)

OP 108 12.15-12.20 **Long-COVID syndrome data from 126,752 patients: a systematic review and meta-analysis**

F. Di Gennaro¹, A. Belati¹, O. Tulone², L. Diella¹, D.F. Bavaro¹, R. Bonica², V. Genna², L. Smith³, M. Trott³, M. Barbagallo², L.J. Dominguez¹, N. Veronese², A. Saracino¹

¹Department of Biomedical Sciences and Human Oncology, Section of Infectious Diseases, University of Bari, Bari, Italy, ²Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy, ³Faculty of Sport Sciences, University of Murcia, Murcia, Spain

OP 109 12.22-12.27 **Post-Acute Sequelae of COVID-19 (PASC): An Italian Experience**

P. Pasculli¹, M.A. Zingaropoli¹, F. Ciccone¹, F. Paribeni¹, R. Merz¹, F. Dominelli¹, G. Siccardi¹, S. Pellegrini¹, G. Galardo², C.M. Mastroianni¹, M.R. Ciardi¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ²Medical Emergency Unit, Sapienza, University of Rome, Policlinico Umberto I, Rome, Italy



OP 110 12.29-12.34 A multidisciplinary model to screen and treat the post COVID-19 Syndrome

N. Squillace¹, V. Cogliandro¹, E. Rossi², G. Bellelli^{3,9}, G. Foti^{4,9}, M. Pozzi⁴, F. Luppi^{5,9}, M. Lettino⁶, M.G. Strepparava^{7,9}, C. Ferrarese^{8,9}, E. Pollastri¹, A. Rugova¹, E. Ricci¹⁰, P. Bonfanti^{1,9} for the STORM Long-COVID Team

¹Infectious Disease Unit, San Gerardo hospital, ASST-Monza, Italy, ²Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, University of Milano-Bicocca, Monza, Italy, ³Acute Geriatric Unit, San Gerardo hospital, ASST-Monza, Italy, ⁴Anesthesia and Intensive Care Unit, San Gerardo hospital, ASST-Monza, Italy, ⁵Respiratory Disease Unit, San Gerardo hospital, ASST-Monza, Italy, ⁶Cardiology Division, San Gerardo Hospital, ASST-Monza, Monza, Italy, ⁷Department of Mental Health, Clinical Psychology Unit, San Gerardo Hospital, ASST-Monza, Monza, Italy, ⁸Neurology Unit, San Gerardo hospital, ASST-Monza, Italy, ⁹School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy, ¹⁰Fondazione ASIA

OP 111 12.36-12.41 Long term complications of COVID-19 in patients hospitalized in Clinica Malattie Infettive, Ospedali Riuniti, Ancona

B. Candelaresi, S. Mazzanti, L. Brescini, V. Barocci, M. Di Pietrantonio, P. Mantini, S. Olivieri, F. Pallotta, F. Ginevri, G. Cesaretti
Clinica Malattie Infettive, Ospedali Riuniti, Ancona

OP 112 12.43-12.48 Outcome of patients with chronic liver disease hospitalized for SARS-CoV-2: a single centre matched cohort

M. Ranzenigo¹, C. Bertoni¹, D. Ceccarelli², L. Galli², E. Messina², H. Hasson², A. Siribelli², R. Lolatto², A. Castagna^{1,2}, C. Uberti-Foppa^{1,2}, G. Morsica²

¹Vita-Salute University, Milan, Italy, ²Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

OP 113 12.50-12.55 Characterization of three waves of COVID-19 occurring in southern Italy: results of a multicentre cohort study

V. Pattapola¹, M. Pisaturo¹, P. Maggi², A. Russo¹, R. Astorri¹, F.G. Numis³, I. Gentile⁴, V. Sangiovanni⁵, V. Esposito⁶, R. Punzi⁷, G. Calabria⁸, C. Rescigno⁹, A. Salomone Megna¹⁰, A. Masullo¹¹, E. Manzillo¹², G. Russo¹³, R. Parrella¹⁴, G. Dell'Aquila¹⁵, M. Gambardella¹⁶, A. Ponticello¹⁷, N. Coppola¹ on behalf of CoviCam group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ²Infectious Diseases Unit, A.O. S Anna e S. Sebastiano Caserta, Italy, ³Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, ⁴Infectious disease unit; University Federico II, Naples, Italy, ⁵Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁶IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁷Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁸IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁹First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁰Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, ¹¹Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, ¹²VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹³Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, ¹⁴Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁵Infectious Diseases Unit, AO Avellino, Italy, ¹⁶Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, ¹⁷Pneumology Unit, AORN Caserta, Italy



ORAL POSTER 12.15-13.05

BERGAMO SCIENCE CENTER

Immunological efficacy of COVID-19 vaccination in vulnerable populations

Chairs: G. Scarlatti (Milano), M. Tavio (Ancona)

OP 114 12.15-12.20 TNF-alfa expression is negatively correlated to seroconversion after SARS-CoV-2 mRNA BNT162b2 vaccine in lung transplant patients

M. Guardiani¹, M.A. Zingaropoli¹, F. Cogliatti-Dezza¹, A. Centofanti², C. Carillo², E. Tortellini¹, F. Dominelli¹, A. Napoli³, A. Gaeta¹, F. Venuta², M. Lichtner^{1,4}, M.R. Ciardi¹, C.M. Mastroianni¹, G. Russo¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, ²Department of General and Specialistic Surgery "Paride Stefanini", Sapienza University of Rome, ³Department of Molecular Medicine, Sapienza University of Rome, ⁴Infectious Diseases Unit, Santa Maria (SM) Goretti Hospital, Sapienza University of Rome, Latina

OP 115 12.22-12.27 Different specific T cell responses to the third dose of mRNA COVID-19 vaccine in multiple sclerosis patients under disease modifying treatments

F. Dominelli¹, M.A. Zingaropoli¹, M. Tartaglia², E. Tortellini¹, M. Guardiani¹, V. Perri¹, P. Pasculli¹, F. Ciccone¹, L. Malimpensa², V. Baione², A. Napoli³, A. Gaeta¹, M. Lichtner^{1,4}, A. Conte², C.M. Mastroianni¹, M.R. Ciardi¹

¹Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza, Università di Roma, ²Dipartimento di Neuroscienze Umane, Centro di Sclerosi Multipla, Sapienza, Università di Roma, ³Dipartimento di Medicina Molecolare, Sapienza, Università di Roma, ⁴Unità di Malattie Infettive, Ospedale S. Maria Goretti/Sapienza Università di Roma, Latina, Italia

OP 116 12.29-12.34 SARS-CoV-2 vaccination effectiveness in Pemphigus Vulgaris Rituximab-treated patients

C. Fenizia¹, O. Utyro², S. Salanitro², C. Moltrasio¹, M. Clerici¹, L. Ottobrini¹, A. Marzano¹, D. Trabattoni²

¹Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ²Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy



OP 117 12.36-12.41 SARS-CoV-2 antibody response in solid organ transplant patients after mRNA BNT162b2: data from an observational prospective study

F. Cogliati Dezza¹, F. Dominelli¹, M. Guardiani¹, E. Tortellini¹, G. Savelloni¹, M. Garofalo², A. Centofanti³, C. Carillo³, A. Gaeta⁴, R. Pretagostini², G. Russo¹, C.M. Mastroianni¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome Italy, ²General Surgery and Organ Transplantation Unit, Sapienza University of Rome, Rome, Italy, ³Division of Thoracic Surgery and Lung Transplant, Sapienza University of Rome, Rome, Italy, ⁴Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

OP 118 12.43-12.48 Durability of SARS-CoV-2 mRNA vaccine immune response in people living with HIV

S. Cicalini¹, A. Cozzi-Lepri², A. Vergori¹, S. Meschi¹, V. Bordoni¹, S. Lanini¹, D. Lapa¹, D. Mariotti¹, L. De Pascale¹, V. D'Aquila¹, M. Fusto¹, C. Castillett¹, A.R. Garbuglia¹, C. Agrati¹, E. Girardi¹, F. Vaia¹, A. Antinori¹

¹National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Roma, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK

OP 119 12.50-12.55 Decay pattern of Anti-SARS-CoV-2 Antibodies in PWH

J. Milic¹, A. Tili², S. Renzetti³, F. Motta¹, M. Meschiari², R. Fogliani², F. Ferrari², B. Meccugni², S. Mimmi², S. Borsari², S. Calza³, A. Cossarizza¹, C. Mussini^{1,2}, G. Guaraldi^{1,2}

¹University of Modena and Reggio Emilia, Modena, Italy, ²Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ³University of Brescia, Brescia, Italy



SYMPOSIUM 13.15-14.15

AUDITORIUM SALA OGGIONI

Immunological control over HIV: from models of spontaneous control to immunotherapeutic approaches

Chairs: C. Agrati (Roma), A. Cossarizza (Modena)

The symposium is intended to address different aspects of the immune control over HIV. In particular, a comprehensive review of the latest notions on known human and animal models of spontaneous control over HIV will be provided. The interaction of the virus with specific cell subpopulations, and in particular stem cell memory cells, will also be illustrated. The most novel specific immunotherapeutic approaches to overcome HIV infection will also be thoroughly reviewed during the symposium.

13.15-13.30	HIV and stem cell memory cells: from pathogenesis to therapeutic approaches	L. Manganaro, Milano
13.30-13.45	Immunotherapy as a tool towards cure interventions	M.S. Clerici, Milano
13.45-14.00	Models of spontaneous control over HIV infection	G. Poli, Milano
14.00-14.15	Discussion on Symposium issues	



ORAL COMMUNICATIONS 13.15-14.15

SALA STUCCHI

Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities

Chairs: T. Bini (Milano), G. Orofino (Torino)

OC 42 13.15-13.25 Incident diabetes in course of antiretroviral therapy

L. Taramasso¹, N. Squillace², E. Ricci³, B. Menzaghi⁴, G. Orofino⁵, G.V. De Socio⁶, C. Molteni⁷, C.V. Martinelli⁸, G. Madeddu⁹, F. Vichi¹⁰, L. Valsecchi¹¹, B.M. Celesia¹², P. Maggi¹³, F. Conti¹⁴, G.F. Pellicanò¹⁵, A. Cascio¹⁶, E. Sarchi¹⁷, R. Gulminetti¹⁸, G. Parruti¹⁹, L. Calza²⁰, K. Falasca²¹, A. Di Biagio^{1,22}, P. Bonfanti² on behalf of CISAI Study Group

¹Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ²Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ³Fondazione ASIA Onlus, Buccinasco (MI), Italy, ⁴Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, Busto Arsizio, Italy, ⁵Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, Torino, Italy, ⁶Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, Perugia, ⁷Infectious Disease Unit, Ospedale A. Manzoni, Lecco, Italy, ⁸SOD Malattie Infettive e Tropicali AOU Careggi, Florence, Italy, ⁹Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ¹⁰Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, Florence, Italy, ¹¹Infectious Disease Unit (I Divisione), ASST Fatebenefratelli Sacco, Milan, Italy, ¹²Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, Italy, ¹³Department of Infectious Disease, University of Campania Luigi Vanvitelli, Naples, Italy, ¹⁴Infectious Diseases Unit, Department of Biomedical and Clinical Sciences 'Luigi Sacco', Università degli Studi di Milano, Milan, Italy, ¹⁵Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', Unit of Infectious Diseases, University of Messina, ¹⁶Infectious and Tropical Diseases Unit- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) - University of Palermo, Palermo, Italy, ¹⁷Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, ¹⁸Fondazione



IRCCS Policlinico San Matteo, University of Pavia, Pavia Italy, ¹⁹Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ²⁰Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S. Orsola-Malpighi Hospital, "Alma Mater Studiorum" University of Bologna, Bologna, Italy, ²¹Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy, ²²Department of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa, Italy

OC 43 13.27-13.37 Treatment with integrase inhibitors among antiretroviral naïve patients is not associated with increased risk of diabetes mellitus

G. Lapadula^{1,2}, A. Soria², G. Micheli³, M.V. Cossu⁴, A. De Vito⁵, G. Guaraldi⁶, A. Castagna⁷, A. Di Biagio⁸, S. Cicalini⁹, P. Bonfanti^{1,2}, A. Cozzi-Lepri, A. d'Arminio Monforte for ICONA cohort Study

¹School of Medicine, University of Milano Bicocca, Milano, Italy, ²Clinic of Infectious Diseases, San Gerardo Hospital, ASST Monza, Monza, Italy, ³Università Cattolica del Sacro Cuore, Infectious Diseases Unit, Roma, Italy, ⁴1st Division of Infectious Diseases, 'Luigi Sacco' University Hospital, Milan, Italy, ⁵Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, ⁶Unit of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, ⁷University "Vita Salute", San Raffaele Hospital, Milano, Italy, ⁸Unit of Infectious Diseases, University of Genoa, Genoa, Italy, ⁹National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy

OC 44 13.39-13.49 Non-Alcoholic to Metabolic Associated Fatty Liver Disease: Cardiovascular Implications of a Change in Terminology in Patients Living With HIV

J. Milic¹, S. Renzetti², F. Motta², L. Gozzi³, A. Cervo³, G. Burastero³, V. Iadernia³, G. Franceschi³, M. Faltoni³, S. Volpi³, A. Mazzocchi³, C. Mussini^{2,3}, G. Sebastiani⁴, S. Calza², P. Raggi⁵, G. Guaraldi^{1,3}

¹University of Modena and Reggio Emilia, Modena, Italy, ²University of Brescia, Brescia, Italy, ³Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy, ⁴McGill University Health Centre, Montreal, Canada, ⁵University of Alberta, Edmonton, Canada

OC 45 13.51-14.01 Syphilis infection and re-infection in PLWH and PrEP users: new insights into epidemic dynamics

R. Rossotti^{1,5}, D. Tesoro^{2,5}, L. Gazzola², A. Tavelli³, A. De Bona^{2,5}, V. Licari⁴, F. D'Amico¹, C. Baiguera¹, D. Calzavara⁵, N.B. Bana¹, V. Ferrara², R. Repposi⁵, M. Cernuschi^{5,6}, M. Puoti^{1,4}, A. d'Arminio Monforte^{2,7}

¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, ²Department of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, ³ICONA Foundation, Milan, ⁴University of Milano-Bicocca, Milan, ⁵Milano Checkpoint, Milan, ⁶Unit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, ⁷University of Milano, Milan



ORAL COMMUNICATIONS 13.15- 14.15

ALABASTRO A

Immunological efficacy of SARS-CoV-2 vaccine II

Chairs: S. Parisi (Padova)

OC 46 13.15-13.25 Monitoring saliva and plasma neutralizing activity induced by the administration of a third BNT162B2 vaccine dose

M. Garziano^{1,2}, O. Utyro³, S. Strizzi¹, C. Vanetti¹, I. Saulle¹, C. Conforti¹, F. Cicilano¹, M. Clerici^{1,2}, M. Biasin¹

¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ³Department of Medical surgical and experimental sciences University of Sassari

OC 47 13.27-13.37 Lower neutralization level against SARS-CoV-2 Omicron (BA.1) variant than against reference strain after a third dose of mRNA vaccine in PLWH

A. Vergori¹, A. Cozzi Lepri², G. Matusali³, F. Colavita³, S. Cicalini¹, P. Galli⁴, A.R. Garbuglia³, M. Fusto¹, V. Puro⁵, E. Girardi⁶, F. Vaia⁷, A. Antinori^{1,4}

¹HIV/AIDS Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK, ³Virology Unit, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, ⁴Health Direction, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁵Risk Management Unit, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁶Scientific Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy, ⁷General Direction, National Institute for Infectious Diseases L.Spallanzani, IRCCS, Rome, Italy

OC 48 13.39-13.49 T-cell responses to SARS-CoV-2 Spike protein after 3 doses of BNT162b2 mRNA vaccination in healthy individuals, crossrecognize Alpha, Delta and Omicron variants of concern

M. Iannetta, A. Di Lorenzo, A. Imeneo, A. Lodi, L. Ferrari, I. Fato, B. Massa, P.G. Pace, I. Spalliera, P. Vitale, B. Rossi, T. Mulas, L. Campogiani, L. Coppola, M. Compagno, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati
Department of System Medicine Tor Vergata University, Rome



OC 49 13.51-14.01 CD4 cell count is critical for specific T cell-mediated response in PLWH before and after third dose of COVID-19 vaccine

E. Tortellini¹, M.A. Zingaropoli¹, G. Mancarella^{1,2}, R. Marocco², A. Carraro^{1,2}, M. Jhamour², V. Perri¹, M. Guardiani¹, F. Dominelli¹, A. Napoli³, A. Gaeta¹, F. Mengoni¹, P. Zuccalà², V. Belvisi², B. Kertusha^{1,2}, A. Parente^{1,2}, C. Del Borgo², V. Vullo¹, M.R. Ciardi¹, C.M. Mastroianni¹, M. Lichtner^{1,2} and LATINA COVID-19 Group

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, ²Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, ³Department of Molecular Medicine, Sapienza University of Rome



ORAL POSTER 13.15-14.05

Open questions about ART efficacy

ALABASTRO B

Chairs: M. Borderi (Bologna), R. Gulminetti (Pavia)

OP 120 13.15-13.20 Blood telomere length gain in virologically suppressed patients switching to dolutegravir plus lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study

F. Lombardi¹, A. Sanfilippo², M. Fabbiani³, A. Borghetti¹, A. Ciccullo⁴, S. Di Giambenedetto^{1,2}

¹Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italia, ²Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica, Roma Italia, ³UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italia, ⁴Unità di Malattie infettive, Ospedale San Salvatore, L'Aquila, Italia

OP 121 13.22-13.27 Real-life use of Doravirine in treatment-experienced people living with HIV: an Italian multicentre study

M. Mazzitelli¹, M. Degli Antoni², F. Castelli², D. Ripamonti³, G. Zuglian³, G. Lapadula⁴, M. Fabbiani⁵, A. Ferraresi⁶, C. Putaggio¹, A.M. Cattelan¹, E. Quiros-Roldan²

¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, ²Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital and University of Brescia, Brescia, ³Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, ⁴University of Milan Bicocca, Monza, ⁵Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, ⁶Division of Infectious Diseases, Cremona Hospital, Cremona

OP 122 13.29-13.34 Forgiveness to imperfect adherence to bicitegravir/emtricitabine/tenofovir alafenamide

F. Maggiolo¹, D. Valenti^{1,2}, R. Teocchi³, L. Comi¹, E. Di Filippo¹, M. Rizzi¹

¹UOC Infectious Diseases, ²FROM foundation, ³Informatics department, ASST Papa Giovanni XXII, Bergamo Italy

OP 123 13.36-13.41 Evaluation of metabolic safety profile in naive and virologically suppressed HIV-1 infected individuals starting/switching to a bicitegravir single-tablet-regimen in a real-life setting

M. Trizzino, C. Gioè, E. Di Marco, A. Mancuso, M. Tolomeo, A. Cascio

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

OP 124 13.43-13.48 Real-world effectiveness of switching to bicitegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in women living with HIV: subgroup analysis from ICONA-BIC

A. d'Arminio Monforte¹, A. Tavelli², A. Cingolani³, C. Mussini⁴, S. Piconi⁵, A. Calcagno⁶, G. Orofino⁷, S. Cicalini⁸, A. Castagna⁹, F. Ceccherini Silberstein¹⁰, A. Gori¹¹, A. Antinori⁸

¹Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, University of Milan, Milan, Italy, ²Icona Foundation, Milan, Italy, ³Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, ⁴Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy, ⁵Infectious Diseases, ASST Lecco, Lecco, Italy, ⁶Unit of Infectious Diseases, Ospedale Amedeo di Savoia, Department of Medical Sciences, University of Turin, Turin, Italy, ⁷"Divisione A" Unit of Infectious Diseases, Ospedale Amedeo di Savoia, ASL Città di Torino, Italy, ⁸Clinical Department, HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, ⁹Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁰Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ¹¹Clinic of Infectious Diseases, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

OP 125 13.50-13.55 Tolerability, viro-immunological, metabolic effects, and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week analysis

M. Mazzitelli¹, M. Trunfio², D. Mengato³, C. Putaggio¹, L. Sasseti¹, D. Leoni¹, E. Castelli¹, A.M. Cattelan¹

¹Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, ²Infectious Disease Unit, Department of Medical Sciences at Amedeo di Savoia Hospital, University of Torino, Torino, Italy, ³Hospital Pharmacy Department, Padua University Hospital, Padua, Italy





ORAL POSTER 13.15-14.05

BERGAMO SCIENCE CENTER

Immunological complexity in COVID-19

Chairs: E. Focà (Brescia), E. Nicastri (Roma)

OP 126 13.15-13.20 Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity

A. Ruggiero¹, C. Piubelli², L. Calciano¹, G. Siracusano³, M.T. Valenti¹, L.G. Delle Carbonare¹, T. Fantoni¹, L. Lopalco³, S. Accordini¹, A. Beretta⁴, Z. Bisoffi², D. Zipeto¹

¹University of Verona, Verona, Italy, ²IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy, ³Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Solongevity Research, Milan, Italy

OP 127 13.22-13.27 Affinity maturation and neutralizing activity of anti-SARS-CoV-2 Spike antibodies

S. Caucci¹, R. Longo¹, B. Corvaro¹, A. Valenza², K. Marinelli², P. Bagnarelli^{1,2}, S. Menzo^{1,2}

¹Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy, ²Virology Laboratory, Azienda Ospedaliera Ospedali Riuniti di Ancona, Ancona, Italy

OP 128 13.29-13.34 Correlation between clinical aspects and serum/CSF cytokine levels in early versus classic onset SARS-CoV-2-related Guillain-Barré Syndrome

S. Boni¹, L. Benedetti², M. Feasi¹, A. Assini³, E. Blasi Vacca¹, S. Grisanti^{2,4}, A. Parisini¹, D. Franciotta², F. Del Puente¹, F. Massa^{2,4}, N. Bobbio¹, T. Vigo², R. Prinapori¹, D. Giunti², E. Mobilia², D. Visigalli², A. Beronio⁵, P. Rivera⁶, F. Bandini⁷, A. Granata⁸, E. Narciso⁷, A. Schenone^{2,4}, E. Pontali¹

¹Department of Infectious Diseases - Galliera Hospital, Genova, Italy, ²IRCCS, Ospedale Policlinico San Martino, Genova, Italy, ³Neurology Unit, Galliera Hospital Genova, Italy, ⁴Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy, ⁵Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy, ⁶Department of Neurology, Imperia Hospital, Imperia, Italy, ⁷Department of Neurology, ASL3 Genovese, Genova, Italy, ⁸Department of Neurology Santa Corona Hospital, Pietra Ligure, Savona, Italy

OP 129 13.36-13.41 A real-life single-center study on the impact of anti-SARS-CoV2 vaccination

C. Leanza¹, S. Covino¹, R.A. Valia¹, A. Destro¹, F. Petrucci¹, E. Motta¹, M. Aneuchoum¹, R. Donà¹, F. Cancelli¹, C.M. Mastroianni¹

Department of Public Health and Infectious Diseases, Sapienza University, Rome

OP 130 13.43-13.48 Short course remdesivir in early Covid-19 as an effective and useful option in both out- and in-patients

C. Del Borgo¹, A. Gasperin², R. Marocco¹, D. Di Trento², S. Garattini², M. De Masi¹, A. Grimaldi², S. Corazza², S.G. De Maria², S. Gismondi¹, P. Fabietti¹, B. Bartolozzi¹, G. Bagaglini³, G. Bonanni³, M. Lichtner^{1,2}

¹Infectious Diseases Unit, SM Goretti Hospital Latina, ²Department of Public Health and Infectious Diseases, "La Sapienza" University, Rome, ³Pharmacy Service Unit, SM Goretti Hospital Latina

OP 131 13.50-13.55 Dendritic cell maturation after infection with a clone of Leishmania tarentolae expressing the SARS-CoV-2 spike protein as a vaccine vehicle

M. Garziano^{1,2}, I. Varotto-Boccazzi^{3,4}, C. Conforti¹, G.M. Cattaneo³, B. Bisaglia³, P. Gabrieli^{3,4}, M. Paroni^{3,4}, A. Manenti⁵, D. Rubolini^{6,7}, M. Clerici^{2,8}, E. Montomoli^{5,9}, G. Zuccotti^{1,4}, C. Vanetti¹, S. Epis^{3,4}, M. Biasin¹, C. Bandi^{3,4}, D. Trabattoni¹

¹Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, ²Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ³Department of Biosciences, University of Milan, Milan, Italy, ⁴Pediatric CRC 'Romeo ed Enrica Invernizzi', University of Milan, Milan, Italy, ⁵VisMederi, Siena, Italy, ⁶Department of Environmental Science and Policy, University of Milan, Milan, Italy, ⁷Water Research Institute-National Research Council of Italy, IRSA-CNR, Brugherio, Italy, ⁸IRCCS Fondazione don Carlo Gnocchi, Milan, Italy, ⁹Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy





SYMPOSIUM 14.15-15.15

AUDITORIUM SALA OGGIONI

COVID-19 from early treatment to long-term care

Chairs: G. Rizzardini (Milano), M. Rizzi (Bergamo)

This symposium will offer insights in the early and late management of COVID-19. On one end, we will discuss risk stratification of vulnerable individuals who qualify for early treatment of SARS-CoV-2 infection. On the other end, we will discuss pathogenesis and care of Post-Acute COVID Syndrome (PACS). A clinical case presentation of a vaccinated individual living with HIV will offer the framework to discuss risk stratification for early treatment of immunologically vulnerable populations, as well as how to assess and manage post-acute COVID Syndrome.

- 14.15-14.30 **From risk stratification to early treatment. How to keep a patient with SARS-CoV-2 out of hospital?** D. Peppia, London UK
- 14.30-14.45 **From acute to post acute SARS-CoV-2 disease: can we prevent or reverse PACS?** S.G. Deeks, San Francisco USA
- 14.45-15.15 **Panel discussion - Clinical models in managing PACS. Is resilience our goal?** Discussants:
S. Deeks, San Francisco USA; G. d'Ettore, Roma; A. M. Geretti, Roma;
G. Guaraldi, Modena; D. Peppia, London UK; A. Vergori, Roma



ORAL COMMUNICATIONS 14.15-15.15


SALA STUCCHI

Dual therapy in naive and switched PLWH

Chairs: S. Carbonara (Bari), B. Celesia (Catania)

- OC 50** 14.15-14.25 **Adherence rates and forgiveness to uncomplete adherence to 3TC/DTG**
F. Maggiolo¹, D. Valenti^{1,2}, R. Teocchi³, L. Comi¹, E. Di Filippo¹
¹UOC Infectious Diseases, ²FROM foundation, ³Informatics department, ASST Papa Giovanni XXII, Bergamo Italy
- OC 51** 14.27-14.37 **12-Month immunological changes in patients randomized to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study)**
A. Cossarizza¹, M. Mattioli¹, A. Paolini¹, A. Neroni¹, S. De Biasi¹, D. Lo Tartaro¹, R. Borella¹, L. Fidanza¹, L. Gibellini¹, B. Beghetto², E. Roncaglia², G. Nardini², M. Menozzi², G. Cuomo², M. Di Gaetano², G. Orlando², V. Borghi², C. Mussini^{1,2}
¹University of Modena and Reggio Emilia, School of Medicine, ²AOU Policlinico di Modena
- OC 52** 14.39-14.49 **Switch to doravirine with dolutegravir dual regimen compared to other dual dolutegravir-based regimens in clinical practice: a 96-week analysis**
R. Rossotti¹, F. D'Amico¹, A. Nava², A. Raimondi¹, D. Fanti², N.B. Bana¹, E. Inglese², L.G. Chianura¹, M.C. Moioli¹, C. Vismara², M. Puoti¹
¹Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Chemical-Clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- OC 53** 14.51-15.01 **Clinical and virological characteristics of people living with HIV who fail to maintain virological suppression after switching to dolutegravir-based two drug regimens. Results from the prospective observational ARCA cohort**
L. Taramasso¹, R. Gagliardini², C. Sepulcri³, A. Shallvari⁴, W. Gennari⁵, F. Lombardi⁶, S. Di Giambenedetto^{6,7}, F. Maggiolo⁸, I. Vicenti⁹, V. Borghi¹⁰, V. Micheli¹¹, D. Francisci¹², E. Pontali¹³, S. Rusconi¹⁴, R. Maserati¹⁵, P. Laghetti¹⁶, B. Bruzzone¹⁷, S.T. Kiro¹⁸, A. Di Biagio^{1,3}, ARCA collaborative group
¹Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ²HIV/AIDS Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, ³Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ⁴InformaPRO S.r.l., Rome, Italy, ⁵Clinical Microbiology, Ospedale Civile di Baggiovara-Policlinico di Modena, Modena, Italy, ⁶Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁷Department of Safety and Bioethics, Catholic University of the Sacred Heart, Rome, Italy, ⁸Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁹Department of Medical Biotechnologies, University of Siena, Siena, Italy, ¹⁰Clinica Malattie infettive, Azienda Ospedaliero Universitaria di Modena, ¹¹Laboratory of Clinical Microbiology, Virology and Bioemergencies, ASST Fatebenefratelli Sacco L. Sacco Hospital, Milan, Italy, ¹²Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, ¹³Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, ¹⁴Infectious Disease Unit, ASST Ovest Milanese, Legnano (MI), Italy; Department of Biomedical and Clinical Sciences DIBIC L. Sacco, University of Milan, Milan, Italy, ¹⁵Dipartimento Scienze mediche e malattie infettive, Fondazione IRCCS Policlinico "San Matteo", Pavia, Italy, ¹⁶Clinic of Infectious Diseases, University Hospital Policlinico, University of Bari, Bari, Italy, ¹⁷Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ¹⁸Infectious Disease Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy





ORAL COMMUNICATIONS 14.15-15.15

ALABASTRO A

Mental health and predictors of AIDS and non-AIDS defining co-pathologies

Chairs: M. Farinella (Roma), P. Maggi (Caserta)

OC 54 14.15-14.25 Relation between genetic polymorphisms or variants and cognitive impairment in a group of HIV-infected people

M. Degli Antoni¹, I. Zanella², E. Zacchi², C. Fornari¹, B. Fumarola¹, E. Focà¹, F. Castelli¹, E. Quiros-Roldan¹

¹University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, ²Department of Molecular and Translational Medicine, University of Brescia and Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia

OC 55 14.27-14.37 A higher CPE score in PLWH with HAND switched to a less neurotoxic regimen is associated to improved memory test (MARAND-X study)

A. Lazzaro¹, D. Vai², A. Barco³, G. Stroppolini^{4,5}, V. Pirriatore⁶, G. Guastamacchia², M. Nigra⁷, V. Ghisetti⁸, M.C. Tettoni⁴, M. Trunfio⁴, A. Trentalange⁴, S. Bonora⁴, G. Di Perri⁴, A. Calcagno⁴

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Roma Italy, ²Unit of Neurology, Maria Vittoria Hospital, ASL Città di Torino, Turin, Italy, ³Infectious Diseases Unit, Ospedale Maggiore della Carità, Novara, Italy, ⁴Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy ⁵Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy, ⁶SC Tropical and Infectious Disease ASL Città di Torino, ⁷Biochemistry and Immunology Laboratory, Maria Vittoria Hospital, ASL "Città di Torino", Turin, Italy, ⁸Microbiology and Molecular Biology Laboratory, Amedeo di Savoia Hospital, ASL Città di Torino, Turin, Italy

OC 56 14.39-14.49 Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART

P. Saltini^{1,2,3}, A. Cozzi-Lepri⁴, G. Bozzi¹, G. Marchetti⁵, L. Taramasso⁶, S. Mazzanti⁷, V. Rizzo⁸, A. Antinori⁹, C. Mussini¹⁰, A. Gori^{1,2,3}, A. D'Arminio Monforte⁵, A. Bandera^{1,2,3}

¹Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy, ³Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy, ⁴Institute for Global Health UCL, University College London, London, UK, ⁵Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy, ⁶Infectious Diseases Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, Genoa, Italy, ⁷Infectious Diseases Clinic, Ospedali Riuniti Umberto I, Ancona, Torrette, Italy, ⁸Immunodeficiency and Gender Related Infectious Diseases Unit, Department of Infectious Disease and Infectious Emergencies, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁹Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS, Rome, Italy, ¹⁰Clinic of Infectious Diseases, University of Modena, Modena, Italy

OC 57 14.51-15.01 Association between HIV-1 DNA and clinical outcome in people living with HIV

M. Bottanelli¹, D. Ceccarelli², R. Lolatto², L. Galli², M. Guffanti², R. Dell'Acqua², G. Ponta¹, G. Mori¹, A. Castagna^{1,2}, C. Muccini^{1,2}

¹School of Medicine and Surgery, Vita Salute San Raffaele University, Milan, Italy, ²Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy



ORAL POSTER 14.20-15.10

ALABASTRO B

Prevention and access to services during COVID pandemic

Chairs: D. Calzavara (Milano), N. Gianotti (Milano)

OP 132 14.20-14.25 Narratives at the time of SARS-CoV-2 vaccination

M.G. Marini¹, E. Volpato^{2,3}, L. Reale¹, M. Portaro⁴, A. Uglietti⁴

¹Fondazione ISTUD, Milan (Italy), ²Department of Psychology, Università Cattolica del Sacro Cuore, Milan (Italy), ³IRCCS Fondazione Don Carlo Gnocchi, Milan (Italy), ⁴Infectious Diseases&Vaccines Medical Affairs Department, Janssen-Cilag SpA, Cologno Monzese (MI) (Italy)

OP 133 14.27-14.32 Vaccine-preventable diseases in PLWH: adherence to recommendations in a single center in Northern Italy

F. Pennati, V. Marchese, R. Zilocchi, S. Arsuffi, I. Polesini, F. Gaffurini, D. Castelli, E. Quiros Roldan, F. Castelli, E. Focà

Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy





OP 134 14.34-14.39 Impact of COVID-19 pandemic on sexual exposure and post-exposure prophylaxis (PEP) prescription appropriateness in a large Hospital, Northern Italy

S. Arsuffi¹, D. Minisci¹, F. Pennati¹, I. Polesini¹, S. di Luglio¹, E. Quiros-Roldan¹, S. Calza², F. Castelli¹, E. Focà¹

¹Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

OP 135 14.41-14.46 Looking for 90-90-90 goals: a real life experience during SARS-CoV-2 pandemia

G. Brucci^{1,2}, S. Dettori^{1,2}, V. Busin³, L. Taramasso², A. Vena^{1,2}, F. Mina³, S. Beltrami³, D. Malucelli⁴, S. Mara⁵, M. Giacomini⁵, M. Bassetti^{1,2}, A. Di Biagio^{1,2}

¹Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, ²Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, ³Pharmacy Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, ⁴Deenova srl, Piacenza, Italy, ⁵Department of Engineering and Informatics University of Genoa, Genoa, Italy

OP 136 14.48-14.53 The impact of COVID-19 pandemic on access to HIV services at urban context-based health facilities supported by CUAMM in collaboration with UNICEF, in Beira Mozambique

N. Ronzoni^{1,2}, C. Di Chiara¹, V. Casigliani², E. Barbieri¹, A. Agazzi¹, A. Zin¹, A. Merolle², F. Chenene², V. Cinturao², E. Occa², D. Donà¹, G. Putoto³, C. Giaquinto¹

¹Department for Women's and Children's Health, University of Padua, Italy, ²Doctors with Africa CUAMM, Beira 2100, Mozambique, ³Operational Research Unit, Doctors with Africa CUAMM, Italy, ⁴Department of translational research and new technologies in medicine and surgery - University of Pisa, Italy

OP 137 14.55-15.00 HAV, HBV and HPV vaccination coverage rate in a community-based pre-exposure prophylaxis program in Milan

C. Muccini^{1,2}, A. Tavelli^{1,3}, R. Rossotti^{1,4}, D. Calzavara¹, P. Vinti¹, A. De Bona^{1,3}, S. Bossolasco^{1,2}, D. Canetti^{1,2}, D. Tesoro^{1,3}, G. Mulè^{1,3}, A. Foschi^{1,5}, R. Repposi¹, V. Ferrara¹, A. D'Arminio Monforte^{1,3}, M. Cernuschi^{1,2}

¹Milano Checkpoint, Milano, ²IRCCS San Raffaele Scientific Institute, Milano, ³ASST Santi Paolo e Carlo, Milano, ⁴ASST Niguarda Hospital, Milano, ⁵ASST Fatebenefratelli Sacco



ORAL POSTER 14.20-15.10

SARS-CoV-2: from in vivo to in vitro

BERGAMO SCIENCE CENTER

Chairs: V. Micheli (Milano), M. Santoro (Roma)

OP 138 14.20-14.25 Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves

R. Scutari^{1,2}, V. Costabile^{1,2}, L. Colagrossi², K. Yu La Rosa², V. Fini², A. Granaglia², E. Agolini², V. Lanari², S. Chiurchiù⁴, L. Romani⁴, A. Markowicz⁴, P. Bernaschi³, C. Russo³, A. Novelli², S. Bernardi⁴, A. Campana⁴, A. Villani⁴, C.F. Perno^{2,3}, C. Alteri^{1,2}

¹Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, ²Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy, ³Microbiology and Diagnostics in Immunology, Bambino Gesù Children Hospital IRCCS, Rome, Italy, ⁴Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

OP 139 14.27-14.32 Rapid change in epidemiological and clinical characteristics of SARS-CoV-2 circulating variants in Italy in April-December 2021

A. Bergna¹, A. Lai¹, C. Della Ventura¹, B. Bruzzone², F. Sagradi³, F. Ceccherini Silberstein⁴, A. Weisz⁵, N. Clementi⁶, G. Brindicci⁷, I. Vicenti⁸, V. De Pace², L. Lanfranchi³, M.C. Bellocchi⁴, G. Giurato⁵, R. Ferrarese⁶, A. Lagioia⁷, D. Francisci⁹, M. Lucente², M.R. Cappelletti³, M. Iannetta⁴, F. Rizzo⁵, C. R. Santoro⁷, C. Fraccalvieri², S. Testa³, L. Carioti⁴, T. Rocco⁵, M. Clementi⁶, L. Sarmati⁴, S. Antinori¹, G. Zehender¹ and SCIRE-SARS-CoV-2 Italian research enterprise-collaborative group

¹Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy, ²Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ³Unit of Infectious Diseases, Azienda Socio Sanitaria Territoriale Cremona, Cremona, Italy, ⁴Infectious Diseases, Tor Vergata University, Rome, Italy, ⁵Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, ⁶Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy, ⁷Infectious Diseases Unit, University of Bari, Bari, Italy, ⁸Department of Medical Biotechnologies, University of Siena, Siena, Italy, ⁹Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy

OP 140 14.34-14.39 Higher viral load (VL) in nasopharyngeal swab (NPS) of individuals infected with Omicron BA.2 SARS-CoV-2, compared to Alpha, Gamma, Delta and Omicron BA.1 Variants Of Concern (VOCs)

I. Mastroianni¹, A. Cozzi-Lepri¹, F. Colavita¹, E. Lalle¹, V. Mazzotta¹, G. Matusali¹, C. Cimaglia¹, J. Paulicelli¹, L. Fabeni¹, F. Carletti¹, S. Rosati¹, S. Vita¹, G. Giannico¹, P. Piselli¹, E. Biliotti¹, S. Al Moghazi¹, S. Mosti¹, E. Girardi¹, E. Nicastrì¹, A.R. Garbuglia¹, F. Vaia¹, A. Antinori¹

¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, United Kingdom



OP 141 14.41-14.46 Dopamine reduces SARS-CoV-2 replication through downregulation of D2 receptors and upregulation of Type-I Interferons

F. Limanaqi^{1,2}, D. Borana², S. Zecchini², G. Cappelletti², S. Strizzi², D. Trabattoni², M. Clerici^{1,3}, M. Biasin²

¹Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ²Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ³Don C. Gnocchi Foundation, IRCCS Foundation, Milan, Italy

OP 142 14.48-14.53 Developmental safety of nirmatrelvir in zebrafish embryos

S. Ferretti¹, E. Quiros-Roldan¹, F. Castelli¹, E. Massardi³, G. Borsani³, S. Storti¹, G. Tiecco¹, I. Zanella², D. Zizioli³

¹Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy, ³Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

OP 143 14.55-15.00 Peptidomimetic covalent reversible inhibitors exhibit broad-spectrum inhibition of CoVs Main protease and cellular activity against SARS-CoV-2: design, synthesis, biological evaluation, and structural biology

R. Cannalire¹, F. Esposito², I. Stefanelli¹, A. Corona², C. Cerchia¹, E. Cassese¹, S. Improta¹, P. Storici³, E. Costanzi³, E. Tramontano², V. Summa¹

¹Dipartimento di Farmacia - Università degli Studi di Napoli Federico II, Napoli, Italy, ²Dipartimento di Scienze della vita e dell'ambiente, Università degli Studi di Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy, ³Eletra-Sincrotrone Basovizza, Trieste, Italy



SYMPOSIUM 15.20-16.20

AUDITORIUM SALA OGGIONI

Update on antiretroviral therapy: answers and suggestions during a pandemic era

Chairs: T. Bini (Milano), P. Cinque (Milano)

Antiretroviral therapy (TARV) has changed the life expectancy of people living with HIV infection and has drastically improved the quality of life of people we care for. The high efficacy of TARV is still hampered by the impossibility of clearing the viral reservoir. Nevertheless, new drugs for modern needs are flourishing and will reach the clinical arena. These compounds will be instrumental for the rapid start of TARV, even in the context of the COVID-19 pandemic, and in the challenge of treating HTE individuals, a polymorphic situation where novel answers are eagerly awaited.

- | | | |
|-------------|---|--|
| 15.20-15.35 | New drugs for modern needs: from phase II trials up to now | A. Di Biagio, Genova |
| 15.35-15.50 | Rapid start in COVID-19 era: what is needed? | C. Mussini, Modena |
| 15.50-16.15 | Clinical case: Novel strategies for HTE people | Presenter: D. Canetti, Milano |
| | | Discussants: D. Ripamonti, Bergamo; S. Rusconi, Legnano (MI) |
| 16.15-16.20 | Discussion on Symposium issues | |



ORAL COMMUNICATIONS 15.20-16.20

SALA STUCCHI

Complexities of SARS-CoV-2 infection

Chairs: P. Bonfanti (Monza), A. Saracino (Bari)

OC 58 15.20-15.30 Prevalence and epidemiological, clinical and microbiological characteristics of bacterial infections in a large cohort of patients admitted for COVID-19 in Campania: a multicentre cohort study

L. Onorato¹, M. Palamone¹, P. Maggi², F.G. Numis³, I. Gentile⁴, V. Sangiovanni⁵, V. Esposito⁶, R. Punzi⁷, G. Calabria⁸, C. Rescigno⁹, A. Salomone Megna¹⁰, A. Masullo¹¹, E. Manzillo¹², G. Russo¹³, R. Parrella¹⁴, G. Dell'Aquila¹⁵, M. Gambardella¹⁶, A. Ponticillo¹⁷, M. Pisaturo¹, N. Coppola¹, on behalf of CoviCam group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ²Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, ³Emergency Department, PO Santa Maria delle Grazie, Pozzuoli, Italy, ⁴Infectious Diseases Unit, University Federico II, Naples, Italy, ⁵Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁶IV Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁷Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁸IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁹First Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁰Infectious Diseases Unit, A.O. San Pio, PO Rummo, Benevento, Italy, ¹¹Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, ¹²VIII Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹³Infectious Diseases Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, ¹⁴Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁵Infectious Diseases Unit, AO Avellino, Italy, ¹⁶Infectious Diseases Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, ¹⁷Pneumology Unit, AORN Caserta, Italy



- OC 59** 15.32-15.42 **Evaluation of SARS-CoV-2 reinfection risk during the different COVID-19 variants' spread**
S. Leone, A. Agresta, G. De Carli, C. De Santis, M.C. Fusco, V. Vantaggio, M. D'Amato, G. Pitti, E. Girardi, F. Vairo
National Institute for Infectious Diseases "L.Spallanzani" IRCCS
- OC 60** 15.44-15.54 **Pre-existent socio-economic status and its role in PASC syndrome: results from the VASCO study (VARIabili Socioeconomiche e COVID-19), on the "Surviving-COVID" Cohort, from Bergamo (Italy)**
S.V. Benatti¹, S. Venturelli¹, R. Buzzetti², F. Binda¹, L. Soavi¹, L. Belotti¹, A.M. Biffi¹, M.S. Spada¹, M. Casati¹, M. Rizzi¹
¹ASST Papa Giovanni XXIII, Bergamo, ²Clinical Epidemiologist, freelance, Bergamo
- OC 61** 15.56-16.06 **Depressive Symptoms Among Covid-19 Survived Patients One Year After Hospital Discharge: Prevalence and Factors Associated**
P. Vassalini¹, R. Serra², L. Tarsitani², G. Ceccarelli¹, A.E. Koukopoulos², C. Borrazzo¹, C. Di Nicolantonio², C. Tosato¹, F. Cherubini¹, F. Alessandri³, C.M. Mastroianni¹, G. d'Ettore¹
¹Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, ²Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, ³Intensive Care Unit, Department of General and Specialist Surgery "Paride Stefanini", Policlinico Umberto I, Sapienza University of Rome, Rome, Italy



ORAL COMMUNICATIONS 15.20-16.20

ALABASTRO A

Insights on epidemiological and clinical management of hepatitis viruses

Chairs: R. Bruno (Pavia), G. Gaiera (Milano)

- OC 62** 15.20-15.30 **Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleo(s)tide analogue systematic discontinuation in non-cirrhotic patients with chronic hepatitis B**
L. Piermatteo¹, R. Salpini¹, S. D'Anna¹, A.F. Guerra², G. Tomassoli², G. Abbati², A. Pietrangelo², P. Ventura², V. Svicher^{1,3}
¹Department of Experimental Medicine, University of Rome "Tor Vergata", ²Internal Medicine and Centre for Hemochromatosis, University Hospital of Modena, University of Modena and Reggio Emilia, Italy, ³Department of Biology, University of Rome "Tor Vergata"
- OC 63** 15.32-15.42 **Hepatitis D virus infection in a large cohort of immigrants in Southern Italy a multicenter, prospective study**
E. Cordua¹, M. Pisaturo^{1,2,7}, L. Alessio^{2,7}, M. Starace¹, A. Di Fraia¹, C. Monari^{2,7}, L. Onorato^{2,7}, C. Sagnelli^{1,2,5}, S. De Pascalis², L. Gualdieri⁶, C. Minichini¹, G. Di Caprio^{3,4}, L. Occhiello^{1,6}, G. Scotto⁸, M. Macera^{2,7}, N. Coppola^{1,2}
¹Department of Mental and Physical Health and Preventive Medicine, Infectious Diseases section, University of Campania Luigi Vanvitelli, Naples, ²L. Vanvitelli University Hospital, Naples, ³UOC of Infectious Diseases, AORN Sant'Anna and San Sebastiano, Caserta, ⁴"Abraham's Tent" Reception Center, Caserta, ⁵Missionary Sisters of Charity Center, Naples, ⁶Center for the Protection of Immigrant Health, Naples, ⁷Social center "ex-canapificio", Caserta, ⁸UOC of Infectious Diseases, Foggia
- OC 64** 15.44-15.54 **Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays**
R. Salpini¹, S. D'Anna¹, M. Alkhatib¹, L. Piermatteo¹, A. Tavelli², E. Quiros³, A. Cingolani⁴, C. Papalini⁵, S. Carrara⁶, V. Malagnino⁷, M. Puoti⁸, L. Sarmati⁷, A. d'Arminio Monforte⁹, F. Ceccherini Silberstein¹, V. Svicher¹ for the Icona Foundation Study Group
¹Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy, ²ICONA Foundation, ³University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁴Unit of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli-Università Cattolica Del Sacro Cuore, Rome, Italy, ⁵Infectious Diseases Clinic, Department of Medicine, University of Perugia, Perugia, Italy, ⁶Microbiology Biobank and Cell Factory Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, ⁷Unit of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy, ⁸Dipartimento Medicina e Chirurgia, Università degli studi di Milano Bicocca, Milan, Italy, ⁹Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Italy
- OC 65** 15.56-16.06 **Hepatitis C testing, linkage to care and treatment during COVID-19 era in a north-east Italian hospital: what can we still need to do to improve elimination?**
E. Garlatti Costa¹, M. Da Re², D. Villalta², M. Tonizzo¹
¹SC Medicina Interna, Azienda sanitaria Friuli Occidentale, Pordenone, ²SSD Immunologia Allergologia, Azienda sanitaria Friuli Occidentale, Pordenone





ORAL POSTER 15.20-16.10

ALABASTRO B

Immunopathogenesis of HIV

Chairs: V. Mazzotta (Roma), G. Nunnari (Messina)

OP 144 15.20-15.25 Distinctive features of immune markers of activation and exhaustion in adolescents and young adults people living with HIV infected perinatally vs. adult age

L. Taramasso¹, C. Dentone¹, D. Fenoglio^{2,3}, T. Altosole², A. Parodi², I. Cama⁴, C. Campi^{4,5}, S. Garbarino⁴, M. Piana^{4,5}, S. Mora⁶, M. Giacomini⁶, L. Labate⁷, G. Filaci^{2,3}, M. Bassetti^{1,7}, A. Di Biagio^{1,7}

¹Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa, Italy, ²Department of Internal Medicine-Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Italy, ³Biotherapy Unit, IRCCS Policlinico San Martino, ⁴MIDA, Dipartimento di Matematica, Università degli studi di Genova, Genova, Italy, ⁵LISCOMP, IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁶Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genova, Genova, Italy, ⁷Department of Health Science (DISSAL), University of Genova and Infectious Disease Clinic, Policlinico San Martino Hospital, Genova, Italy

OP 145 15.27-15.32 Lack of HIV Type 1 Antibody seroconversion in Acutely Infected Individuals Treated with Early Antiretroviral Therapy

A. Bertoldi¹, A. Primavera¹, M. Tamburello², A. Morellini², V. Ferraro², S. Vituliano², V. D'Urbano², T. Lazzarotto¹, L. Calza³, I. Bon¹

¹Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ²Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy, ³Clinics of Infectious Diseases, Department of Medical and Surgical Sciences, School of Medicine, University of Bologna, Bologna, Italy

OP 146 15.34-15.39 Evaluation of HCMV specific T-cell responses in PLwHIV and their correlation with the immunovirological status and clinical parameters

M. Iannetta, A. Lodi, L. Ferrari, A. Imeneo, A. Di Lorenzo, I. Fato, B. Massa, I. Spalliera, B. Rossi, M. Zordan, L. Campogiani, L. Coppola, V. Malagnino, E. Teti, M. Andreoni, L. Sarmati

Department of System Medicine Tor Vergata University, Rome

OP 147 15.41-15.46 Crosstalk between gut microbiota and T cell responses in ART-treated HIV-1 infected patients

L. Santinelli¹, L. Maddaloni¹, A. Lazzaro¹, P. Vassalini¹, F. Frasca², C.M. Lofaro¹, S. Caiazza¹, G. Ceccarelli¹, G. Antonelli^{2,3}, C.M. Mastroianni¹, C. Scagnolari², G. d'Etterre¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy, ³Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy

OP 148 15.48-15.53 Large proportion of new HIV diagnoses sustained by non-B subtypes – clinical and immunological correlates

G. Bozzi¹, P. Saltini¹, G. Butta², C. Bobbio¹, A. Muscatello¹, S. Ludovisi¹, A. Gori^{1,3}, A. Bandera^{1,3}, L. Manganaro^{1,2}

¹Infection Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milan, Italy, ²Virology Unit, INGM-Istituto Nazionale di Genetica Molecolare - Milan, Italy, ³Department of Pathophysiology and Transplantation, University of Milan - Milan, Italy





ICAR 2022 SPECIAL AWARDS AND CLOSING REMARKS

AUDITORIUM
SALA OGGIONI

Chairs: A. Antinori (Roma), M. Cernuschi (Milano), A. d'Arminio Monforte (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)

16.25-16.40

The 14th edition of ICAR Awards:



ICAR-CROI Awards 2022 for young Italian investigators

Selected Italian Investigators who presented their works at CROI 2022:

- **A model to eradicate HCV in undocumented migrants and low-income refugees in Italy**
Loredana Alessio, Napoli
- **GDF-15 as a predictor of mortality in COVID-19: implications for treatment**
Valeria Bono, Milano
- **HPV differently hijacks anal interferon response in HIV-positive and HIV-negative MSM**
Eugenio Nelson Cavallari, Roma
- **Persistence of SARS-CoV-2 antibodies in children and adults 1 year after infection**
Costanza Di Chiara, Padova
- **Mental health disorders in HIV-positive adolescents and youths: data from Mozambique**
Francesco Di Gennaro, Bari
- **Methylprednisolone pulses in hospitalized patients with severe COVID-19 pneumonia**
Giovanni Dolci, Modena
- **How HIV modulates the safety and immunogenicity of the BNT162b2 COVID-19 vaccine**
Ludovica Ferrari, Roma
- **Detection of circulating and airway autoantibodies to IFN in severe COVID-19 patients**
Federica Frasca, Roma
- **Longitudinal study of anti-spike antibodies in children after SARS-CoV-2 infection**
Federica Frasca, Roma
- **The effects of type I & II IFNs disclose a role for dopamine in SARS-CoV-2 infection**
Fiona Limanaqi, Milano
- **Sarilumab plus standard of care (soc) versus soc for severe COVID-19 (escape study)**
Ilaria Mastroianni, Roma
- **Is there a role of novel art regimens in the declining prevalence of hand?**
Ilaria Mastroianni, Roma
- **Post-COVID-19 quality of life: low satisfaction with physical and mental health status**
Ilaria Mastroianni, Roma
- **A real-world comparison of bam/ete vs cas/imd for COVID-19 clinical progression risk**
Valentina Mazzotta, Roma
- **The pathway of nafld vs mafld toward significant fibrosis**
Jovana Milic, Modena
- **Chest ct body composition changes at 3 and 6 months after severe COVID-19 pneumonia**
Jovana Milic, Modena
- **Real-life use of high-dose anakinra in COVID-19 patients treated with remdesivir**
Roberta Monardo, Milano



- **Mannose-binding lectin (mbl) inhibits SARS-CoV-2 infection and replication in vitro**
Isabel Pagani, Milano
- **Efavirenz plasma levels, cognition, and central nervous system side effects**
Alice Ranzani, Monza
- **SARS-CoV-2 plasma viremia and dysregulated immunity in severe COVID-19**
Roberta Rovito, Milano
- **Gut barrier integrity and microbiota in HIV patients receiving oral bacteriotherapy**
Letizia Santinelli, Roma
- **Expression of IFN receptors in anal cells from HIV-positive men during HPV infection**
Mirko Scordio, Roma
- **Differential IFN genes expression in the upper airways of children and adults**
Leonardo Sorrentino, Roma
- **Reversibility of central nervous system adverse events in course of art**
Lucia Taramasso, Genova
- **Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors**
Alessandro Tavelli, Milano
- **Syphilis reinfections among HIV+ and HIV- patients: a retrospective study**
Giorgio Tiecco, Brescia
- **Serum and csf ultrasensitive detection of nfl and alzheimer biomarkers in PLWH**
Mattia Trunfio, Torino
- **Characterization of HIV and SARS-CoV-2 coinfection: role of IL-10**
Claudia Vanetti, Milano
- **Neuropsychologic performance following COVID-19: prevalence and predictors**
Alessandra Vergori, Roma
- **Immunogenicity to COVID-19 mrna vaccine booster shot in PLWH by current cd4+ count**
Alessandra Vergori, Roma



ICAR 2022 Scientific Committee Awards



SIMIT Awards to Best Oral Communications for young researchers



16.40-16.45

ICAR 2022 Closing remarks

A. Antinori (Roma), M.Cernuschi (Milano), F. Maggiolo (Bergamo), M. Zazzi (Siena)



Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

Digital

**POSTER
EXHIBITION**



Antiretroviral therapy

ISSUES ON ANTIRETROVIRAL THERAPY

P 1 Real-world data on the effectiveness and safety of bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV: 12-month results of the Italian BICSTaR cohort

A. Antinori¹, S. Rusconi², D. Canetti³, V. Esposito⁴, E. Quiros-Roldan⁵, B. Candelares⁶, A. D'Arminio Monforte⁷, M. Andreoni⁸, A. Saracino⁹, A. Marongiu¹⁰, L. Albini¹⁰, R. Caldera¹¹, G. Forcina¹⁰, G. Di Perri¹²

¹HIV/AIDS Department, National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy, ²Infectious Diseases Unit, ASST Ovest Milanese - University of Milan, Milan, Italy, ³Clinic of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁴Infectious Diseases and Gender Medicine Unit D. Cotugno Hospital-A.O. dei Colli, Naples, Italy, ⁵Division of Infectious and Tropical Medicine, ASST Spedali Civili, Brescia, Italy, ⁶Infectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy, ⁷Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, "ASST Santi Paolo e Carlo", Milan, Italy, ⁸Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy, ⁹Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Italy, ¹⁰Gilead Sciences Europe Ltd, Stockley Park, Uxbridge, UK, ¹¹Gilead Sciences Srl, Milan, Italy, ¹²Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy

P 2 Antiretroviral therapy in naïve patients: Perugia's cohort during COVID pandemic

A. Lanzi, G. De Socio, E. Schiaroli, S. Benedetti, P. Milani, E. Stolaj, D. Francisci

Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, "Ospedale Santa Maria della Misericordia", Perugia, Italy

P 3 Durability of doravirine co-formulated with lamivudine and tenofovir disoproxil fumarate in people living with HIV (PLWH)

F. Aliberto¹, D. Ceccarelli¹, R. Lolatto¹, S. Nozza¹, S. Bossolasco¹, V. Spagnuolo¹, E. Bruzzesi², M. Chiurlo², A. Castagna^{1,2}, N. Gianotti¹

¹Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

P 4 Evaluation of switch therapy to antiretroviral regimens with doravirine in people living with HIV

C. Candela², D. Ceccarelli¹, R. Lolatto¹, D. Canetti¹, M. Cernuschi¹, P. Cinque¹, M. Ranzenigo², F. Badalucco², A. Castagna^{1,2}, N. Gianotti¹

¹Unit of Infectious and Tropical Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

P 5 Switching to BICTegravir in Elderly people living with HIV-1 under virologic control: week 96 results from the BICTEL cohort

A. Lazzaro¹, D. Bianchini¹, E. Gentilini¹, E.N. Cavallari¹, C. Fimiani¹, I. Mezzaroma², C.M. Mastroianni¹, G. d'Ettore¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Rome, Italy, ²Department of Translational and Precision Medicine; Sapienza University of Rome, AOU Policlinico Um-ber-to I of Rome, Rome, Italy

P 6 Real life experience with Doravirine: impact on metabolic aspects and immune-viral control

C. Papalini, A. Lanzi, C. Pallotto, D. Francisci

Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Università degli studi di Perugia, Perugia, Italy

P 7 Strength of 2DR-HIV-therapy in heavy poly-pharmacological treatment of multi-comorbidity patients

L. Pagnucco, R. Gulminetti, R. Bruno

UOC Malattie Infettive 1, Dipartimento di Scienze Mediche e Malattie Infettive, Fondazione IRCCS Policlinico San Matteo - Università degli Studi di Pavia. Pavia

P 8 Use of doravirine in experienced people living with HIV: a real-life experience

A. Bitti, A. De Vito, M. Fois, A. Colpani, B. Zauli, M.C. Meloni, S. Bacciu, S. Babudieri, G. Madeddu

Unit of Infectious Diseases, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy

P 9 Statin induced anti-HMGCR myopathy in a patient undergoing ARV therapy: a case report

A. Destro¹, R.A. Valia¹, D. Fago¹, R. Aronica¹, V. Mauro¹, F. Cancelli¹, M. Candy¹, S. Valeri¹, M. Ridolfi¹, P. Pasculli¹, P. Guariglia², A. Brogi², A. Lazzaro¹, C.M. Mastroianni¹, G. d'Ettore¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, Roma Italy, ²Department of Infectious Diseases, Azienda Ospedaliera Universitaria Policlinico Umberto I of Rome, Roma Italy

P 10 Cardiovascular risk in PLWHs with IP-based ARV

N. Leoni, A. Leonardi, M. Garau, F. Ferrari, S. Perra, S. Bergamin, M. Buffa, F. Cabras, G. Caligaris, M.F. Nurchi, G. Sanna, G. Angioni

SC Malattie Infettive, Cagliari; Università degli Studi di Sassari, Sassari Issues on new anti-HIV drugs





ISSUES ON NEW ANTI-HIV DRUGS

P 11 Real-life outcomes of Doravirine-based dual regimens as salvage and simplification therapy for multidrug-resistant HIV in a series of seven cases in Lecco Hospital

V. Morena¹, F. Conti¹, C. Molteni¹, M. Bottanelli^{1,2}, L. Bradanini¹, G. Castaldo¹, L. Donghi¹, A. Pandolfo¹, S. Pontiggia¹, S. Piconi¹

¹Infectious Diseases Unit, A. Manzoni Hospital, ASST Lecco, Lecco, Italy, ²Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

Clinical HIV

LATE PRESENTERS FOR HIV/AIDS INFECTION

P 12 Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma in the era of HAART: a case report

M. Trizzino, S. Bonura, L. Pipitò, P. Di Carlo, G. Boncori, A. Cascio

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

P 13 A fatal case of diffuse large B-cell lymphoma with intestinal perforation in AIDS patient: a case report

M. Trizzino, R. Rubino, A. Medaglia, G. Valenti, M. Alfonzo, V. Garbo, A. Cascio

Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy

P 14 Clinical management of an elderly patient, late presenter, with Kaposi's sarcoma and mycobacteriosis

G. Panto', S. A. Sofia, G. Strano, C. Iacobello

Unit of infectious diseases Cannizzaro Hospital, Catania

MANAGEMENT OF HIV INFECTIONS

P 15 Resolved Hepatitis B Virus (HBV) infection and lower nadir of CD4+ are risk factors for progressive increase of CD8+ T-cells absolute count in course of antiretroviral therapy (ART)

T. Mulas, V. Malagnino, E. Teti, M. Compagno, L. Ferrari, G. De Simone, F. Caldara, D. Checchi, A. Crea, S. Tedde, L. Dori, M. Iannetta, M. Andreoni, L. Sarmati

Università degli Studi di Roma Tor Vergata

P 16 Does CD4+ T-Lymphocytes count over 200 cell/mm³ affect the epidemiology of AIDS defining illnesses? An overview from a large italian clinical center

V. Iannone¹, A. Dusina¹, D. Farinacci¹, F. Lamanna¹, R. Passerotto¹, A. Borghetti¹, E. Visconti¹, E. Tamburrini¹, S. Di Giambenedetto¹, A. Ciccullo²

¹Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Malattie Infettive, Roma, ²Ospedale San Salvatore Unità di Malattie Infettive, L'Aquila

OPPORTUNISTIC INFECTIONS (OIS)

P 17 Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis associated to Immune Reconstitution Inflammatory Syndrome in a HIV-infected patient

A. Forniti, C. Caroselli, F. Almerigogna, S. Verdenelli, R. Iapoce, G. Tiseo, M. Falcone

Infectious Disease Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Coinfections and Hepatitis

BACTERIAL AND FUNGAL INFECTIONS IN IMMUNOCOMPROMISED HOST

P 18 Hansen's disease, a neglected disease? Case report of a patient with HIV and Mycobacterium Leprae infection

L. Alessio¹, S. De Pascalis¹, C. Curatolo², V. Pattapola², M. Pisaturo², N. Coppola²

¹Luigi Vanvitelli Hospital - Naples (Italy), ²University of Campania, luigi Vanvitelli - Naples (Italy)





P 19 Tropheryma whipplei infection in HIV: report of two cases and literature review

F. Raumer¹, A. Ferrari¹, M. Trevenzoli¹, M. Fassin², M. Cola¹, A.M. Cattelan¹

¹Azienda Ospedale-Università di Padova, Department of Infectious Disease, Padova, ²Azienda Ospedale-Università di Padova, Department of Pathological Anatomy, Padova

HCV ELIMINATION

P 20 Hepatitis C infection among people who use drugs: a retrospective cohort study using administrative health records

G. Moretti¹, L. Ceccarelli^{1,2}, M. Vainieri¹, L. Tavoschi²

¹Sant'Anna School of Advanced Studies – Management and Healthcare Laboratory, Pisa, Italy, ²University of Pisa – Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy

P 21 HCV prevalence in a over 65 years old population attending general practitioner

A. Di Fraia¹, M. Pisaturo¹, V. Messina², M. Starace¹, C. Minichini¹, L. Occhiello¹, L. Onorato¹, N. Coppola¹

¹Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, ²Department of Infectious Diseases, Sant'Anna Hospital, Caserta, Italy

HDV CURE

P 22 Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

H. Wedemeyer¹, S. Aleman², P. Andreone³, A. Blank⁴, M. Brunetto⁵, P. Bogomolov⁶, V. Chulanov⁷, N. Geyvandova⁸, G. Hilgard⁹, N. Mamonova¹⁰, U. Merle⁴, M. Viacheslav¹¹, O. Sagalova¹², T. Stepanova¹³, J. Schulze zur Wiesch¹⁴, S. Zotov¹⁵, S. Zeuzem¹⁶, P. Lampertico^{17,18}

¹Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany, ²Karolinska University Hospital/Karolinska Institutet, Department of Infectious Diseases, Stockholm, Sweden, ³Internal Medicine, University of Modena and Reggio Emilia, Italy, ⁴University Hospital Heidelberg, Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany, ⁵U.O. Epatologia - Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, ⁶State budgetary institution of health care of Moscow region "Moscow regional research clinical institute after M.F. Vladimirov", Moscow, Russian Federation, ⁷Federal Budget Institute of Science "Central Research Institute for Epidemiology" of Federal Service on Consumers Rights Protection and Human Well-Being Surveillance, Moscow, Russian Federation, ⁸Stavropol Regional Hospital, Stavropol, Russian Federation, ⁹Universitätsklinikum Essen (AöR), Klinik für Gastroenterologie und Hepatologie, Essen, Germany, ¹⁰FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ¹¹LLC Medical Company "Hepatolog", Samara, Russian Federation, ¹²Federal state-funded institution of higher education "Southern Ural State Medical University of Ministry of Health of the Russian Federation" of Ministry of Health of the Russian Federation, Chelyabinsk, Russian Federation, ¹³Limited liability company "Clinic of Modern Medicine", Moscow, Russian Federation, ¹⁴Universitätsklinikum Hamburg-Eppendorf Medizinische Klinik Studienambulanz Hepatologie, Hamburg, Germany, ¹⁵State budgetary institution of health care "Specialized Clinical Infectious Diseases Hospital" of Ministry of Health of Krasnodar Region, Krasnodar, Russian Federation, ¹⁶University Hospital Frankfurt, Department of Medicine, Frankfurt am Main, ¹⁷Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ¹⁸CRC "A. M. and A. Migliavacca" Center for Liver Disease, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy

HEPATITIS EPIDEMIOLOGY

P 23 Seroprevalence of HCV-Ab and Awareness in People Who Inject Drugs (PWID) from Addiction Services

C. Marcia¹, E. Prinčič¹, G. Seu², L. Denti¹, M. Fois¹, S. Babudieri¹, I. Maida¹

¹Department of Medical, Surgical and Experimental Sciences, University of Sassari, ²Addiction Services of Sassari

HIV-ASSOCIATED TUBERCULOSIS

P 24 Socio-demographic and clinical characteristics of HIV-associated tuberculosis in Tor Vergata Hospital, Rome: a 9-year analysis

B. Rossi, M. Zordan, A.M.A. Crea, M. Compagno, M. Iannetta, L. Campogiani, L. Coppola, L. Sarmati, M. Andreoni and the PTV group

Infectious Diseases Department, Tor Vergata Hospital, Rome, Italy





MANAGEMENT AND TREATMENT OF VIRAL HEPATITIS

P 25 Improving organizational effectiveness for chronic hepatitis C linkage to care and treatment: a case report

L. Ceccarelli^{1,2}, I. Corazza², M. Vainieri², L. Tavoschi¹

¹University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy, ²Sant'Anna School of Advanced Studies, Management and Healthcare Laboratory, Pisa, Italy

P 26 Analysis of patients characteristics and treatment profile of persons who use drugs (PWUD) with and without a co-diagnosis of viral hepatitis C: a real-world retrospective Italian study

F. Nava¹, A. Mangia², M. Riglietta³, L. Somaini⁴, F.G. Foschi⁵, E. Claar⁶, I. Maida⁷, C. Ucciferri⁸, F. Frigerio⁹, C. Hernandez¹⁰, D.D. Ancona¹¹, M. Andretta¹², A. Barbieri¹³, F. Bartolini¹⁴, A. Ciaccia¹⁵, A. Costantini¹⁶, S. Dell'Orco¹⁷, R. Moscogiuri¹⁸, E. Mosele¹⁹, C. Procacci¹¹, F. Santolieri¹⁶, M. Dovizio²⁰, D. Sangiorgi²⁰, V. Perrone²⁰, L. Degli Esposti²⁰, M. Puoti²¹

¹U.O. Sanità Penitenziaria e Area Dipendenze, Azienda ULSS 6 Euganea, Padova, Italy, ²UOS Epatologia, Istituto di Ricovero e Cura 'Casa Sollievo della Sofferenza', S. Giovanni Rotondo, Italy, ³UOC Dipendenze, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁴Servizio per le Dipendenze, SERT di Cossato, Biella, Italy, ⁵UOC Medicina Interna, Ospedale di Faenza, Faenza, Italy, ⁶UOC Medicina Interna, Ospedale Evangelico Villa Betania, Napoli, Italy, ⁷UOC Malattie Infettive e Parassitarie, Azienda Ospedaliera Universitaria, Sassari, Italy, ⁸Clinica di Malattie Infettive Ospedale "SS Annunziata" Chieti, Italy, ⁹Gilead Sciences, Milano, Italy, ¹⁰Gilead Sciences, Global Medical Affairs, Stockley Park, London, UK 16, ¹¹Pharmaceutical Department, Local Health Unit BAT, Andria, Italy, ¹²UOC Territoriale Farmaceutica, Azienda ULSS 8 Berica, Vicenza, Italy, ¹³Territoriale Farmaceutica Complex Structure, Local Health Unit VC, Vercelli, Italy, ¹⁴Pharmaceutical Department, Local Health Unit Umbria 2, Terni, Italy, ¹⁵Territoriale Farmaceutica Service, Local Health Unit Foggia, Italy, ¹⁶Hospital Pharmacy, "Santo Spirito" Hospital, Pescara, Italy, ¹⁷Local Pharmaceutical Service, Roma 6 Local Health Unit, Albano Laziale RM, Italy, ¹⁸Pharmaceutical Department of Taranto Local Health Unit, Hospital SS. Annunziata, Taranto, Italy, ¹⁹U.O.C. Territoriale Farmaceutica Assistenza, ULSS 7 Pedemontana, Bassano del Grappa, Vicenza, Italy, ²⁰CliCon S.R.L. Società Benefit, Health Economics and Outcomes Research, Bologna, Italy, ²¹SC Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Comorbidities

CANCERS IN HIV

P 27 Rare bone involvement of Kaposi's sarcoma in HIV late presenter: a case report

V. Crosato¹, S. Arsuffi¹, F. Pennati¹, V. Ferrari², M.A. Forleo¹, E. Quiros-Roldan¹, A. Berruti², F. Castelli¹, E. Focà¹

¹Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, ²Division of Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy

P 28 Outcomes in HIV carriers with or without recurrence of hepatocellular carcinoma after invasive therapy

C. Bertoni¹, L. Galli², E. Messina², H. Hasson², A. Siribelli², S. Bagaglio², A. Castagna¹, C. Uberti-Foppa¹, G. Morsica²

¹Vita-Salute University, Milan, Italy, ²Dept. of Infectious Diseases, San Raffaele Hospital, Milan, Italy

P 29 AIDS-defining cancers and non AIDS-defining cancers in a cohort of PLWH

F. Ginevri, S. Mazzanti, L. Brescini, V. Barocci, M. Di Pietrantonio, G. Cesaretti, B. Candelaesi, S. Olivieri, F. Pallotta, P. Mantini

Clinica Malattie Infettive Ospedali Riuniti Ancona

P 30 Don't forget prevention, screening with cytology, genotyping and high resolution anoscopy for anal HPV-related precancerous lesions in PLWH continues during COVID19 pandemic

M. Digaetano¹, A. Catania¹, M.D. Di Trapani¹, M. Menozzi¹, R.P. Iachetta², R.D. Villani², A. Farinetti^{3,5}, G. Rolando³, S. Tagliacucchi⁴, M. Pecorari⁴, R. Gelmini^{3,5}, C. Mussini^{1,5}

¹Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, ²Pelvic Floor Center, Department of Proctology, Nuovo Ospedale Civile di Sassuolo, Modena, Italy, ³Surgery Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, ⁴Microbiology and Virology Unit, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy, ⁵Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy





HIV AND NERVOUS SYSTEM

P 31 A rare case of HIV-related vacuolar myelopathy in a living patient

A. Giacinta, A. Londero, P. Della Siega, C. De Carlo, C. Tascini

Unit of Infectious Diseases "Santa Maria della Misericordia (University Hospital)", Udine, Italy

NON INFECTIOUS COMORBIDITIES IN HIV

P 32 Positive correlation between bone and endothelial damage in patients with HIV

A. Masiello, V. Zollo, F. Simeone, A. Iodice, P. Maggi

AORN "S. Anna e San Sebastiano", Caserta, University of Campania "L. Vanvitelli"

P 33 Limb-girdle muscular dystrophy in a patient with recent diagnosis of HIV infection

D. Checchi¹, A. Lodi¹, P.G. Pace¹, S. Tedde¹, F. Barreca¹, F. Caldara¹, A. Crea¹, T. Mulas¹, L. Ferrari¹, G. De Simone¹, M. Compagno¹, G. Merlonghi², M. Garibaldi², L. Sarmati¹, M. Andreoni¹, M. Iannetta¹

¹Fondazione PTV and University of Rome Tor Vergata, Rome, ²SAPIENZA University of Rome, Sant'Andrea Hospital, Rome

SEXUALLY TRANSMITTED INFECTIONS (STIS)

P 34 Sense and hypersensitivity - A case series of Jarisch-Herxheimer Reaction following gonorrhea treatment

D. Moschese¹, M.V. Cossu¹, S. Merli¹, R. Giorgi¹, L. Caron², A. Capetti¹, G. Rizzardini¹

¹I Division of Infectious Diseases - Department of Infectious Diseases - Luigi Sacco University Hospital - Milan, Italy, ²Allergology Unit - Department of Infectious Diseases - Luigi Sacco University Hospital - Milan, Italy

P 35 On the importance of the sexual health screening: the impact of a newborn service in the post Covid-19 era in Southern Italy

E. Milano¹, L. Ronga², D. Fiordelisi¹, A. Ricciardi¹, E. Pallara¹, M. Camporeale¹, E. De Vita¹, R. Novara¹, G. Patti¹, V. Totaro¹, E. M. Ranieri², R. Del Prete², M.T. Montagna², A. Saracino¹

¹Clinic of Infectious Diseases, University of Bari, Bari, ²Section of Microbiology and Virology, University of Bari

P 36 Malignant syphilis and a newly HIV infection diagnosis

G. Quartini¹, A. Lavagna¹, L. Ricci², M.E. Laurenti², M. Papini³, M.B. Pasticcini¹

¹Clinica di Malattie Infettive, Università degli Studi di Perugia, Ospedale Santa Maria di Terni, Terni, ²Struttura Complessa di Anatomia Patologica, Università degli Studi di Perugia, Ospedale Santa Maria di Terni, Terni, ³Clinica Dermatologica, Università degli Studi di Perugia, Ospedale Santa Maria di Terni, Terni

COVID-19

COVID-19 THERAPIES

P 37 Monlupiravir for the early treatment of COVID-19

D. Altobelli, G.V. De Socio, G. Gamboni, S. Benedetti, M. Albagini, E. Baranello, D. Veramonti, E. Schiaroli, D. Francisci

Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy

P 38 Baricitinib alone and in combination with Remdesivir for the late treatment of adults hospitalized with COVID-19

M. Niglio¹, M. Poliseo¹, D. Lacedonia², F. De Gregorio¹, G. Minafra¹, T. Campanino², I. Cassiti², T.A. Santantonio¹, M.P. Foschino Barbaro², S. Lo Caputo¹

¹Unit of Infectious Diseases, Foggia University Hospital - Foggia, Italy, ²Unit of Respiratory Diseases, Foggia University Hospital - Foggia, Italy

P 39 Type of patients treated with mAb in COVID-19: the reality of Amedeo di Savoia

C. Marchiaro¹, E. Catellani¹, D. Piccioni¹, S. Bertini¹, F. Donato¹, M. Ferrara², G. Cinnirella¹

¹ASL Città di Torino, SSD Infectious Diseases Pharmacy - HCV, Hospital Amedeo di Savoia, ²Unity of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino

P 40 Efficacy of Sotrovimab as early COVID treatment of BA.1 sublineage of Omicron variant

E. Drappero¹, M. Ferrara¹, A. Gaviraghi¹, F. Alladio¹, F. Venuti¹, G. Stroffolini¹, G. Accardo¹, S. Fantino¹, F. Traverso¹, G. Trevisan¹, D. Vita¹, L. Di Girolamo¹, L. Ponzetta¹, M. Quaranta¹, F. Ranzani¹, A. Serra¹, L. Trentini¹, E. Burdino², G. Gregori², F. Cerutti², V. Ghisetti², C. Marchiaro³, E. Catellani³, G. Cinnirella³, G. Di Perri¹, S. Bonora¹

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ²Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, ASL Città di Torino, Torino, ³SDD Infectious Diseases Pharmacy - HCV, Amedeo di Savoia Hospital, ASL Città di Torino, Torino



**P 41 Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants**

T. Alonzi¹, A. Aiello¹, F. Repele¹, L. Falasca¹, M. Francalancia¹, A.R. Garbuglia¹, G. Delogu^{3,4}, M. Piacentini^{1,2}, D. Goletti¹

¹National Institute for Infectious Diseases "L. Spallanzani" IRCCS, ²Department of Biology, University of Rome "Tor Vergata", ³Institute of Microbiology, Università Cattolica del Sacro Cuore - Fondazione Policlinico Gemelli, ⁴Mater Olbia Hospital

P 42 A possible treatment algorithm for the use of antiviral therapies and monoclonal antibodies against COVID-19

L. Diella¹, D.F. Bavaro¹, D. Fiordelisi¹, G. Guido¹, A. Belati¹, G. Brindicci¹, G. Loseto², C. Minoia², A. Guarini², I. Attolico³, T. Perrone³, P. Musto⁴, S. Simone⁵, L. Gesualdo⁵, M. Rendina⁶, A. Di Leo⁶, M. Santoro⁷, M. Dell'Aera⁷, F. Di Gennaro¹, A. Saracino¹

¹Clinic of Infectious Diseases, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy, ²Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy, ³Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy, ⁴Department of Emergency and Organ Transplantation, "Aldo Moro" University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy, ⁵Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari Aldo Moro, Bari, Italy, ⁶Section of Gastroenterology, Department of Emergency and Organ Transplantation, University "Aldo Moro" of Bari, Bari, Italy, ⁷Farmacia Ospedaliera AOU Policlinico di Bari – Bari, Italy

P 43 Therapies consumption to treat COVID-19 patients hospitalized in a large tertiary Hospital in Northern Italy during the first three pandemic waves

E. Focà¹, S. Calza², S. Piva³, I. Ettori¹, C. De Ciuceis⁴, F. Rasulo³, A. Paini⁵, S. Gipponi⁶, G. Levi⁷, M. Metra⁸, M. Castellano⁹, M. Nardin¹⁰, C. Ricci¹¹, R. Badolato¹², F. Odicino¹³, R. Orabonai¹³, F. Scolari¹⁴, E. Quiros Roldan¹, F. Marinoni¹⁵, A.M. Roccaro¹⁶, C. Rossi¹⁷, F. Castelli¹

¹Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, ²Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, ³Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, ⁴Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, ⁵Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, ⁶Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁷Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, ⁸Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁹Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁰Third Unit of Internal Medicine, ASST Spedali Civili, Italy, ¹¹Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹²Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹³Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁴Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁵Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, ¹⁶Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, ¹⁷Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

P 44 Remdesivir in combination with casirivimab/imdevimab monoclonal antibodies for the treatment of severe COVID-19

I. Gentile, I. Di Filippo, N. Esposito, M. Sarno, L. Fusco, F. Licciardi, A. Truono, N. Schiano Moriello, R. Scotto, B. Pinchera, G. Viceconte, A. Iuliano, E. Zap-pulo, M. Foggia, A.R. Buonomo

Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University "Federico II", Naples, Italy

P 45 Monoclonal antibodies administration against SARS-CoV-2. The experience of the Tor Vergata Hospital

R.A. Cavasio¹, N. Braccialarghe¹, D. Zaçe¹, I. Spalliera¹, L. Coppola¹, L. Campogiani¹, L. Piermatteo², M.C. Bellocchi², F. Ceccherini Silberstein², M. Iannetta¹, L. Sarmati¹, M. Andreoni¹ and the Tor Vergata Hospital group

¹Infectious Diseases Department, University of Rome Tor Vergata, Rome, Italy, ²Virology Department, University of Rome Tor Vergata, Rome, Ital

P 46 Oral antivirals against SARS-CoV-2: the experience of the Tor Vergata Hospital

N. Braccialarghe, R.A. Cavasio, D. Zaçe, I. Spalliera, L. Coppola, M. Iannetta, L. Sarmati, M. Andreoni and the Tor Vergata Hospital group

Infectious Diseases Department, University of Rome Tor Vergata, Rome, Italy

P 47 SARS COV 2 viral variants and mabs: the results of a cohort study in southern Italy

S. De Pascalis¹, L. Alessio¹, M. Pisaturo¹, A. Russo¹, R. Palladino¹, A.R. Buonomo², B. Pinchera², I. Gentile², C. Tiberio³, L. Atripaldi³, N. Coppola¹

¹AOU L.Vanvitelli, Naples, ²AOU FedericoII, Naples, ³AORN dei Colli, PO D.Cotugno, Naples

HIV AND COVID-19**P 48 Lack of anti-N IgG after symptomatic COVID-19 in an immunocompetent PLWH: a case report**

Y. Rusotto¹, C. Micali¹, G. Nunnari¹, E. Venanzi Rullo¹, G.F. Pellicanò²

¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ²Unit of Infectious Diseases, Department of Adult and Childhood Human Pathology "Gaetano Barresi", University of Messina, Messina, Italy





P 49 COVID-19 Outcomes among people living with HIV in comparison to the General Population of the Lombardy Region

L. Galli¹, D. Ceccarelli¹, O. Leoni³, D. Cereda⁴, A. D'Arminio-Monforte⁵, G. Rizzardini⁶, R. Rossotti⁷, M. Rizzi⁸, F. Castelli⁹, F. Franzetti¹⁰, L. Pusterla¹¹, S. Dal Zoppo¹², P. Bonfanti¹³, S. Rusconi¹⁴, A. Regazzetti¹⁵, L. Palvarini¹⁶, S. Antinori¹⁷, A. Gori¹⁸, S. Piconi¹⁹, R. Bruno²⁰, P.A. Grossi²¹, A. Lazzarin², A. Castagna^{1,2}

¹Infectious Diseases Unit, IRCCS San Raffaele Hospital, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Struttura Epidemiologia e Valutazione delle performance, U.O. Osservatorio Epidemiologico Regionale, Milan, Italy, ⁴UO Prevenzione Direzione Generale Welfare di Regione Lombardia, Milan, Italy, ⁵ASST Santi Paolo e Carlo Ospedale San Paolo, Milan, Italy, ⁶ASST BFB-Sacco Ospedale Luigi Sacco, UOC Malattie Infettive 1-2, Milan, Italy, ⁷ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁸ASST Papa Giovanni XXIII, Bergamo, Italy, ⁹ASST Spedali Civili, UOC Malattie Infettive, Brescia, Italy, ¹⁰ASST Valle Olona Ospedale di Busto Arsizio, Busto Arsizio, Italy, ¹¹ASST Lariana Ospedale Sant'Anna, Como, Italy, ¹²ASST Cremona Ospedale di Cremona, Cremona, Italy, ¹³ASST Monza Ospedale San Gerardo, Monza, Italy, ¹⁴ASST Ovest Milanese Ospedale Nuovo di Legnano, Legnano, Italy, ¹⁵ASST Lodi Ospedale Delmati, Sant'Angelo Lodigiano, Italy, ¹⁶ASST Mantova Ospedale Carlo Poma, Mantova, Italy, ¹⁷ASST BFB-Sacco Ospedale Luigi Sacco, UOC Malattie Infettive 3, Milan, Italy, ¹⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹⁹ASST Lecco Ospedale A. Manzoni, Lecco, Italy, ²⁰Fondazione IRCCS Policlinico San Matteo, UOC Malattie Infettive, Pavia, Italy, ²¹ASST Sette Laghi Ospedale di Circolo, Varese, Italy

P 50 Who's no-vax? SARS-CoV2 vaccination adherence in PLWHA: a single center experience. Check to help

G. Orofino¹, M. Guastavigna¹, L. Carani², M. Farenga¹, F. Berf³, A. Pivi³, B. Mollero³, A. Russo³, GD Greco⁴, G. Calleri¹

¹Divisione A di Malattie Infettive e Tropicali, Ospedale Amedeo di Savoia, Torino, ²Dipartimento di Scienze Mediche, Università di Torino, Torino, ³Dipartimento di Salute Pubblica, Università di Torino, Torino, ⁴SSD SISP Emergenze infettive e Prevenzione, ASL Città di Torino, Torino

P 51 The "Unknown"- Lost to follow-up and virological failure in the COVID-19 era: comparison between the three waves, determinants of VF and failure for all causes in PLWH in cART

L. Montemurro¹, G. Di Teodoro^{2,3}, A. Borghetti⁴, F. Conti⁵, F. Lombardi⁶, L. Pezzati⁵, M. Poliseo¹, A. Shallvari^{3,7}, A. Bezenchek^{3,7}, S. Rusconi^{5,8}, V. Borghi⁹

¹U.O. Malattie Infettive Universitaria, University of Foggia, Foggia, Italy, ²Dipartimento di Ingegneria informatica automatica e gestionale A. Ruberti, Sapienza Università di Roma, Roma, Italy, ³EuResist Network GEIE, Roma, Italy, ⁴Policlinico Gemelli, Roma, Italy, ⁵Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milano, Italy, ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy, ⁷InformaPRO SRL, Roma, Italy, ⁸UOC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano, Milano, Italy, ⁹Clinica Malattie Infettive, Azienda Ospedaliero Universitaria di Modena, Modena, Italy

MANAGEMENT OF COVID-19

P 52 Acute mesenteric ischemia in a patient with COVID-19 infection: a case report

G. D'Aguanno¹, F. Savalli¹, G. Consuelo¹, P. Miraglia¹, M.C. Morsellino¹, S. Cianchino¹, G. Ribauda², P. Colletti¹

¹Department of Infection Diseases, Paolo Borsellino Hospital, Marsala TP, ²Department of Surgery, Paolo Borsellino Hospital, Marsala TP

P 53 Obesity and Covid-19: the results of a multicentric cohort study in Campania

V. Zollo¹, M. Pisaturo¹, P. Maggi², F. G. Numis³, I. Gentile⁴, V. Sangiovanni⁵, V. Esposito⁶, R. Punzi⁷, G. Calabria⁸, C. Rescigno⁹, A. Salomone Megna¹⁰, A. Masullo¹¹, E. Manzillo¹², G. Russo¹³, R. Parrella¹⁴, G. Dell'Aquila¹⁵, M. Gambardella¹⁶, A. Ponticciello¹⁷, N. Coppola¹ on behalf of CoviCam group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, Italy, ²Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, Italy, ³Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, ⁴Infectious disease unit; University Federico II, Naples, Italy, ⁵Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁶IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁷Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁸IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ⁹First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁰Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, Italy, ¹¹Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy, ¹²VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹³Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, ¹⁴Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, Italy, ¹⁵Infectious Diseases Unit, AO Avellino, Italy, ¹⁶Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, ¹⁷Pneumology Unit, AORN Caserta, Italy

P 54 Epidemiological and clinical factors related to late negativization of SARS-CoV 2 nasopharyngeal swab

P. Grimaldi¹, M. Pisaturo¹, P. Maggi², F. G. Numis³, I. Gentile⁴, V. Sangiovanni⁵, V. Esposito⁶, R. Punzi⁷, G. Calabria⁸, C. Rescigno⁹, A. Salomone Megna¹⁰, A. Masullo¹¹, E. Manzillo¹², G. Russo¹³, R. Parrella¹⁴, G. Dell'Aquila¹⁵, M. Gambardella¹⁶, A. Ponticciello¹⁷, N. Coppola¹ on behalf of CoviCam group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "L. Vanvitelli", Napoli, ²Infectious Diseases Unit, A.O. S Anna e S Sebastiano Caserta, ³Emergency unit, PO Santa Maria delle Grazie, Pozzuoli, ⁴Infectious disease unit; University Federico II, Naples, ⁵Third Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, ⁶IV Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, ⁷Hepatic Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, ⁸IX Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, ⁹First Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, ¹⁰Infectious Disease Unit, A.O. San Pio, PO Rummo, Benevento, ¹¹Infectious disease unit, A.O. San Giovanni di Dio e Ruggi D'Aragona Salerno, ¹²VIII Infectious Disease Unit, AORN dei Colli, PO Cotugno, Naples, ¹³Infectious Disease Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, ¹⁴Respiratory Infectious Diseases Unit, AORN dei Colli, PO Cotugno, Naples, ¹⁵Infectious Diseases Unit, AO Avellino, ¹⁶Infectious Disease Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, ¹⁷Pneumology Unit, AORN Caserta



**P 55 Major bleeding events in COVID-19 patients admitted to hospital: a case series**

G. Casalini^{1,2}, A. Giacomelli², G. Pozza^{1,2}, A. Poloni^{1,2}, V. Colombo¹, F. Petri¹, M. Gerbi¹, C. Fusetti¹, G. Carrozzo^{1,2}, G. Rizzardini¹, S. Antinori^{1,2}

¹Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Italy, ²III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy

P 56 Secondary organizing pneumonia (SOP) in two late Covid-19 haematological patients

A. Tommasi¹, A. Tosti¹, N. Murgia², E. Stojaj¹, G. Genga¹, L. Malincarne¹, S. Morosi¹, D. Francisci¹

¹Infectious Disease Clinic, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia - Perugia (Italy), ²Occupational and Respiratory Medicine, Department of Medicine and Surgery, Santa Maria della Misericordia Hospital, University of Perugia - Perugia (Italy)

P 57 Campylobacter coli bacteremia in patient with Common Variable Immunodeficiency (CVID) and SARS-CoV-2 infection

N. Esposito¹, S. Di Bari^{2,3}, F. Taglietti³, M. Sarno¹, F. Gavaruzzi^{2,3}, S. Al Moghazi³, D.R. Donno³, E. Caraffa³, G. Granata³, P. Chinello³

¹Department of Clinical Medicine and Surgery, Infectious Diseases Unit, University "Federico II", Naples, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ³Clinical and Research Department for Infectious Diseases, National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy

P 58 Haematological malignancies and COVID-19: do we have effective treatments? A case report

E. Binetti, A. Pupo, R. Donà, D. Giangiulio, S. Lobello, F. Romano, V. Vola, F. Cogliati Dezza, G. Russo, G. Siccardi, C. M. Mastroianni

Università La Sapienza, Roma

P 59 Pre-existing chronic kidney disease (CKD) is associated with an increase in the duration of hospitalization in Covid-19 patients but not with increased mortality: results of a case-control study

M.G. Palamone¹, F. Calò¹⁰, A. Russo¹, P. Maggi^{1,2}, V. Sangiovanni³, F.G. Numis⁴, I. Gentile⁵, A. Masullo⁶, C. Rescigno³, G. Calabria³, A. Salomone Megna⁷, M. Gambardella⁸, E. Manzillo³, G. Russo⁹, V. Esposito³, N. Coppola^{1,10}, Simit Campania Group

¹Infectious Diseases, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli" Naples, Italy, ²Infectious Diseases Unit, A.O. S. Anna e S. Sebastiano Caserta, Italy, ³Infectious Diseases Unit, AORN dei Colli, P.O. Cotugno, Naples, Italy, ⁴Emergency Unit, PO Santa Maria delle Grazie, Pozzuoli, Italy, ⁵Infectious Diseases Unit; University Federico II, Naples, Italy, ⁶Infectious Diseases Unit, A.O. San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy, ⁷Infectious Diseases Unit, A.O. San Pio, PO Rummo, Benevento, Italy, ⁸Infectious Diseases Unit, PO S. Luca, Vallo della Lucania, ASL Salerno, Italy, ⁹Infectious Diseases Unit, Ospedale Maria S.S. Addolorata di Eboli, ASL Salerno, Italy, ¹⁰AOU L. Vanvitelli, Naples, Italy

P 60 Evolution of mortality among the first three waves in the largest Italian Hospital receiving SARS-CoV-2 infected patients. Results from the Brescia HUB project

E. Focà¹, S. Calza², S. Piva³, I. Ettori¹, M.L. Muesan⁴, M. Salvetti⁵, F. Rasulo³, A. Padovani⁶, M. Bezzi⁷, M. Metra⁸, M. Castellano⁹, F. Legati¹⁰, C. Ricci¹¹, R. Badolato¹², F. Odicino¹³, R. Orabona¹³, F. Scolari¹⁴, F. Marinoni¹⁵, A.M. Roccaro¹⁶, C. Rossi¹⁷, F. Castelli¹

¹Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili, Brescia, Italy, ²Unit of Biostatistics and Bioinformatics, University of Brescia, Brescia, Italy, ³Unit of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, Italy, ⁴Second Unit of Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, ⁵Unit of Emergency Internal Medicine, University of Brescia and ASST Spedali Civili, Italy, ⁶Unit of Neurology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁷Unit of Pneumology, ASST Spedali Civili, Brescia, Italy, ⁸Unit of Cardiology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ⁹Unit of Internal Medicine and Endocrinology, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁰Third Unit of Internal Medicine, ASST Spedali Civili, Italy, ¹¹Unit of Gastroenterology University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹²Unit of Pediatrics, Children's Hospital University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹³Unit of Gynecology and Obstetrics, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁴Unit of Nephrology and Dialysis, University of Brescia and ASST Spedali Civili, Brescia, Italy, ¹⁵Unit of Planning and Management Control Service, ASST Spedali Civili, Brescia, Italy, ¹⁶Unit of Clinical Research and Phase I Studies, ASST Spedali Civili, Brescia, Italy, ¹⁷Chief Medical Officer Institution, ASST Spedali Civili, Brescia, Italy

P 61 A case report of adenovirus infection and HSV-1 hepatitis in a non-transplanted hematological patient with COVID-19 pneumonia

N. Corti^{1,2}, G. Lapadula^{1,2}, M. Rossi¹, E. Colella¹, A. Rugova¹, P. Columpsi¹, A. Soria¹, E. Pollastri¹, L. Bisi¹, S. Limonta¹, F. Sabbatini¹, A. Cappelletti¹, A. Ranzani¹, N. Squillace¹, G.M. Migliorino¹, S. Foresti¹, P. Bonfanti^{1,2}

¹Infectious Disease Unit, San Gerardo Hospital, ASST Monza-Brianza, ²Department of Medicine and Surgery, University of Milano-Bicocca, Monza

P 62 Overlooked clinical signs in early SARS-CoV-2 infection among elderly people: acute kidney injury and altered state of consciousness

C. Fanelli, A. Puggioni, L. Firino, I. Maida, G. Madeddu, S. Rubino, S. Babudieri

University of Sassari, Italy





P 63 Comparative analysis between the different epidemic waves of SARS - CoV-2 infection: the experience of the Pontine hospital

P. Zuccalà¹, R. Marocco¹, S. Gismondi¹, V. Belvisi¹, B. Kertusha¹, T. Tieghi¹, M. Del Borgo¹, A. Gasperin^{1,2}, S. Cacace^{1,2}, A. Carraro^{1,2}, A. Parente^{1,2}, A. R. Cacciotti³, S. Parrocchia³, M. Lichtner^{1,2}

¹UOC Infectious Diseases, "S.Maria Goretti Hospital", Latina, ²Department of Public Health, Microbiology and Infectious Diseases, Sapienza University of Rome, Polo Pontino ³Health Management, "S.Maria Goretti Hospital", Latina

P 64 Invasive cryptococcal disease in COVID-19: a case report, Systematic Review of the literature and analysis

G. Pipitone¹, G. Ciusa¹, D. Spicola¹, F. Di Lorenzo¹, A. Sanfilippo¹, F. Onorato¹, A. Ficalora¹, C. Buscemi¹, T. Prestileo¹, C. Imburgia¹, I. Alongi¹, F. Guida Marascia², A. Gizzi², M. Abbott², M.S. Verde³, F. Di Bernardo³, A. Scafidi⁴, V. Mazzaresse⁴, A. Cascio², N. Petrosillo⁵, C. Iaria¹

¹Infectious Disease Unit - ARNAS Civico-Di Cristina Hospital, Palermo, ²Infectious Disease Unit - University Hospital "P. Giaccone", Palermo, ³Microbiology Unit - ARNAS Civico-Di Cristina Hospital, Palermo, ⁴Intensive Care Unit - ARNAS Civico-Di Cristina Hospital, Palermo, ⁵Infectious Disease Unit - University Hospital "Campus Bio-Medico", Rome

POST-ACUTE COVID-19 SYNDROME (PASC)

P 65 The use of lung ultrasound to monitoring the lung damage after Covid19 pneumonia

S. Mazzanti, L. Brescini, V. Barocci, P. Mantini, M. Di Pietrantonio, B. Candelaresi, F. Pallotta, S. Olivieri, G. Cesaretti, F. Ginevri
Clinica Malattie Infettive, Ospedali Riuniti di Ancona, Università Politecnica delle Marche

SARS-COV-2 VACCINES

P 66 Safety and immunogenicity of a third-dose COVID-19 BNT162b2 boosting vaccination in People Living with HIV

L. Gianserra¹, M.G. Donà¹, E. Giuliani², C. Stingone¹, M. Pontone³, A.R. Buonomini¹, M. Giuliani¹, F. Pimpinelli³, A. Morrone², A. Latini¹

¹STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy, ²Scientific Direction, San Gallicano Dermatological Institute IRCCS, Rome, Italy, ³Microbiology and Clinical Pathology, San Gallicano Dermatological Institute IRCCS, Rome, Italy

P 67 Fatal outcome of COVID-19 relapse in a fully vaccinated patient with Non-Hodgkin's lymphoma in maintenance therapy with anti-B cells monoclonal antibodies: a case report

F. Calò¹, L. Onorato¹, C. Monari¹, M. Pisaturo¹, L. Alessio¹, A. Di Fraia¹, C. Minichini¹, L. Atripaldi², A. Pinto³, N. Coppola¹

¹Department of Mental Health and Public Medicine – Infectious Diseases Unit. University of Campania Luigi Vanvitelli, Naples, Italy, ²Unit of Microbiology and Virology, AORN Ospedali dei Colli, Cotugno-Monaldi Hospital, Naples, Italy, ³Hematology-Oncology & Stem Cell Transplantation Unit. National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy

P 68 A recent SARS-CoV-2 Omicron variant re-infection shortly after SARS-CoV-2 Delta variant related severe pneumonia in an immunocompromised patient with three-dose vaccination (BNT162b2 mRNA vaccine): immunological characterization and therapeutic approach

A. Di Lorenzo¹, M. Iannetta¹, B. Rossi¹, V. Malagnino¹, M. Zordan¹, L. Ansaldo¹, N. Braccialarghe¹, M. L. Minardi¹, C. Sorace¹, C. Cerini¹, D. Zace¹, L. Alborghetti¹, S. Tedde¹, L. Piermatteo², E. Andreassi², M.C. Bellocchi², F. Ceccherini Silberstein², L. Sarmati¹, M. Andreoni¹

¹Department of System Medicine, Tor Vergata University, Rome, Italy, ²Virology department, University of Rome Tor Vergata, Rome, Italy

P 69 Evaluation of humoral and T-specific responses after the booster dose of BNT162b2 COVID-19 vaccine in residents of a Long Term Care Facility

A. Lai¹, B. Caimi², A. Bergna¹, A. Gatti², M. Franzetti³, A. Gabrieli¹, M. Tarkowski¹, P.L. Rossi², M. D'Orso⁴, F. Pregliasco⁵, C. Balotta^{1,2}, A. Riva¹, G. Calicchio²

¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ²Azienda Servizi alla Persona, Istituti Milanese Martinitt e Stelline e Pio Albergo Trivulzio, Milan, Italy, ³Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Legnano, Italy, ⁴Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy, ⁵Department of Biomedical Sciences, University of Milan and IRCCS Istituto Ortopedico Galeazzi, Milan, Italy

P 70 Detection of maternal antibodies elicited by COVID-19 vaccination in amniotic fluid

F. Colavita, A. Oliva, A. Bettini, E. Girardi, A. Antinori, C. Castilletti, F. Vaia, G. Liuzzi

National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy

P 71 Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail patients

R. Campagna¹, L. Mazzuti¹, G. Guerrizio¹, C. Nonne¹, G. Migliara², C. De Vito², I. Mezzaroma³, V. Pistolesi⁴, S. Morabito⁴, O. Turriziani¹

¹Department of Molecular Medicine Sapienza University, Rome, ²Department of Public Health and Infectious Diseases Sapienza University, Rome,

³Department of Translational and Precision Medicine Sapienza University, Rome, ⁴Department of Internal Medicine and Medical Specialties Sapienza University, Rome



**P 72 Early evidence on vaccine effectiveness of COVID Vaccines in PLWHA**

M. Sane Schepisi¹, A. Meggiolaro¹, A. Mammone¹, S. Farina², C. Castagna², A. Siddu¹, A. Caraglia¹, F. Maraglino¹, S. Boccia², G. Rezza¹

¹Italian Ministry of Health, General Directorate for Health Prevention, Rome, Italy, ²Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy

Pathogenesis and Immunology**COVID-19 PATHOGENESIS****P 73 Longitudinal evaluation of QuantiFERON-TB gold plus responses in COVID-19 patients**

G. Alessio, A. Imeneo, A. Di Lorenzo, B. Rossi, M. Compagno, L. Coppola, L. Campogiani, M. Andreoni, L. Sarmati, M. Iannetta
Policlinico Tor Vergata, Roma

P 74 Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with Immune Mediated Inflammatory Diseases

L. Petrone¹, A. Picchianti-Diamanti², G.D. Sebastiani³, A. Aiello¹, B. Laganà², G. Cuzzi¹, V. Vanini^{1,4}, G. Gualano⁵, A. Grifoni⁶, M. Ferraioli⁷, C. Castilletti⁸, S. Meschi⁹, F. Vaia⁹, E. Nicastrì¹⁰, A. Sette⁶, D. Goletti¹

¹Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ²Department of Clinical and Molecular Medicine, "Sapienza" University, S. Andrea University Hospital, Rome, Italy, ³Department of Rheumatology, San Camillo Hospital, Rome, Italy, ⁴Unità Operativa Semplice (UOS) Professioni Sanitarie Tecniche, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ⁵Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ⁶Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA, ⁷Rheumatology, Allergology and Clinical Immunology, Dipartimento di medicina dei sistemi, University of Rome Tor Vergata, Rome, Italy, ⁸Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ⁹UOC Direzione Sanitaria, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ¹⁰UOC Malattie Infettive ad Alta Intensità di Cura, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

P 75 Serum levels of Surfactant Proteins A and D in SARSCoV2 infected patients

L. Maddaloni¹, L. Santinelli¹, V. Zullino², C. De Panfilis², A. Lazzaro¹, C.M. Lofaro¹, S. Caiazza¹, F. Ruberto², C. Scagnolari³, C.M. Mastroianni¹, G. d'Ettore¹, G. Ceccarelli¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, ²Department of Anesthesia, Sapienza University of Rome, Italy, ³Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Italy

P 76 Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave

A. Aiello¹, A. Grossi², S. Meschi³, M. Meledandri⁴, V. Vanini^{1,5}, L. Petrone¹, R. Casetti⁶, G. Cuzzi¹, A. Salmi¹, A.M.G. Altera¹, L. Pierelli⁷, G. Gualano⁸, T. Ascoli Bartoli⁹, C. Castilletti⁸, C. Agrati⁴, E. Girardi¹⁰, F. Palmieri⁹, E. Nicastrì⁹, E. di Rosa², D. Goletti¹

¹Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ²UOC Public Health Hygiene Service, ASL Roma 1, ³Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ⁴UOC Microbiology and Virology, ASL Roma 1-San Filippo Neri Hospital, Rome, Italy, ⁵UOS Professioni Sanitarie Tecniche, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, ⁶Laboratory of Cellular Immunology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ⁷UOC Transfusion Medicine and Stem Cell Unit, San Camillo Forlanini Hospital, Rome, Italy, ⁸Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ⁹Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, ¹⁰Clinical Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

Social science, Epidemiology and Prevention**HIV EPIDEMIOLOGY AND RETENTION IN CARE****P 77 Creation of a model of data collection and survey on long-acting HIV medications in the transgender population**

M. Formisano, M. Errico, A. Moznich, M. Cascio, A. Lascari, L. Brogonzoli
NPS ITALIA, Milano

P 78 Anti-HIV antibodies and Avidity Index: comparison between two fourth-generation immunoassays

A. Morellini¹, M. Tamburello¹, S. Vituliano¹, V. Ferraro¹, A. Primavera², A. Bertoldi², G. Gallinella³, T. Lazzarotto^{1,2}, I. Bon²

¹Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ²Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ³Department of Pharmacy and Biotechnology, University of Bologna, Bologna





HIV PREVENTION (PREP AND PEP)

P 79 The ANLAIDS forum between old and new tools for HIV prevention

A. Venturelli, C. Balotta, R. Galipò, G.V. Calvino, B. Marchini
Anlaids Onlus, Rome, Italy

P 80 Anlaids in the Schools - What usefulness for adolescents and what impact on their behaviors

R. Galipò¹, V. Calvino¹, F. Caramaschi², L. Carniato², A. De Faveri³, P. Ferri², S. Negrì³, A. Palummieri¹, M. Viscoli⁴, B. Marchini¹
¹Anlaids, Rome, ²Anlaids Lazio, Rome, ³Anlaids Lombardia, Milan, ⁴Anlaids Liguria, Genoa, ⁵Anlaids Mantova, Mantua, ⁶Anlaids Torino, Turin, ⁷Anlaids Treviso, Treviso

P 81 Role of general practitioners in HIV early diagnosis and prevention: an online local survey

M. Jamhour¹, G. Mancarella², S. Garattini², A. Carraro^{1,2}, R. Marocco¹, V. Belvisi¹, M. De Masi¹, M. Lichtner^{1,2}
¹Infectious Diseases Unit, S.M. Goretti Hospital, Latina, ²Department of Public Health and Infectious Diseases, "Sapienza" University, Rome

P 82 Trend of sexually transmitted infections in patients on HIV pre-exposure prophylaxis (PrEP): the experience of two Italian centre between 2019 and 2022

M. Menozzi¹, A. Di Biagio², G.J. Burastero¹, S. Volpi¹, L. Labate³, M. Fasce³, L. Gozzi¹, A. Tili¹, V. Todisco¹, M. Pellegrino¹, C. Mussini¹
¹Infectious Disease Clinic, University Hospital of Modena, Italy, ²Infectious Diseases Unit, Ospedale Policlinico San Martino IRCCS – Genoa, Italy, ³Department of Health Sciences (DISSAL), University of Genoa – Genoa, Italy

IMPACT OF COVID-19 ON HIV CARE

P 83 Home Care Assistance: has Covid-19 had an impact on the complex management of HIV patients?

A. Dusina¹, F. Lombardi¹, E. Tamburrini^{1,2}, F. Onorati¹, M. Petrucci¹, S. Di Giambenedetto^{1,2}
¹Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy, ²Università Cattolica del Sacro Cuore, Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Rome, Italy

P 84 Impact of COVID-19 on HIV testing: our Lab experience

E. Garlati Costa¹, M. Da Re², D. Villalta², M. Tonizzo¹
¹SC Medicina Interna, Azienda sanitaria Friuli Occidentale, Pordenone, ²SSD Immunologia Allergologia, Azienda sanitaria Friuli Occidentale, Pordenone

P 85 Has COVID-19 pandemic changed the epidemiology of AIDS-defining illnesses? Data from a large Italian clinical center

V. Iannone¹, A. Dusina¹, D. Farinacci¹, A. D'Angelillo¹, P.F. Salvo¹, A. Borghetti¹, E. Visconti¹, E. Tamburrini¹, S. Di Giambenedetto¹, A. Ciccullo²
¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC di Malattie Infettive, Roma IT, ²Ospedale San Salvatore Unità di Malattie Infettive, L'Aquila IT

P 86 COVID-19 pandemic's impact on the clinical-care management of naïve HIV + patients

C. Bitello, R. Caprara, S. Vitale, G. Ferraro, L. Appolloni, G. Pensalfine, A. Stancari
IRCCS S. Orsola-Malpighi, Bologna

P 87 Impact of COVID-19 pandemic on a HIV Counselling and Testing Site at "D. Cotugno" Hospital, Naples: what lessons can be learned?

F.M. Fusco¹, P. Piselli², M. De Cenzo¹, O. Tambaro¹, N. Cuomo³, F. Borrelli¹, R. Viglietti¹, V. Bruner¹, C. Camaioni¹, N. Sangiovanni¹, A. Mariniello¹, A. Galano¹, A. Laudiero¹, V. Sangiovanni¹
¹UOC Infezioni sistemiche e dell'Immunodepresso, "D. Cotugno" Hospital, AOS dei Colli, Napoli, ²Dipartimento di Epidemiologia e Ricerca Pre-clinica, INMI "L. Spallanzani", Roma, ³UOC Microbiologia e Virologia, "D. Cotugno" Hospital, AOS dei Colli, Napoli

SARS-COV-2 EPIDEMIOLOGY

P 88 SARS-CoV-2 infection in dialysis patients in Marsala Hospital, Southern Italy: a single-centre experience in a pre- and postvaccination era, preliminary data

G. Marino¹, P. Colletti², P. Di Carlo³, C. Barracco⁴, G. Oddo⁵
¹Student in degree course of Medicine and Surgery, University of Palermo (Hypatia), Caltanissetta, Italy, ²MD, Head of Infectious Disease Unit at "Paolo Borsellino" hospital, Marsala, Italy, ³MD, PROMISE Department, University of Palermo, Italy, ⁴Head Nurse of Dialysis Unit at "Paolo Borsellino" hospital, Marsala, Italy, ⁵MD, Head of Dialysis Unit at "Paolo Borsellino" hospital, Marsala, Italy



**P 89 Distribution of SARS-CoV-2 viral variants in a cohort of subjects treated with monoclonal antibodies targeting spike protein in Campania**

A. Di Fraia¹, M. Pisaturo¹, M. Starace¹, C. Minichini¹, L. Occhiello¹, I. Gentile², L. Atripaldi³, C. Tiberio³, I. Cavallaro³, F. Ferrentino³, N. Coppola¹

¹Infectious Diseases Unit, Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, ²Department of Clinical Medicine and Surgery, University of Naples "Federico II", Napoli, Italy, ³Cotugno Hospital, AORN Ospedali dei Colli, Napoli, Italy

SOCIAL AND BEHAVIOURAL SCIENCE, MARGINALIZED GROUPS, COMMUNITY ASPECTS AND COMMUNITY SURVEYS**P 90 Perceptions of an online serious game activity as formative assessment in higher education applied to a lecture on HIV and sexual health**

S. Licchelli, L. Barnett

University of Surrey, Guildford

P 91 Determinants of Quality of Life in PLWH effectively treated with ART

F. Maggiolo¹, E. Di Filippo¹, P. Meli², D. Valenti³, F. Radici⁴, I. Mercurio⁵, L. Comi¹

¹ASST Papa Giovanni XXIII, ²Comunità Emmaus & Caritas Bergamasca, ³Associazione FROM, ⁴Arcigay Bergamo Cives, ⁵CRI-Comitato di Bergamo, Bergamo

P 92 A Theatre-Counseling workshop on chemsex: the experience of Plus Roma

A. Infante, F. Leserri, G.M. Corbelli

Plus Roma, Roma

P 93 PAMP: Prevention among migrant people: a pilot project

G.V. Calvino¹, C. Sforza², C. Vajiro³, C. Sfara⁴, S. Ondedei⁵, E. Teti⁶, B. Rossi⁶, V. Barchi⁶, L. Ansaldo⁶, L. Campogiani⁶, S. Tedde⁶, A. Cavasio⁶, M.L. Minardi⁶, D. Kontogiannis⁶, M. Andreoni⁶, B. Marchini¹

¹Anlaidi Onlus-Ets, ²Consiglio Italiano per i Rifugiati, ³Cooperativa Famiglia Nuova, ⁴Anlaidi Umbria, ⁵INMI L. Spallanzani, Roma, ⁶UOC Malattie Infettive Policlinico Tor Vergata, Roma

P 94 Mapping Italian HIV checkpoints and testing centers: the Check Point Index

M. Carlevari¹, S. Mattioli², P. Meli³, M. Viscoli⁴, G.M. Corbelli⁵, L. Saracini⁶, D. Calzavara⁷

¹Director Public Affairs Gilead sciences Italy, ²BLQ Checkpoint, ³Bergamo Checkpoint, ⁴Checkpoint IOC'ENTRO Genova, ⁵Roma Checkpoint, ⁶Ancona Checkpoint, ⁷Milano Checkpoint, Elma Research Srl

P 95 People with HIV - The psychological and social intervention of Anlaidi Lazio

R. Galipò¹, V. Calvino², M. Falaguasta², P. Ferri¹

¹Anlaidi Lazio, Rome, ²Anlaidi, Rome

P 96 A protocol for a systematic review of predictors of quality of life and health-related quality of life in OPLWHIV

S. Licchelli, K. Smith, A. King, F. Trevisan

University of Surrey, Guildford

P 97 HIV and STI awareness project among adolescent population

F. Rossi¹, A. Bianchi¹, P. Testoni¹, D. Zagato¹, R. Repossi¹, A. Antonino¹, E. Garavaglia¹, D. Pennisi¹, M. Cernuschi²

¹ASA Associazione Solidarietà AIDS, Milano, Italy, ²San Raffaele Hospital, Milano, Italy

P 98 Nathan Never character by Bonelli Editore combats AIDS and STIGMA

G. Dessi, V. Mascia, B. Mocchi, A. Pontis

Lila Cagliari OdV, Cagliari

P 99 Villa Maraini: syndemic approach against social stigma

T. Di Giovanni¹, P. Sammarco¹, D. Masci¹, G. F. M. Direnzo¹, E. Teti², B. Coladarce¹, G. Rodoquino¹, M. Andreoni², E. Rossi¹, M. Barra¹

¹Fondazione Villa Maraini, Rome, Italy, ²Infectious Disease Clinic, Tor Vergata University, Rome, Italy

P 100 The rise and fall of the news media interest for HIV/AIDS impact on people's life: an observational study of the Italian press

C. Capelli¹, M. Pasquali¹, G.M. Corbelli², P. Lalli¹

¹Department of Political and Social Sciences, University of Bologna, ²Plus, Network persone LGBT+ sieropositivo



**P 101 Covid 19: let's go with the vaccine Accompanying the booking of the anticovid-19 vaccine for migrants and LGBTI migrants + APS Arcigay Cassero**

R. Cerbo, S. Degasperi

APS Arcigay Cassero, Gruppo Salute, Bologna

P 102 Measuring impact of a scalable peer education-based sexuality education programme in multiple Arcigay local committeesB. Allegretti, A. Barretta, A. Biondi, W. Bravi, M. Breveglieri, G. Cioffi, G. D'Ambrosio, B. Diana, D. Enicchiario, M. Marocco, I. Mele, F. Merolle, N. Piazza
Arcigay, Caserta**P 103 In and Out testing/counseling approach in pandemic era: a nine months experience at Checkpoint and Hospital center**G. Mancarella², M. Jamhour¹, A. Carraro^{1,2}, S. Garattini², A. Pontrelli², A. Gasperin², D. Di Trento², R. Marocco¹, A. Petrillo³, V. Vitale³, D. Coletta⁴, M. Lichtner^{1,2}¹Infectious Diseases Unit, S.M. Goretti Hospital, Latina, ²Department of Public Health and Infectious Diseases, "Sapienza" University, Rome, ³Arci Gay Latina/Sei come sei, ⁴Municipality of Latina**P 104 HIV Written Informed Consent: Time to Reconsider the Italian Standard?**J. Testa^{1,2}, N. Cocco^{2,3}, F. Nicolini^{2,4}, D. Radrizzani¹, C. Abeli¹, M. Farinazzo^{1,2}, B. Menzaghi¹¹Infectious Diseases Unit, ASST Valle Olona, Busto Arsizio, ²Research Group of Italian Society of Migration Medicine (SIMM), ³Infectious Diseases Service, Penitentiary Health System, ASST Santi Paolo e Carlo, Milan; ⁴Clinical Ethics Service "Domus Salutis" Clinic, Teresa Camplani Foundation, Brescia**P 105 Chemsex in Milan**S. Giacalone², S. Ramoni¹, M. Cusini¹¹UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy**P 106 Bringing comprehensive sexuality education into Italian lower secondary schools' practice: a pilot study**E. Torri¹, A. Chinelli¹, L. Ceccarelli¹, L. Rancilio⁶, M. Farinella⁷, R. Galipò³, P. Meli⁴, A. Camposeragna⁵, L. Colaprico⁸, M. Oldrini⁹, M.C. Salfa¹⁰, A. Cellini¹¹, M. Ubbiali¹², A. Caraglia¹³, L. Mortari¹², A.T. Palamara¹¹, B. Suligo¹⁰, L. Tavoschi¹, D. Martinelli²¹University of Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, ²University of Foggia, Department of Medical and Surgical Sciences, ³ANLAIDS - National Association for the Fight against AIDS, Rome, ⁴CICA - Italian Coordination of HIV/AIDS Housing Homes, Bergamo, ⁵CNCA - National Coordination of the Hospitality Community, Rome, ⁶Caritas Ambrosiana, Milan, ⁷Circolo di cultura omosessuale Mario Mieli, Rome, ⁸Italian Red Cross, Rome, ⁹LILA - Italian league for the fight against AIDS, Rome, ¹⁰Italian National Institute of Health, Rome, ¹¹Sapienza University of Rome, ¹²University of Verona, Department of Human Sciences, ¹³Ministry of Health, Department of Prevention, Rome**P 107 Sexual Health in Migrant Population: Analysis of the risk of contracting HIV and STDs**V. Manca¹, V. Fiore¹, A. De Vito¹, N. Geremia², E. Prinic¹, G. Madeddu¹, S. Babudieri¹¹Unit of Infection Diseases, Department of Medical, Surgical and Experimental Sciences, AOU, Sassari, ²Unit of Infection Diseases, Department of Clinical Medicine, Ospedale dell'Angelo, Venezia

Virology and Pharmacology

HIV VIROLOGY

P 108 Evaluating the dual-target Aptima HIV-1 Quant Dx assay: comparison between viral loads measured with the pol and LTR targets in the same samplesG. Sberna¹, S. Sarti¹, A. Antinori², S. Cicalini², A.R. Garbuglia¹, A. Amendola¹¹Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy, ²HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy**P 109 Inhibitory activity of the polyphenolic extract of Cistus Monspelienensis L. against HIV-1 under cell culture conditions**M. Tamburello¹, V. Ferraro¹, S. Vituliano¹, A. Morellini¹, A. Primavera², A. Bertoldi², M. Mandrone³, F. Poli³, G. Gallinella³, T. Lazzarotto^{1,2}, I. Bon²¹Section of Microbiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ²Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ³Department of Pharmacy and Biotechnology, University of Bologna, Bologna**P 110 Evaluation of a new real-time PCR commercial test for HIV-DNA quantification in PBMC**

T. Allice, M.G. Milia, E. Burdino, G. Gregori, F. Cerutti, S. Crisavola, S. Monteleone, E. Scuccimarra, V. Ghisetti

Laboratory of Microbiology and Virology, ASL Città di Torino, Italy





PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

P 111 Exploratory analysis of potential drug-drug interactions between molnupiravir and HAART in PLWH with COVID-19 in Udine

D. D'Elia¹, A. Londero¹, F. Pratavera¹, L.M. Ditaranto¹, M. Fusi², C. Resnati², C. Tascini¹, D. Cattaneo²

¹Unit of Infectious Disease, Santa Maria della Misericordia University Hospital, Udine, Italy, ²Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Milano, Italy

P 112 Dolutegravir plasma and intracellular pharmacokinetics in the clinical setting

F. Alladio¹, M. Ferrara¹, G. Accardo¹, S. Fantino¹, G. Trevisan¹, E. Drappero¹, A. Serra¹, L. Trentini¹, M. Tettoni¹, E. De Vivo², A. Ianniello², J. Mula², A. De Nicolò², A. D'Avolio², A. Calcagno¹, G. Di Perri¹, S. Bonora¹

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ²Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino

P 113 Isoenzymes subfamilies and symptomatic adverse events: is there a link?

E. Gentilini Cacciola, A. Lazzaro, P. Vassalini, C. Borrazzo, C.M. Mastroianni, G. d'Ettore

University of Roma "LaSapienza", Roma

SARS-COV-2 VIROLOGY

P 114 Discerning the molecular mechanism beyond the UV-photoinactivation of SARS-CoV-2

S. Strizzi¹, L. Bernardo², A. Bianco³, D. Trabattoni¹, A. De Palma², G. Pareschi³, P. D'Ursi², M. Clerici¹, P. Mauri², M. Biasin¹

¹DIBIC University of Milan, ²Proteomic Unit of Institute for Biomedical Technologies – CNR, Segrate (MI), Italy, ³INAF- Brera Astronomical Observatory Merate

P 115 Qualitative and quantitative approach to SARS-CoV-2 RNA detection

C. Orlandi¹, A. De Maria², M. Magnani¹, A. Casabianca¹

¹Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy, ²Department of Internal Medicine, Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy

VACCINES (OTHER THAN SARS-COV-2)

P 116 Persistence of immune responses after the administration of the meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) in HIV-vertically transmitted young patients

C. Vanetti¹, C. Fenizia², F. Ardizzone¹, I. Saulle¹, M. Stracuzzi³, F. Da Pozzo³, L. Paradiso³, E. Longoni³, L. Barcellini⁴, M. Biasin¹, M. Clerici^{2,5}, G.V. Zuccotti^{3,4}, V. Giacomo³, D. Trabattoni¹

¹University of Milan, Department of Biomedical and Clinical Sciences "Luigi Sacco", Milan, ²University of Milan, Department of Pathophysiology and Transplantation, Milan, ³Ospedale "Luigi Sacco", University of Milan, Department of Pediatric Infectious Diseases, Milan, ⁴University of Milan, Ospedale dei Bambini V. Buzzi, Department of Pediatrics, Milan, ⁵IRCCS Fondazione Don Gnocchi, Milan





Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

GENERAL INFORMATION



Congress Venue



Centro Congressi Giovanni XXIII

Viale Papa Giovanni XXIII, 106
24121 Bergamo BG
www.centrocongressibergamo.com



Bergamo Science Center

Viale Papa Giovanni XXIII, 57
24121 Bergamo BG
www.bergamoscienza.it

How to reach the Conference Venue



Railway Station

Bergamo: 150 m from station



Bergamo Orio al Serio Airport

5 Km from the airport – 10 minutes by car



Car

Wide pay parking available near the Conference Venue

Conference registration

It is possible to attend the conference in both residential and webinar mode.

For both of them, participants must submit the registration form through **MyICAR on the Conference website www.icar2022.it**. After completing the form, you will receive an email with a link to confirm the activation of your personal account; you will receive a message with the instruction to access the congress webinar or you will be contacted by the Organizing Secretariat for your participation.

Official languages

Italian and English. No simultaneous translation provided.





Pre-conference advanced courses and Congress dates

Pre-conference advanced courses: Tuesday, June 14 from 14.30 to 16.30

Conference: from Tuesday, June 14 h. 17.00 to Thursday, June 16 h. 16.45

Conference Secretariat opening times

- **Tuesday, June 14** from 10.30 to 20.00
- **Wednesday, June 15** from 08.30 to 19.00
- **Thursday, June 16** from 08.30 to 17.00

Exhibition Area opening times

- **Tuesday, June 14** from 13.30 to 20.00
- **Wednesday, June 15** from 09.00 to 18.45
- **Thursday, June 16** from 09.00 to 16.45

Lunches

- **Tuesday, June 14** from 12.30 to 14.30 (only for Pre-conference advanced Courses)
- **Wednesday, June 15** from 12.00 to 14.30
- **Thursday, June 16** from 12.00 to 14.30



Registered participants will receive lunch coupons from the Organizing Secretariat

Two different locations for lunches in the congress venue, just outside the Conference Center:

- Hotel NH Bergamo
- Hotel Piemontese - Sapore Puro

Same menu in both restaurants





Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least **2 hours before the session**. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power point presentations
- Last minute changes of power point presentations
- Being supported by technical staff
- Uploading power point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

A slides template for Speakers' presentations is available for download on the Conference website www.icar2022.it

Oral Communication Sessions

Selected abstract will be presented in Oral Communication Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 8/10 (power point) slides** resuming their abstract. Time allowed for presentation: **10 minutes followed by 2 minutes for discussion**.

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.



Oral Poster Sessions

Selected abstract will be presented in Oral Poster Sessions. Authors of the selected abstract are requested to attend their sessions and **provide max 5 (power point) slides** resuming their abstract. Time allowed for presentation: **5 minutes followed by 2 minutes for discussion**.

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.



Digital Poster Exhibition

All the posters can be viewed through dedicated monitors located at **Centro Congressi Giovanni XXIII**.

Con la sponsorizzazione non condizionante di Gilead Sciences

POSTER 4 YOU
ICAR 2022





Official events

Quick test for HIV, HCV and Syphilis

In front of Bergamo Science Center:

- **Tuesday, June 14** from 11.00 to 13.00
and from 16.00 to 19.00
- **Wednesday, June 15** from 11.00 to 13.00
and from 16.00 to 19.00
- **Thursday, June 16** from 11.00 to 13.00

Healthcare personnel will perform free rapid testing for HIV, HCV and Syphilis at the request of citizens in a confidential and anonymous way. The test is noninvasive, requires few minutes and is highly reliable.



Con la sponsorizzazione non condizionante di ViiV Healthcare
In collaborazione con Abbott e Meridian Biosciences

RaccontART


Presentation of the finalist works

- **Tuesday, June 14, Centro Congressi Giovanni XXIII**
Auditorium Sala Oggioni from 13.30 to 16.00

Winners' Awards

- **Auditorium Sala Oggioni** from 18.20 to 18.40

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS, Covid and STIs through various forms of expression. During the Conference Opening Session the winners will be awarded by the Jury composed of leading representatives of the national cultural, scientific and technical world.



Con la sponsorizzazione di Gilead Sciences





Exhibition “40 anni POSITIVI, dalla pandemia di AIDS ad una generazione HIV free”

Forty years ago New York Times published an article documenting the arrival of a new and unknown disease later identified as AIDS, an acronym for “Acquired Immunodeficiency Syndrome.”

To celebrate four decades of battles against HIV infection, the Bergamo Science Center is hosting, from 1 to 16 June, 2022, the exhibition “40 ANNI POSITIVI - dalla pandemia di AIDS ad una generation HIV free”, after the great success of the Milan 2021 edition.

Promoted and organized by **Milano Check Point**, with the support of **Bergamo Fast Track City**, in collaboration with **ICAR2022**, the exhibition presents **archival documents, posters and installations** that tell the story of the great revolution in HIV treatment, scientific research and civil society resistance movements.

Bergamo Science Center

- **Tuesday, June 14**
from 09.00 to 20.00
- **Wednesday, June 15**
from 09.00 to 20.00
- **Thursday, June 16**
from 09.00 to 16.00

June 1-16, 2022

Bergamo Science Center
Viale Papa Giovanni XXIII, 57
Bergamo

Progetto a cura di:



Sponsorizzato da ViiV Healthcare





Special Awards

The work of young researchers and community representatives continues to be widely recognized by ICAR, not only through Scholarships, but also with special prizes. The 14th edition of ICAR awards as follows:

ICAR-CROI Awards 2022

The absolute winners among the young Italian investigators who presented their work at CROI 2022

- **N. 1 Award** of € 1.000,00 for the best work in **Clinical**
- **N. 1 Award** of € 1.000,00 for the best work in **Basic Sciences**

Winners will be announced during the ICAR-CROI Awards 2022 session in Auditorium Sala Oggioni on Thursday June 16 from 16.25



ICAR 2022 Scientific Committee Awards

The 14th ICAR Chairs and Scientific Secretariat will announce the "Scientific Committee Awards": the ICAR awards to the best abstracts

- **N. 1 Award** of € 1.000,00 for the best **Clinical** abstract
- **N. 1 Award** of € 1.000,00 for the best **Basic Science** abstract
- **N. 1 Award** of € 1.000,00 for the best **Social Science** abstract

Winners will be announced during the ICAR 2022 Special Awards Session in Auditorium Sala Oggioni on Thursday June 16 from 16.25



SIMIT Special Awards

The 14th ICAR Chairs and Scientific Secretariat wish to thank SIMIT for the Special Awards dedicated to Young Investigators, whose abstracts have been accepted as Oral Communications:

- **N. 1 Award** of € 2.000,00 for the best **Clinical HIV** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical Hepatitis Virus** abstract
- **N. 1 Award** of € 2.000,00 for the best **Clinical SARS-CoV-2** abstract
- **N. 1 Award** of € 2.000,00 for the best **Virology and Immunopathogenesis** abstract
- **N. 1 Award** of € 2.000,00 for the best **Epidemiology and Social Science** abstract



Only young investigators under 45 years of age and regularly registered to SIMIT for years 2021 and 2022 have been selected.

Abstracts will be evaluated at the Congress Venue by a dedicated SIMIT Commission and winners will be announced during the ICAR 2022 Special Awards Session in Auditorium Sala Oggioni on Thursday June 16 from 16.25





ICAR 2022 APP

Designed to facilitate participation in ICAR 2022 and to respond to request for effective and high performance digital tools and supports. Two simple steps to access:

1. Download the ICAR App for free from the main stores (Apple Store and Google Play) "Minimum system requirements required for the App: Android 8.0 and iOS 13"
2. Login App: enter your personal login credentials (username and password) sent to you by the Organizing Secretariat Effetti



Menu Functions

HOME: Simple and immediate with a usability designed specifically for the Conference. Each menu item corresponds to a precise and useful feature.

PROGRAMMA SCIENTIFICO: Complete Scientific Programme day by day with detailed information about each session (title, speaker, time, room). Users can also select favorite Lectures, clicking on the calendar icon: these will be saved in My Agenda

MY AGENDA: User can customize their own Agenda using this function. ICAR 2022 App will create the list of favorite selected sessions in a chronological order

PROGRAMME AT A GLANCE: to quickly check Programme, rooms and sessions schedule

VOTAZIONE: It allows user to vote when sessions require this functionality

RACCONTART: To access the Art Contest, consult the works in competition, learn about participating schools, and much more

ABSTRACT: All abstracts accepted, broken down by type of presentation (Oral, Oral poster, Poster) and Abstract Reviewers. From June 14, the Abstract Repository at your fingertips with keyword search, Authors names, Abstract IDs

ICAR AWARDS: The official rewards that ICAR assign to young investigators and Community ambassadors

WORDCLOUD: Allows to select the key-words that represent the Congress main concept, creating a "cloud" that will highlight the most selected words

TEST RAPIDO HIV-HCV- SYPHILIS: Where, when and at what times: all the appointments of the Quick test for HIV, HCV and Syphilis

MOSTRA 40 ANNI POSITIVI: Archival documents, posters and installations retrace the forty years of the fight against the HIV virus

ICAR SOCIAL: Direct links to ICAR 2022 Social. Stay connect #ICAR2022

INFORMAZIONI GENERALI: A menu item for the most useful and important links: Congress Venue, Transportation and much more...



Con la sponsorizzazione non condizionante di Gilead Sciences





Community Village

A specific area of the Bergamo Science Center dedicated to the Community Village: a meeting point for all participants to visit the booths of patient associations and meet the Community activists.



Nice to ICAR YOU

The ICAR 2022 welcome point, in front of **Centro Congressi Giovanni XXIII**: all registered participants can ask for all the information and collect the ICAR 2022 T-shirt.



POSTER 4 YOU

A free service for selected posters' Authors to create their own posters and record their comments. ICAR Poster-4-you USB pendrive can be requested showing the coupon at the Gilead Sciences booth.

Con la sponsorizzazione non condizionante di Gilead Sciences



Abstract USB Pendrive

All registered participants can ask for the ICAR Abstract USB pendrive showing the coupon at the ViiV Healthcare booth: it contains all accepted abstracts.

Con la sponsorizzazione non condizionante di ViiV Healthcare



ICAR On-Demand and Web Repository

After the congress, on the official website www.icar2022.it you will find: ICAR 2022 web repository of abstracts, presentations, oral communications and accepted posters, podcasts and photo gallery.



ICAR SOCIAL

 Direct links to ICAR 2022 Social.

Stay connect #ICAR2022

www.instagram.com/icarcongress

www.twitter.com/ICARcongress

www.facebook.com/ICARcongress



Participants are hereby informed that in some spaces where the conference and ancillary activities will take place, photographs/video footage intended for online publication may be taken; participants will be notified through dedicated signage.





Conference

The 14th ICAR Conference has been accredited to the Italian Ministry of Health for 14 CME Credits.

Every single day has been accredited for the following professionals:

ID ECM Number	Credits	Professionals
Tuesday, June 14 150-345043	2,1	Medical Doctor (all disciplines)
Wednesday, June 15 150-345052	7,0	Healthcare Assistant, Biologist, Hospital Pharmacist, Nurse, Medical laboratory technician, Psychologist, Psychotherapist, Professional Educator
Thursday, June 16 150-345056	4,9	

Pre-conference advanced Courses

The 14th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course:

ID ECM Number	Credits	Professionals
Focus on viral resistance and variability 150-345000	2	Medical Doctor Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical pathology; Biologist; Medical laboratory technician
Clinical and point of care diagnostics for STIs in PreP service 150-345015	2	Medical Doctor Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical pathology; Dermatology and Venereology; Psychotherapy; Clinical pharmacology and toxicology Healthcare Assistant, Biologist, Hospital Pharmacist, Nurse, Psychologist, Psychotherapist
New psychoactive substances and chemsex. David Stuart course 150-345026	2	Medical Doctor Allergology and Clinical Immunology; Hygiene, Epidemiology and Public Health; Gastroenterology; Infectious and Tropical Diseases; Internal Medicine; Microbiology and Virology; Clinical pathology; Clinical pharmacology and toxicology; Dermatology and Venereology - Healthcare Assistant, Hospital Pharmacist, Professional educator, Psychologist, Psychotherapist





Obtaining credits

Participants

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide their signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day on the official website www.icar2022.it
(questionnaires will remain available from Friday 17 to Friday 24 June)

Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see participants).

Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

CME certification

Credits will be given only if a participant attends 90% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

SVC Assobiomedica

The pre-conference courses and the Congress were assessed as compliant with the Ethics' Code by the Assobiomedica Conference Evaluation System (SVC).





Pre-conference advanced Courses

Free of charge (registrations available on a "first come, first served" basis).

Conference

Conference registration fees (22% VAT not included)

Physicians	€ 750,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 350,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on June 14, coffee breaks and lunches on June 15 and 16, CME registration, Conference USB/abstract and poster.

Daily Conference registration fees (22% VAT not included)

Physicians	€ 330,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€180,00
Students/PhD and Post-graduate medical trainees	Free
Members of HIV/AIDS Community	Free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance to the sessions of the day), coffee break and lunch for the day, CME registration, Conference USB/abstract and poster.



Alliance to leave no-one behind



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso: **A. Antinori, M. Cernuschi, F. Maggiolo, M. Zazzi**

**CONGRESS
MAP**



**CENTRO CONGRESSI
PAPA GIOVANNI XXIII
SPAZIO ESPOSITIVO**

GROUND FLOOR

Exhibition area Ground floor

- 1a MSD
- 1b
- 2 FAST-TRACK CITIES ITALIA
- 3 ViiV Healthcare
- 4 gsk
- 5

LED TOWERS Ground floor

- A GILEAD
Creating Possible
- B VIATRIS
- D Janssen Infectious Diseases & Vaccines
PHARMACEUTICAL COMPANIES OF Johnson & Johnson
- E Roche
- F Angelini Pharma

DIGITAL AREA Ground floor

- Y ABSTRACT POINT
- POSTER YOU
ICAR 2022




ENTRATA
CENTRO CONGRESSI



14° CONGRESSO NAZIONALE
Bergamo 14-16 Giugno 2022

ICAR 2022 Welcome area
the ICONA and ReadFiles
meeting points






- | | | | |
|---|--|----|--|
| 1 | Anlaids ONLUS | 7 | LEGA ITALIANA PER LA LOTTA CONTRO L'AIDS |
| 2 | ARCIGAY Associazione LGBTI+ Italiana | 8 | mariomieli |
| 3 | ARCOBALENOAIDS ODV | 9 | Milano CHECKPOINT |
| 4 | ASA ONLUS | 10 | NPS Italia onlus Network Persone Sieropositive |
| 5 | C.I.C.A. COORDINAMENTO ITALIANO DELLE CASE ALLOGGIO PER PERSONE CON HIV/AIDS | 11 | SECRETARIATO ITALIANO STUDENTI MEDICINA |
| 6 | FONDAZIONE VILLA MARAINI | 12 | PLUS PERSONE LGBT+ SIEROPOSITIVE |

BERGAMO SCIENCE CENTER SPAZIO ESPOSITIVO

GROUND FLOOR



1st FLOOR





**CENTRO CONGRESSI
 PAPA GIOVANNI XXIII
 SPAZIO ESPOSITIVO**

1st FLOOR

EXHIBITION AREA 1st floor

- 6 **GILEAD**
Creating Possible

- 7

- 8 **janssen** Infectious Diseases & Vaccines
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

- 9

- 10 **Abbott**


LED TOWERS 1st floor

- C **SHIONOGI**

POP UP 1st floor

- 11 **SHIONOGI**

- 12 **VIATRIS**







**CENTRO CONGRESSI
 PAPA GIOVANNI XXIII
 SPAZIO ESPOSITIVO**

2nd FLOOR

EXHIBITION AREA 2nd floor

12 **sobi**
more strength

ICAR ENERGY HALL 2nd floor

13 **Agilent**

14 **meridian** BIOSCIENCE
LIFE DISCOVERED. LIFE DRUGGED.


15 **JSS** BIO PHARMA
Strategic Partners


18 **Cepheid.**
A better way.

HOSPITALITY SUITE 2nd floor

16 **GILEAD**
Creating Possible

17 **ICAR TG**







Italian Conference on AIDS and Antiviral Research

effetti

THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and CME Provider wish to thank the following Companies for the support given to the Congress, as unrestricted educational grants:

Platinum



Gold



Silver



Others



Seguici su



www.icar2022.it

